Major Lipids, Apolipoproteins, and Risk of Vascular Dis

JAMA - Journal of the American Medical Association
302, 1993
DOI: 10.1001/jama.2009.1619

Citation Report

#	Article	IF	Citations
1	Selective release of newly synthesised and newly captured GABA from synaptosomes by potassium depolarisation. Nature, 1975, 258, 254-256.	13.7	41
2	Poly-ADP-ribosylation in health and disease. Cellular and Molecular Life Sciences, 2005, 62, 739-750.	2.4	115
3	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	2,331
4	Thinking big: large-scale collaborative research in observational epidemiology. European Journal of Epidemiology, 2009, 24, 727-731.	2.5	44
5	Major Lipids, Apolipoproteins, and Risk of Vascular Disease. Yearbook of Vascular Surgery, 2010, 2010, 42-44.	0.0	3
6	Cardiovascular risk assessment and cholesterol management in adolescents: getting to the heart of the matter. Current Opinion in Pediatrics, 2010, 22, 398-404.	1.0	28
7	Pitavastatin: a distinctive lipid-lowering drug. Clinical Lipidology, 2010, 5, 309-323.	0.4	14
8	Clinical implications of the BARI 2D and COURAGE trials of coronary artery disease. Coronary Artery Disease, 2010, 21, 391-396.	0.3	2
10	Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. Current Opinion in Cardiology, 2010, 25, 622-626.	0.8	8
11	Hyperlipidemia and cardiovascular disease: should we abandon HDL cholesterol as a therapeutic target in coronary heart disease. Current Opinion in Lipidology, 2010, 21, 392-393.	1.2	1
12	Meta-analysis and causality: what about evidence-based biochemistry?. Current Opinion in Lipidology, 2010, 21, 466-468.	1.2	1
13	Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 240-246.	1.2	85
14	Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia, 2010, 53, 1846-1855.	2.9	67
15	HbA1c: a useful cardiovascular risk marker in those without diabetes?. Diabetologia, 2010, 53, 2468-2469.	2.9	1
16	A systematic review of the effect of TNF-Î± antagonists on lipid profiles in patients with rheumatoid arthritis. Clinical Rheumatology, 2010, 29, 947-955.	1.0	55
17	Antiepileptic Drugs and Markers of Vascular Risk. Current Treatment Options in Neurology, 2010, 12, 300-308.	0.7	85
18	Recent Findings from Mendelian Randomization Studies of Cardiovascular Disease. Current Cardiovascular Risk Reports, 2010, 4, 429-436.	0.8	1
19	Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study. European Journal of Epidemiology, 2010, 25, 789-798.	2.5	84

#	Article	IF	Citations
20	A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations. Brain Research, 2010, 1344, 185-191.	1.1	14
21	Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovascular Diabetology, 2010, 9, 77.	2.7	35
22	Lipoproteinâ€associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality. Journal of Internal Medicine, 2010, 268, 348-358.	2.7	38
23	Apolipoprotein B, nonâ€HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. Journal of Internal Medicine, 2010, 268, 567-577.	2.7	57
24	Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than nonâ€HDL cholesterol and LDL cholesterol. Journal of Internal Medicine, 2010, 268, 549-551.	2.7	6
25	Are there socioeconomic inequalities in cardiovascular risk factors in childhood, and are they mediated by adiposity? Findings from a prospective cohort study. International Journal of Obesity, 2010, 34, 1149-1159.	1.6	53
26	Phenomics: the next challenge. Nature Reviews Genetics, 2010, 11, 855-866.	7.7	1,070
27	Lipoprotein patterns in adult cystic fibrosis: A cause for concern or marker for survival?. Respirology, 2010, 15, 731-732.	1.3	2
28	Editorial Are we getting to lipid targets in real life?. Archives of Medical Science, 2010, 5, 639-641.	0.4	17
29	Influence of demographic and metabolic variables on forearm blood flow and vascular conductance in individuals without overt heart disease. Vascular Health and Risk Management, 2010, 6, 431.	1.0	5
30	Risk Estimation in 2009. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 4-5.	0.9	2
31	Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Cmaj, 2010, 182, 1961-1967.	0.9	59
32	A Case-Control Study on the Effect of Apoliprotein E Genotype on Head and Neck Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2839-2846.	1.1	15
33	Combination Lipid Therapy in Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 692-695.	13.9	213
34	Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. International Journal of Epidemiology, 2010, 39, 1345-1359.	0.9	110
35	The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?. Journal of Lipid Research, 2010, 51, 2058-2073.	2.0	179
36	Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Circulation, 2010, 122, 850-852.	1.6	37
37	Genetic Determinants of Major Blood Lipids in Pakistanis Compared With Europeans. Circulation: Cardiovascular Genetics, 2010, 3, 348-357.	5.1	25

#	Article	IF	Citations
38	Impact of Microalbuminuria on Incident Stroke. Stroke, 2010, 41, 2625-2631.	1.0	86
39	Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?. Expert Review of Cardiovascular Therapy, 2010, 8, 345-358.	0.6	25
40	Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology, 2010, 3, 649-661.	1.3	0
41	Using Apolipoprotein B to Manage Dyslipidemia. Mayo Clinic Proceedings, 2010, 85, 769.	1.4	2
44	When is equal not equal?. Journal of Clinical Lipidology, 2010, 4, 83-88.	0.6	27
45	Why is nonâ˜high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?. Journal of Clinical Lipidology, 2010, 4, 152-155.	0.6	83
46	Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. Journal of Clinical Lipidology, 2010, 4, 365-370.	0.6	14
47	Estimation of the low-density lipoprotein (LDL) subclass phenotype using a direct, automated assay of small dense LDL-cholesterol without sample pretreatment. Clinica Chimica Acta, 2010, 411, 1361-1366.	0.5	21
48	Hypervariability in a minisatellite 3' of the apolipoprotein B gene: Allelic distribution and influence on lipid profiles in Han Children from central China. Clinica Chimica Acta, 2010, 411, 2092-2096.	0.5	3
49	LIPIDS IN CHRONIC KIDNEY DISEASE. Journal of Renal Care, 2010, 36, 27-33.	0.6	14
50	All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study. Atherosclerosis, 2010, 211, 618-623.	0.4	25
51	Using large-scale epidemiological evidence to help evaluate biomarkers in cardiovascular disease. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2010, 22, 33-35.	0.4	0
52	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, The, 2010, 375, 132-140.	6.3	1,946
53	Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, The, 2010, 375, 1536-1544.	6.3	544
54	Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, The, 2010, 375, 2215-2222.	6.3	3,807
55	Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, The, 2010, 375, 1634-1639.	6.3	606
56	Mendelian randomisation, triglycerides, and CHD. Lancet, The, 2010, 375, 1584-1586.	6.3	15
57	Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE) Tj ETQq1 1 0.784314 rgBT /Overl	6.3	2,565

#	Article	IF	Citations
58	Genetic causes of high and low serum HDL-cholesterol. Journal of Lipid Research, 2010, 51, 2032-2057.	2.0	172
59	Using Apolipoprotein B to Manage Dyslipidemiaâ€“Replyâ€“I. Mayo Clinic Proceedings, 2010, 85, 769-771.	1.4	1
60	Incidence of and risk factors for type-2 diabetes in a general population: The TromsÃ¸ Study. Scandinavian Journal of Public Health, 2010, 38, 768-775.	1.2	41
61	Frequencies of Four ATP-Binding Cassette Transporter G8 Polymorphisms in Patients with Ischemic Vascular Diseases. Genetic Testing and Molecular Biomarkers, 2010, 14, 667-672.	0.3	7
62	Primary prevention using statins: to be or not to be?. Current Medical Research and Opinion, 2010, 26, 2701-2706.	0.9	3
63	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal, 2011, 32, 1345-1361.	1.0	993
64	Serum apolipoproteins, apoB/apoA-I ratio and objectively measured physical activity in elderly. Scandinavian Cardiovascular Journal, 2011, 45, 105-111.	0.4	5
65	Consumption of Fructose and High Fructose Corn Syrup Increase Postprandial Triglycerides, LDL-Cholesterol, and Apolipoprotein-B in Young Men and Women. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1596-E1605.	1.8	260
66	Role of different dietary saturated fatty acids for cardiometabolic risk. Clinical Lipidology, 2011, 6, 209-223.	0.4	39
67	Triglycerides and Cardiovascular Disease. Circulation, 2011, 123, 2292-2333.	1.6	1,511
68	Opening a New Lipid â€œApo-thecaryâ€: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. Mayo Clinic Proceedings, 2011, 86, 762-780.	1.4	32
69	HDL-cholestÃ©rol et approche thÃ©rapeutique. Archives of Cardiovascular Diseases Supplements, 2011, 3, 273-279.	0.0	0
70	Nonâ€“High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification. Journal of the American College of Cardiology, 2011, 58, 457-463.	1.2	132
71	Comparative prognostic utility of conventional and novel lipid parameters for cardiovascular disease risk prediction: Do novel lipid parameters offer an advantage?. Journal of Clinical Lipidology, 2011, 5, 82-90.	0.6	27
72	Potential effects on clinical management of treatment algorithms on the basis of apolipoprotein-B/A-1 and total/high-density lipoprotein-cholesterol ratios. Journal of Clinical Lipidology, 2011, 5, 159-165.	0.6	4
73	Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients. Journal of Clinical Lipidology, 2011, 5, 179-187.	0.6	5
74	The surprising AIM-HIGH results are not surprising when viewed through a particle lens. Journal of Clinical Lipidology, 2011, 5, 368-370.	0.6	16
75	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	0.6	235

#	Article	IF	Citations
76	Laboratory Testing, Electrocardiography and Imaging. , 2011, , 111-131.		0
77	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology, 2011, 8, 253-265.	6.1	90
78	Apolipoproteins: metabolic role and clinical biochemistry applications. Annals of Clinical Biochemistry, 2011, 48, 498-515.	0.8	164
79	Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. New England Journal of Medicine, 2011, 364, 829-841.	13.9	2,182
80	Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart, 2011, 97, 350-356.	1.2	87
81	Race-ethnic differences in the association between lipid profile components and risk of myocardial infarction: The Northern Manhattan Study. American Heart Journal, 2011, 161, 886-892.	1.2	50
82	Institutional, provider, and patient correlates of low-density lipoprotein and nonâ€“high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. American Heart Journal, 2011, 161, 1140-1146.	1.2	43
83	Barriers to Non-HDL Cholesterol Goal Attainment by Providers. American Journal of Medicine, 2011, 124, 876-880.e2.	0.6	30
84	Risk of Cardiovascular Mortality in Relation to Optimal Low-Density Lipoprotein Cholesterol Combined with Hypertriglyceridemia: Is There a Difference by Gender?. Annals of Epidemiology, 2011, 21, 807-814.	0.9	6
85	Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: Data from the MedPed CZ database and the Czech population. Clinica Chimica Acta, 2011, 412, 920-924.	0.5	4
86	Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders. Clinica Chimica Acta, 2011, 412, 1213-1220.	0.5	34
87	Silent myocardial ischaemia in diabetic patients after general anaesthesia with 24Âh intravenous opioids or with epidural analgesia. Egyptian Journal of Anaesthesia, 2011, 27, 279-286.	0.2	2
88	Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends in Molecular Medicine, 2011, 17, 594-603.	3.5	383
89	Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. Journal of Heart and Lung Transplantation, 2011, 30, 674-678.	0.3	35
90	Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?. Trends in Pharmacological Sciences, 2011, 32, 694-699.	4.0	24
92	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
93	Republished review: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Postgraduate Medical Journal, 2011, 87, 776-782.	0.9	8
94	Introduction. Atherosclerosis Supplements, 2011, 12, 265-266.	1.2	8

#	Article	IF	Citations
95	HDL-C: Role as a risk modifier. Atherosclerosis Supplements, 2011, 12, 267-270.	1.2	87
96	High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: A nested caseâ€“control study. Atherosclerosis, 2011, 217, 249-252.	0.4	29
97	Genetic variation in ABCA1 and risk of cardiovascular disease. Atherosclerosis, 2011, 218, 281-282.	0.4	7
98	Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. Atherosclerosis, 2011, 218, 102-106.	0.4	21
99	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 1-44.	0.4	180
100	Importance of HDL functionality to cardiovascular risk. Atherosclerosis, 2011, 218, 19-20.	0.4	5
101	Do current criteria for â€˜healthy BMIâ€™ in adolescence warrant a re-think?. Atherosclerosis, 2011, 219, 30-32.	0.4	0
102	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 3-46.	0.4	561
103	Physical (in)activity over 20y in adulthood: Associations with adult lipid levels in the 1958 British birth cohort. Atherosclerosis, 2011, 219, 361-367.	0.4	25
104	Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis, 2011, 219, 855-863.	0.4	87
105	Dietary omega-3 polyunsaturated fatty acid intake is related to a protective high-density lipoprotein subspecies profile independent of genetic effects: A monozygotic twin pair study. Atherosclerosis, 2011, 219, 880-886.	0.4	19
106	Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet, The, 2011, 377, 1085-1095.	6.3	941
107	Efficacy and safety of more intensive lowering of LDL cholesterol â€“ Authors' reply. Lancet, The, 2011, 377, 715-716.	6.3	6
108	Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet, The, 2011, 377, 1681-1692.	6.3	159
109	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice, 2011, 17, 1-53.	1.1	387
110	Cohort study for monitoring cardiovascular risk factors in children using a primary health care service: methods and initial results. Cadernos De Saude Publica, 2011, 27, 510-520.	0.4	5
111	Translation: Non-HDL Cholesterol Shows Improved Accuracy for Cardiovascular Risk Score Classification Compared to Direct or Calculated LDL Cholesterol in a Dyslipidemic Population. Laboratory Medicine Online, 2011, 1, 121.	0.0	1
112	Promoting knowledge of statins in patients with low health literacy using an audio booklet. Patient Preference and Adherence, 2011, 5, 397.	0.8	11

#	Article	IF	Citations
113	Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ: British Medical Journal, 2011, 343, d6829-d6829.	2.4	55
114	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Design, Development and Therapy, 2011, 5, 325.	2.0	201
115	HDL scavenger receptor class B type I and platelet function. Current Opinion in Lipidology, 2011, 22, 277-282.	1.2	33
116	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. Aids, 2011, 25, 1497-1504.	1.0	39
117	Optimal pharmacotherapy to combat the atherogenic lipid triad. Current Opinion in Cardiology, 2011, 26, 403-411.	0.8	15
118	Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?. Clinical Lipidology, 2011, 6, 639-651.	0.4	6
119	Vitamin D deficiency and cardiovascular disease: the missing link. Diabetes Management, 2011, 1, 151-155.	0.5	0
120	Hyperlipidemia and cardiovascular disease. Current Opinion in Lipidology, 2011, 22, 319-321.	1.2	6
122	Analysis of the Correlation between Non-high Density Lipoprotein Cholesterol and Coronary Heart Disease in Elderly Chinese. Internal Medicine, 2011, 50, 1279-1285.	0.3	5
123	Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels. Annals of Internal Medicine, 2011, 155, 742.	2.0	52
124	Therapies for diabetic dyslipidaemia. Diabetes, Obesity and Metabolism, 2011, 13, 313-325.	2.2	31
125	Donâ€™t think once, think twice! the cardiovascular effects of androgen deprivation therapy. BJU International, 2011, 107, 1023-1028.	1.3	5
126	Combined cardiovascular and diabetes risk assessment in primary care. Diabetic Medicine, 2011, 28, 19-22.	1.2	12
127	The potential for a twoâ€stage diabetes risk algorithm combining nonâ€laboratoryâ€based scores with subsequent routine nonâ€fasting blood tests: results from prospective studies in older men and women. Diabetic Medicine, 2011, 28, 23-30.	1.2	34
128	Ageâ€•and genderâ€specific reference intervals for serum lipid levels (measured with an Advia 1650) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.2	5
129	Vascular function and cardiovascular risk factors in women with severe flushing. Clinical Endocrinology, 2011, 74, 97-103.	1.2	31
130	The THEMA study: a sociodemographic survey of hypercholesterolaemic individuals. Journal of Human Nutrition and Dietetics, 2011, 24, 572-581.	1.3	12
131	Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. Journal of Internal Medicine, 2011, 269, 232-242.	2.7	63

#	Article	IF	Citations
132	Replacing dairy fat with rapeseed oil causes rapid improvement of hyperlipidaemia: a randomized controlled study. Journal of Internal Medicine, 2011, 270, 356-364.	2.7	64
133	The Effect of TNF-alpha Blocking Therapy on Lipid Levels in Rheumatoid Arthritis: A Meta-Analysis. Seminars in Arthritis and Rheumatism, 2011, 41, 393-400.	1.6	84
134	Why have total cholesterol levels declined in most developed countries?. BMC Public Health, 2011, 11, 641.	1.2	41
135	Cardiovascular risk factors prior to conception and the length of pregnancy: population-based cohort study. American Journal of Obstetrics and Gynecology, 2011, 204, 526.e1-526.e8.	0.7	65
136	Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 577	0.7	80
137	Lower Serum Paraoxonase-1 Activity Is Related to Higher Serum Amyloid A Levels in Metabolic Syndrome. Archives of Medical Research, 2011, 42, 219-225.	1.5	45
138	HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events. Clinical Chemistry, 2011, 57, 392-410.	1.5	417
139	HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nature Reviews Cardiology, 2011, 8, 222-232.	6.1	506
140	Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. Clinical Research in Cardiology, 2011, 100, 955-971.	1.5	3
141	Do men develop type 2 diabetes at lower body mass indices than women?. Diabetologia, 2011, 54, 3003-3006.	2.9	234
142	Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin. Archives of Pharmacal Research, 2011, 34, 99-107.	2.7	19
143	What intervention trials donâ€™t tell us: the residual risk in primary prevention. Internal and Emergency Medicine, 2011, 6, 53-60.	1.0	2
144	Fish Oil Supplementation During Late Pregnancy Does Not Influence Plasma Lipids or Lipoprotein Levels in Young Adult Offspring. Lipids, 2011, 46, 1091-1099.	0.7	20
145	The Role of Triglycerides in Atherosclerosis. Current Cardiology Reports, 2011, 13, 544-552.	1.3	260
146	Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. BMC Public Health, 2011, 11, 704.	1.2	28
147	Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. Lipids in Health and Disease, 2011, 10, 212.	1.2	4
148	Inverse association between adiposity and telomere length: The fels longitudinal study. American Journal of Human Biology, 2011, 23, 100-106.	0.8	175
149	Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Annals of Neurology, 2011, 69, 628-634.	2.8	95

#	Article	IF	Citations
150	Obesity and its measurement in a communityâ€based sample of women with systemic lupus erythematosus. Arthritis Care and Research, 2011, 63, 261-268.	1.5	59
151	Genetic and Nutritional Interactions in Cardiovascular Disease. World Review of Nutrition and Dietetics, 2011, 102, 150-155.	0.1	2
152	Management of dyslipidemia in HIV-infected patients. Clinical Lipidology, 2011, 6, 447-462.	0.4	28
153	Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy. Expert Opinion on Pharmacotherapy, 2011, 12, 99-117.	0.9	5
154	Clinical trials of lipid-modifying agents: design considerations. Clinical Lipidology, 2011, 6, 109-116.	0.4	0
155	Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of â€œHeart Positive,â€•a Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2236-2247.	1.8	53
156	Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement. Current Vascular Pharmacology, 2011, 9, 258-270.	0.8	265
157	Cardiovascular Disease and Primary Ovarian Insufficiency. Seminars in Reproductive Medicine, 2011, 29, 328-341.	0.5	23
158	HIV-associated dyslipidemia: the Heart Positive study. Nature Reviews Endocrinology, 2011, 7, 443-444.	4.3	0
159	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2011, 12, 1429-1438.	0.9	16
160	LDL-apheresis depletes apoE-HDL and pre-Î²1-HDL in familial hypercholesterolemia: relevance to atheroprotection. Journal of Lipid Research, 2011, 52, 2304-2313.	2.0	36
161	Epidemiology and Risk Factors. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 1213-1232.	0.4	12
162	Red meat consumption and risk of stroke in Swedish men. American Journal of Clinical Nutrition, 2011, 94, 417-421.	2.2	55
163	Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. American Journal of Clinical Nutrition, 2011, 93, 243-252.	2.2	243
164	A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 337-345.	0.9	491
165	Health aspects of saturated fatty acids. , 2011, , 77-97.		5
166	Estimation of Plasma Small Dense LDL Cholesterol From Classic Lipid Measures. American Journal of Clinical Pathology, 2011, 136, 20-29.	0.4	42
168	Functional foods and coronary heart disease (CHD). , 2011, , 153-201.		4

#	Article	IF	Citations
169	Genetic Variant of the Scavenger Receptor BI in Humans. New England Journal of Medicine, 2011, 364, 136-145.	13.9	291
170	Nonâ€“HDL Cholesterol Shows Improved Accuracy for Cardiovascular Risk Score Classification Compared to Direct or Calculated LDL Cholesterol in a Dyslipidemic Population. Clinical Chemistry, 2011, 57, 490-501.	1.5	98
171	Elevated Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Predicts Atherosclerotic Cardiovascular Events in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1112-1120.	2.2	105
172	Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart, 2011, 97, 564-568.	1.2	115
173	Triglycerides and Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1716-1725.	1.1	187
174	TRIB1 and GCKR Polymorphisms, Lipid Levels, and Risk of Ischemic Heart Disease in the General Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 451-457.	1.1	73
175	LDL-C or apoB as the best target for reducingcoronary heart disease: should apoB be implemented into clinical practice?. Clinical Lipidology, 2011, 6, 35-48.	0.4	3
176	A new look at HDL in coronary disease: can we escape natural history?. Heart, 2011, 97, 1899-1901.	1.2	5
177	Fruit and vegetable intake and mortality from ischaemic heart disease: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study. European Heart Journal, 2011, 32, 1235-1243.	1.0	225
178	Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals with and without Diabetes: 58 434 Individuals from the Copenhagen General Population Study. Clinical Chemistry, 2011, 57, 482-489.	1.5	121
179	Using Nonfasting Lipidsâ€”Hemodilution or Convenience?. Clinical Chemistry, 2011, 57, 1336-1338.	1.5	9
180	Whither the Lipid Profile: Feast, Famine, or No Free Lunch?. Clinical Chemistry, 2011, 57, 363-365.	1.5	8
181	Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?. Expert Review of Cardiovascular Therapy, 2011, 9, 987-997.	0.6	6
182	Lipid parameters for measuring risk of cardiovascular disease. Nature Reviews Cardiology, 2011, 8, 197-206.	6.1	177
183	Agreement Between Fasting and Postprandial LDL Cholesterol Measured with 3 Methods in Patients with Type 2 Diabetes Mellitus. Clinical Chemistry, 2011, 57, 298-308.	1.5	20
184	Threshold Haemoglobin Levels and the Prognosis of Stable Coronary Disease: Two New Cohorts and a Systematic Review and Meta-Analysis. PLoS Medicine, 2011, 8, e1000439.	3.9	28
185	Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy. Heart, 2012, 98, 780-785.	1.2	21
186	Folded functional lipid-poor apolipoprotein A-I obtained by heating of high-density lipoproteins: relevance to high-density lipoprotein biogenesis. Biochemical Journal, 2012, 442, 703-712.	1.7	25

#	Article	IF	Citations
187	Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3228-3234.	0.4	17
188	Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of Lipid Research, 2012, 53, 1755-1766.	2.0	125
189	LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E248-E256.	1.8	234
190	HDL functionality in diabetes mellitus: potential importance of glycation. Clinical Lipidology, 2012, 7, 561-578.	0.4	4
191	Offspring Birth Weight and Cardiovascular Risk in Parentsâ€"A Population-based HUNT 2 Study. American Journal of Epidemiology, 2012, 175, 546-555.	1.6	20
192	The genetics of coronary artery disease. Current Opinion in Cardiology, 2012, 27, 221-227.	0.8	34
193	Postprandial dyslipidaemia and diabetes. Current Opinion in Lipidology, 2012, 23, 303-309.	1.2	21
194	Functions of scavenger receptor class B, type I in atherosclerosis. Current Opinion in Lipidology, 2012, 23, 487-493.	1.2	62
195	Low-density lipoprotein-lowering strategies. Current Opinion in Cardiology, 2012, 27, 405-411.	0.8	16
196	The fats of life in diabetes. British Journal of Diabetes and Vascular Disease, 2012, 12, 216-220.	0.6	3
197	Tachometer for Reverse Cholesterol Transport?. Journal of the American Heart Association, 2012, 1, e003723.	1.6	8
198	Association of LDL Cholesterol, Nonâ€"HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. JAMA - Journal of the American Medical Association, 2012, 307, 1302.	3.8	650
199	Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA - Journal of the American Medical Association, 2012, 307, 2499-506.	3.8	352
200	Prevalence of Dyslipidemia and Lipid Goal Attainment in Statinâ€Treated Subjects From 3 Data Sources: A Retrospective Analysis. Journal of the American Heart Association, 2012, 1, e001800.	1.6	96
201	Screening, Diagnosis, and Treatment of Dyslipidemia Among Persons With Persistent Mental Illness: A Literature Review. Psychiatric Services, 2012, 63, 693-701.	1.1	16
202	Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. European Heart Journal, 2012, 33, 1712-1715.	1.0	30
203	PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials. Clinical Lipidology, 2012, 7, 621-640.	0.4	16
204	HDL and Cardiovascular Risk. Circulation Research, 2012, 111, 1117-1120.	2.0	54

#	Article	IF	Citations
205	Cardiovascular disease in patients with HIV. Future Virology, 2012, 7, 413-423.	0.9	6
206	Associations of 25-Hydroxyvitamin D₂and D₃with Cardiovascular Risk Factors in Childhood: Cross-Sectional Findings from the Avon Longitudinal Study of Parents and Children. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1563-1571.	1.8	49
207	Impact of the apolipoprotein B/apolipoprotein A-I ratio on renal outcome in immunoglobulin A nephropathy. Scandinavian Journal of Urology and Nephrology, 2012, 46, 148-155.	1.4	12
208	The inhibition of cholesteryl ester transfer protein: a long and winding road. Journal of Lipid Research, 2012, 53, 1039-1041.	2.0	2
209	Serum Apolipoproteins Are Associated With Systemic and Retinal Microvascular Function in People With Diabetes. Diabetes, 2012, 61, 1785-1792.	0.3	31
210	Minimal and Null Predictive Effects for the Most Popular Blood Biomarkers of Cardiovascular Disease. Circulation Research, 2012, 110, 658-662.	2.0	61
211	Elevated ApoB serum levels strongly predict early cardiovascular events. Heart, 2012, 98, 1242-1245.	1.2	18
212	Fasting for Lipid Testing: Is It Worth the Trouble?. Archives of Internal Medicine, 2012, 172, 1710.	4.3	22
213	Cohort profile: The Tromso Study. International Journal of Epidemiology, 2012, 41, 961-967.	0.9	547
214	Carotid intima-media thickness and apolipoproteins in patients of ischemic stroke in a rural hospital sett ing in central India: A cross-sectional study. Journal of Neurosciences in Rural Practice, 2012, 03, 21-27.	0.3	7
215	Associations between Coronary Heart Disease and Individual Components of the Metabolic Syndrome according to Glucose Tolerance Status. Journal of International Medical Research, 2012, 40, 934-942.	0.4	1
216	Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. International Journal of Epidemiology, 2012, 41, 1419-1433.	0.9	230
217	Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrology Dialysis Transplantation, 2012, 27, 2839-2847.	0.4	40
218	Efficacy of Colesevelam on Lowering Glycemia and Lipids. Journal of Cardiovascular Pharmacology, 2012, 59, 198-205.	0.8	29
219	High-density lipoprotein levels and risk of cardiovascular events. Journal of Cardiovascular Medicine, 2012, 13, 575-586.	0.6	22
220	Obesity, hypertension, and cardiovascular health. Journal of Hypertension, 2012, 30, 1103-1105.	0.3	8
221	Response to Hoenselaar from Pedersen et al.. British Journal of Nutrition, 2012, 107, 452-454.	1.2	2
222	Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet, The, 2012, 380, 572-580.	6.3	1,937

#	Article	IF	Citations
223	Mendelian randomisation, lipids, and cardiovascular disease. Lancet, The, 2012, 380, 543-545.	6.3	26
224	Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis, 2012, 225, 444-449.	0.4	105
225	Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes. Current Cardiology Reports, 2012, 14, 721-731.	1.3	20
226	9p21 and the Genetic Revolution for Coronary Artery Disease. Clinical Chemistry, 2012, 58, 104-112.	1.5	53
227	Plasma HDL cholesterol and risk of myocardial infarction. Lancet, The, 2012, 380, 1990-1991.	6.3	3
228	Plasma HDL cholesterol and risk of myocardial infarction â€“ Authors' reply. Lancet, The, 2012, 380, 1991.	6.3	27
229	Fasting Time and Lipid Levels in a Community-Based Population. Archives of Internal Medicine, 2012, 172, 1707.	4.3	232
230	Omnipresent Atherosclerotic Disease: Time to Depart From Analysis of Individual Vascular Beds. Mount Sinai Journal of Medicine, 2012, 79, 641-653.	1.9	15
231	Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants. Atherosclerosis, 2012, 220, 22-33.	0.4	189
232	CETP inhibition in perspective. Atherosclerosis, 2012, 220, 325-328.	0.4	2
233	Non-high-density lipoprotein cholesterol is a practical predictor of long-term cardiac death after coronary artery bypass grafting. Atherosclerosis, 2012, 221, 206-211.	0.4	11
234	Adrenalectomy stimulates the formation of initial atherosclerotic lesions: Reversal by adrenal transplantation. Atherosclerosis, 2012, 221, 76-83.	0.4	21
235	Controversies in dyslipidaemia management. Atherosclerosis, 2012, 221, 321-324.	0.4	1
236	Dietary fats and dietary cholesterol and risk of stroke in women. Atherosclerosis, 2012, 221, 282-286.	0.4	73
237	High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population: The JPHC study. Atherosclerosis, 2012, 221, 565-569.	0.4	58
238	Pancreatic Î²-cell function relates positively to HDL functionality in well-controlled Type 2 diabetes mellitus. Atherosclerosis, 2012, 222, 567-573.	0.4	38
239	Weight change and lipoprotein particle concentration and particle size: A cohort study with 6.5-year follow-up. Atherosclerosis, 2012, 223, 239-243.	0.4	32
240	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68.	0.4	414

#	Article	IF	Citations
241	A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2. Atherosclerosis, 2012, 224, 150-153.	0.4	35
242	A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: Comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis, 2012, 225, 208-215.	0.4	58
243	Lower carotid intima media thickness is predicted by higher serum bilirubin in both non-diabetic and Type 2 diabetic subjects. Clinica Chimica Acta, 2012, 414, 161-165.	0.5	32
244	Nonâ€“high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. Journal of Clinical Lipidology, 2012, 6, 50-57.	0.6	14
245	Difference between calculated and direct-measured low-density lipoprotein cholesterol in subjects with diabetes mellitus or taking lipid-lowering medications. Journal of Clinical Lipidology, 2012, 6, 114-120.	0.6	17
246	Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and nonâ€“high-density lipoprotein cholesterol in men. Journal of Clinical Lipidology, 2012, 6, 374-381.	0.6	29
247	Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialistsâ€™ Collaboration meta-analysis for low-density lipoprotein lowering. Journal of Clinical Lipidology, 2012, 6, 303-309.	0.6	42
248	Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 2012, 6, 450-461.	0.6	54
249	Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Journal of Cardiology, 2012, 60, 383-388.	0.8	9
250	Genomics: Is It Ready for Primetime?. Medical Clinics of North America, 2012, 96, 113-122.	1.1	2
251	Low-Density Lipoprotein Cholesterol, Nonâ€“High-Density Lipoprotein, Apolipoprotein, or Low-Density Lipoprotein Particle. Journal of the American College of Cardiology, 2012, 60, 2616-2617.	1.2	6
254	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	1.0	5,247
255	Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?. Expert Review of Clinical Pharmacology, 2012, 5, 43-54.	1.3	3
257	Apolipoprotein Câ€III as a Potential Modulator of the Association Between HDLâ€Cholesterol and Incident Coronary Heart Disease. Journal of the American Heart Association, 2012, 1, .	1.6	115
258	Niacin: another look at an underutilized lipid-lowering medication. Nature Reviews Endocrinology, 2012, 8, 517-528.	4.3	41
259	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Journal of Preventive Cardiology, 2012, 19, 585-667.	0.8	359
260	The Role and Impact of Research Agendas on the Comparative-Effectiveness Research Among Antihyperlipidemics. Clinical Pharmacology and Therapeutics, 2012, 91, 685-691.	2.3	10
261	Epidemiology and prevention of stroke: a worldwide perspective. Expert Review of Neurotherapeutics, 2012, 12, 199-208.	1.4	105

#	Article	IF	Citations
262	Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2969-2989.	1.8	641
263	Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?. European Heart Journal, 2012, 33, 2258-2264.	1.0	14
264	Risk factors for ischemic stroke; results from 9 years of follow-up in a population based cohort of Iran. BMC Neurology, 2012, 12, 117.	0.8	51
265	Caveats to aggressive lowering of lipids by specific statins. International Journal of Cardiology, 2012, 154, 97-101.	0.8	21
266	Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 416-424.	1.2	50
267	Serum triglycerides and risk of cardiovascular disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 867-875.	1.2	122
268	Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia. Diabetes Research and Clinical Practice, 2012, 97, 51-56.	1.1	7
269	Carotid intima media thickness is related positively to plasma pre ÃŸ-high density lipoproteins in non-diabetic subjects. Clinica Chimica Acta, 2012, 413, 473-477.	0.5	18
270	Nutritional genomics for the characterization of the effect of bioactive molecules in lipid metabolism and related pathways. Electrophoresis, 2012, 33, 2266-2289.	1.3	23
271	Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutrition and Metabolism, 2012, 9, 25.	1.3	75
272	What Is the Role of Advanced Lipoprotein Analysis in Practice?. Journal of the American College of Cardiology, 2012, 60, 2607-2615.	1.2	19
273	Role of HDL-C as a cardiovascular risk factor: clinical relevance of pitavastatin. Clinical Lipidology, 2012, 7, 17-24.	0.4	0
274	Cardiovascular disease risk reduction by raising HDL cholesterol â€“ current therapies and future opportunities. British Journal of Pharmacology, 2012, 167, 1177-1194.	2.7	203
275	Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. Expert Opinion on Investigational Drugs, 2012, 21, 667-676.	1.9	36
276	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American Journal of Human Genetics, 2012, 91, 823-838.	2.6	227
277	Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials. American Journal of Cardiology, 2012, 110, 1468-1476.	0.7	108
278	Dyslipidaemia and age-related involutional blepharoptosis. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2012, 65, e146-e150.	0.5	24
279	The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: A prospective nested caseâ€“control study. European Journal of Internal Medicine, 2012, 23, 755-759.	1.0	53

#	Article	IF	Citations
282	Are Novel Serum Biomarkers Informative?. Medical Clinics of North America, 2012, 96, 1-11.	1.1	4
284	Increased high-density lipoprotein cholesterol is associated with a high prevalence of pre-hypertension and hypertension in community-dwelling persons. Endocrine, 2012, 42, 321-328.	1.1	10
285	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine, 2012, 19, 403-488.	0.8	224
286	Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease. Journal of the American College of Cardiology, 2012, 60, 2631-2639.	1.2	696
287	Trends and risk factors of hypercholesterolemia among Kuwaiti adults: National Nutrition Surveillance Data from 1998 to 2009. Nutrition, 2012, 28, 917-923.	1.1	9
288	Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management. Canadian Journal of Cardiology, 2012, 28, 667-677.	0.8	6
289	Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction. Clinical Pharmacology and Therapeutics, 2012, 91, 109-122.	2.3	62
290	Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: The Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan. Lipids in Health and Disease, 2012, 11, 162.	1.2	12
291	Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500â€‰mg/dl despite conventional triglyceride lowering therapy. Lipids in Health and Disease, 2012, 11, 143.	1.2	14
292	Comparison of Apolipoprotein (apoB/apoA-I) and Lipoprotein (Total Cholesterol/HDL) Ratio Determinants. Focus on Obesity, Diet and Alcohol Intake. PLoS ONE, 2012, 7, e40878.	1.1	14
293	Associations between Apolipoprotein E Genotype, Diet, Body Mass Index, and Serum Lipids in Lithuanian Adult Population. PLoS ONE, 2012, 7, e41525.	1.1	36
294	Population-Based Resequencing of LIPG and ZNF202 Genes in Subjects with Extreme HDL Levels. Frontiers in Genetics, 2012, 3, 89.	1.1	6
295	The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk. , 2012, , .		12
296	Usefulness of LDL-C-Related Parameters to Predict Cardiovascular Risk and Effect of Pravastatin in Mild-to-Moderate Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2012, 19, 176-185.	0.9	11
297	Lipid levels do not influence the risk of venous thromboembolism. Thrombosis and Haemostasis, 2012, 108, 923-929.	1.8	32
298	Cholesterol Efflux and Atheroprotection. Circulation, 2012, 125, 1905-1919.	1.6	772
299	Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study. Circulation, 2012, 125, 2469-2478.	1.6	185
300	Leukocyte Telomere Length: A Focus on Cerebrovascular Events. Rejuvenation Research, 2012, 15, 274-280.	0.9	3

#	Article	IF	Citations
301	Molecular mechanisms of vascular effects of Highâ€density lipoprotein: alterations in cardiovascular disease. EMBO Molecular Medicine, 2012, 4, 251-268.	3.3	172
302	Proteomic profiling following immunoaffinity capture of highâ€density lipoprotein: Association of acuteâ€phase proteins and complement factors with proinflammatory highâ€density lipoprotein in rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 1828-1837.	6.7	133
303	Genetics of Coronary Artery Disease in the 21st Century. Clinical Cardiology, 2012, 35, 536-540.	0.7	24
304	A Review on Metaanalysis of Biomarkers: Promises and Pitfalls. Clinical Chemistry, 2012, 58, 1192-1204.	1.5	14
305	HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. Diabetologia, 2012, 55, 1564-1567.	2.9	19
306	Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes and Control, 2012, 23, 1289-1296.	0.8	31
307	The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease. Current Atherosclerosis Reports, 2012, 14, 130-134.	2.0	56
308	Clinical Trials of HDL Cholesterolâ€“Raising Therapy: What Have We Learned About the HDL Hypothesis from AIM-HIGH?. Current Atherosclerosis Reports, 2012, 14, 190-192.	2.0	5
309	Age- and Gender-Specific Reference Intervals for Fasting Blood Glucose and Lipid Levels in School Children Measured With Abbott Architect c8000 Chemistry Analyzer. Indian Journal of Clinical Biochemistry, 2012, 27, 141-146.	0.9	6
310	Effects of oral estradiol and levonorgestrel on cardiovascular risk markers in postmenopausal women. Archives of Gynecology and Obstetrics, 2012, 285, 1647-1656.	0.8	16
311	Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. Diabetic Medicine, 2012, 29, 5-13.	1.2	42
312	Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study. Journal of Evaluation in Clinical Practice, 2012, 18, 159-168.	0.9	35
313	New lipid-lowering drugs: an update. International Journal of Clinical Practice, 2012, 66, 270-280.	0.8	61
314	Role of Non-High-Density Lipoprotein Cholesterol in Predicting Cerebrovascular Events in Patients Following Myocardial Infarction. American Journal of Cardiology, 2012, 109, 1694-1699.	0.7	18
315	Surrogate End Points in Secondary Analyses of Cardiovascular Trials. Progress in Cardiovascular Diseases, 2012, 54, 343-350.	1.6	8
316	Nonâ€highâ€density lipoprotein cholesterol: An important predictor of stroke and diabetesâ€related mortality in Japanese elderly diabetic patients. Geriatrics and Gerontology International, 2012, 12, 18-28.	0.7	40
317	Chylomicrons: A Key Biomarker and Risk Factor for Cardiovascular Disease and for the Understanding of Obesity. Current Cardiovascular Risk Reports, 2012, 6, 27-34.	0.8	10
318	The combined effects of genetic variation in the SIRT1 gene and dietary intake of n-3 and n-6 polyunsaturated fatty acids on serum LDL-C and HDL-C levels: a population based study. Lipids in Health and Disease, 2013, 12, 4.	1.2	18

#	Article	IF	Citations
320	Lipid profile components and incident cerebrovascular events versus coronary heart disease; the result of 9 years follow-up in Tehran Lipid and Glucose Study. Clinical Biochemistry, 2013, 46, 716-721.	0.8	17
321	Selective peroxisome proliferator-activated receptorÎ± modulators (SPPARMÎ±): The next generation of peroxisome proliferator-activated receptor Î±-agonists. Cardiovascular Diabetology, 2013, 12, 82.	2.7	148
322	Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988–1991 to 2005–2008. Cardiovascular Diabetology, 2013, 12, 26.	2.7	18
323	Statins in cardiometabolic disease: what makes pitavastatin different?. Cardiovascular Diabetology, 2013, 12, S1.	2.7	17
324	How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?. Current Cardiology Reports, 2013, 15, 400.	1.3	142
325	Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield. Current Atherosclerosis Reports, 2013, 15, 321.	2.0	5
326	The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease. Current Atherosclerosis Reports, 2013, 15, 312.	2.0	35
327	Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. Current Cardiology Reports, 2013, 15, 397.	1.3	31
328	Genetics of Lipid Traits and Relationship to Coronary Artery Disease. Current Cardiology Reports, 2013, 15, 396.	1.3	13
329	Lipoprotein and Lipid Metabolism. , 2013, , 1-33.		4
330	Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: A meta-analysis of prospective cohort studies. Diabetes Research and Clinical Practice, 2013, 102, 65-75.	1.1	36
331	HDL-C: clinical equipoise and vascular endothelial function. Expert Review of Cardiovascular Therapy, 2013, 11, 343-353.	0.6	19
332	Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 799-807.	1.1	111
333	The positive relationship of serum paraoxonase-1 activity withÂapolipoprotein E is abrogated in metabolic syndrome. Atherosclerosis, 2013, 230, 6-11.	0.4	22
334	High-density lipoproteins: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2013, 7, 484-525.	0.6	276
335	Effect of Equivalent On-Treatment Apolipoprotein Levels on Outcomes (from the AIM-HIGH and) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	11
336	Risk factors for stroke in Tanzania. The Lancet Global Health, 2013, 1, e241-e242.	2.9	7
337	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. Atherosclerosis, 2013, 231, 300-307.	0.4	66

#	Article	IF	Citations
338	Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies. Clinical Lipidology, 2013, 8, 321-328.	0.4	0
339	Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. International Journal of Cardiology, 2013, 170, S16-S20.	0.8	32
340	Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. Journal of Clinical Lipidology, 2013, 7, 414-422.	0.6	37
341	Common variants associated with plasma triglycerides and risk for coronary artery disease. Nature Genetics, 2013, 45, 1345-1352.	9.4	754
342	Molecular Biology of Atherosclerosis. Physiological Reviews, 2013, 93, 1317-1542.	13.1	418
343	Interleukin 6 Stimulates Endothelial Binding and Transport of High-Density Lipoprotein Through Induction of Endothelial Lipase. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2699-2706.	1.1	31
344	Lipid-Lowering Agents. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 401-411.	1.0	28
345	Role of HDL Cholesterol and Estimates of HDL Particle Composition in Future Development of Type 2 Diabetes in the General Population: The PREVEND Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1352-E1359.	1.8	98
346	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	1.0	1,758
347	Molecular Mechanisms Linking Diabetes to the Accelerated Development ofÂAtherosclerosis. Canadian Journal of Diabetes, 2013, 37, 345-350.	0.4	52
348	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. Circulation, 2013, 128, 1504-1512.	1.6	162
350	Dyslipidemia, atherosclerosis and cardiovascular disease: an increasingly important triad in an aging population living with HIV. Future Virology, 2013, 8, 1021-1034.	0.9	8
351	Evidence that periodontal treatment improves biomarkers and CVD outcomes. Journal of Periodontology, 2013, 84, S85-S105.	1.7	68
352	Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2013, 7, 304-383.	0.6	346
353	Demystifying the management of hypertriglyceridaemia. Nature Reviews Cardiology, 2013, 10, 648-661.	6.1	92
354	Evidence that periodontal treatment improves biomarkers and <scp>CVD</scp> outcomes. Journal of Clinical Periodontology, 2013, 40, S85-105.	2.3	156
355	Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain. Annals of Medicine, 2013, 45, 322-327.	1.5	8
356	Apolipoprotein AI and High-Density Lipoprotein Have Anti-Inflammatory Effects on Adipocytes via Cholesterol Transporters. Circulation Research, 2013, 112, 1345-1354.	2.0	99

#	Article	IF	Citations
357	Metabolic syndrome in patients with the polycystic ovary syndrome. Expert Review of Endocrinology and Metabolism, 2013, 8, 559-568.	1.2	2
358	What have we learnt about high-density lipoprotein cholesterol measurements during 32years? Experiences in Finland 1980â€“2012. Clinica Chimica Acta, 2013, 415, 118-123.	0.5	13
359	Sex differences in assessment of obesity in rheumatoid arthritis. Arthritis Care and Research, 2013, 65, 62-70.	1.5	49
360	Prise en charge des hypertriglycÃ©ridÃ©mies sÃ©vÃ¨res. Medecine Des Maladies Metaboliques, 2013, 7, 421-429	0.1	1
361	Gender-specific association of coronary artery calcium and lipoprotein parameters: The Heinz Nixdorf Recall Study. Atherosclerosis, 2013, 229, 531-540.	0.4	31
362	Remnant Cholesterol. Journal of the American College of Cardiology, 2013, 61, 437-439.	1.2	26
363	Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease. Journal of the American College of Cardiology, 2013, 61, 427-436.	1.2	768
364	High-Density Lipoprotein and Residual Cardiovascular Risk. Journal of the American College of Cardiology, 2013, 62, 1842-1844.	1.2	4
365	Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication. Journal of the American College of Cardiology, 2013, 62, 1834-1841.	1.2	42
366	Relevance of intermediate-density lipoprotein cholesterol to Framingham risk score of coronary heart disease in middle-aged men with increased non-HDL cholesterol. International Journal of Cardiology, 2013, 168, 3853-3858.	0.8	23
367	Gender aspects in type 2 diabetes mellitus and cardiometabolic risk. Best Practice and Research in Clinical Endocrinology and Metabolism, 2013, 27, 501-507.	2.2	132
368	Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia. Atherosclerosis, 2013, 230, 52-60.	0.4	26
369	Evidence for a role of CETP in HDL remodeling and cholesterol efflux: Role of cysteine 13 of CETP. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1644-1650.	1.2	21
370	Impaired antioxidant action of high density lipoprotein in patients with type 1 diabetes with normoalbuminuria and microalbuminuria. Diabetes Research and Clinical Practice, 2013, 99, 321-326.	1.1	13
371	Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. Lancet Diabetes and Endocrinology,the, 2013, 1, 71-78.	5.5	39
372	Common variation in Cholesteryl Ester Transfer Protein: Relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio. Journal of Clinical Lipidology, 2013, 7, 56-64.	0.6	11
373	Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations. Clinical Biochemistry, 2013, 46, 1509-1515.	0.8	11
374	Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. International Journal of Cardiology, 2013, 167, 1696-1702.	0.8	31

#	Article	IF	Citations
375	Egg on their faces (probably not in their necks); The yolk of the tenuous cholesterol-to-plaque conclusion. Atherosclerosis, 2013, 227, 182-183.	0.4	2
376	What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 104-117.	0.4	6
377	A new accurate, simple formula for LDL-cholesterol estimation based on directly measured blood lipids from a large cohort. Annals of Clinical Biochemistry, 2013, 50, 13-19.	0.8	100
378	Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. International Journal of Clinical Practice, 2013, 67, 6-13.	0.8	36
379	Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population. International Journal of Clinical Practice, 2013, 67, 81-88.	0.8	9
380	HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?. Current Cardiology Reports, 2013, 15, 349.	1.3	15
381	Atherosclerosis: lessons from LXR and the intestine. Trends in Endocrinology and Metabolism, 2013, 24, 120-128.	3.1	57
382	Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment. Clinical Lipidology, 2013, 8, 69-79.	0.4	9
383	Parental obesity and risk factors for cardiovascular disease among their offspring in mid-life: findings from the 1958 British Birth Cohort Study. International Journal of Obesity, 2013, 37, 1590-1596.	1.6	28
384	Genetics of HDL-C: A Causal Link to Atherosclerosis?. Current Atherosclerosis Reports, 2013, 15, 326.	2.0	23
385	Physical activity in obesity and metabolic syndrome. Annals of the New York Academy of Sciences, 2013, 1281, 141-159.	1.8	194
386	Bias in Associations of Emerging Biomarkers With Cardiovascular Disease. JAMA Internal Medicine, 2013, 173, 664.	2.6	91
387	Triglyceride-rich lipoproteins and HDL: What do recent trials tell us?. Atherosclerosis, 2013, 228, 329-331.	0.4	1
388	Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomarkers in Medicine, 2013, 7, 457-472.	0.6	62
389	Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages. Inflammation Research, 2013, 62, 711-720.	1.6	11
390	Is walking to school associated with improved metabolic health?. International Journal of Behavioral Nutrition and Physical Activity, 2013, 10, 12.	2.0	58
391	Effects of pitavastatin on HDL metabolism. Clinical Lipidology, 2013, 8, 55-68.	0.4	3
392	Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nature Reviews Rheumatology, 2013, 9, 513-523.	3.5	212

#	Article	IF	Citations
393	Circulating Biomarkers for Predicting Cardiovascular Disease Risk; a Systematic Review and Comprehensive Overview of Meta-Analyses. PLoS ONE, 2013, 8, e62080.	1.1	97
394	Lipids in Women. , 2013, , 965-974.		0
395	The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. Current Cardiology Reports, 2013, 15, 391.	1.3	9
396	Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia, 2013, 56, 686-695.	2.9	140
397	ApoB versus non-HDL-cholesterol: Diagnosis and cardiovascular risk management. Critical Reviews in Clinical Laboratory Sciences, 2013, 50, 163-171.	2.7	21
398	High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. Journal of Lipid Research, 2013, 54, 3227-3243.	2.0	132
399	Lipid management: maximising reduction of cardiac risk. Clinical Medicine, 2013, 13, 618-620.	0.8	3
400	Non-high-density lipoprotein cholesterolvslow-density lipoprotein cholesterol as a risk factor for ischemic stroke: a result from the Kailuan study. Neurological Research, 2013, 35, 505-511.	0.6	23
401	High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. European Heart Journal, 2013, 34, 3563-3571.	1.0	110
402	Twenty-Four-Year Trends in the Incidence of Ischemic Stroke in Sweden From 1987 to 2010. Stroke, 2013, 44, 2388-2393.	1.0	145
403	Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. European Heart Journal, 2013, 34, 1826-1833.	1.0	353
404	Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement. Therapeutic Advances in Cardiovascular Disease, 2013, 7, 169-182.	1.0	3
405	Lipoprotein(a): epidemiology, atherogenic activity and impact on cardiovascular risk. Clinical Lipidology, 2013, 8, 195-203.	0.4	2
406	HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal, 2013, 34, 1279-1291.	1.0	581
407	Frail HDLs and Stiff Arteries in Type 2 Diabetes in Juveniles. Diabetes, 2013, 62, 2662-2664.	0.3	2
408	NHLBI integrated pediatric guidelines: battle for a future free of cardiovascular disease. Future Cardiology, 2013, 9, 13-22.	0.5	5
409	Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. Clinical Science, 2013, 125, 257-264.	1.8	78
410	Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studies. BMJ, The, 2013, 346, e8539-e8539.	3.0	302

#	Article	IF	Citations
411	Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. European Heart Journal, 2013, 34, 972-981.	1.0	33
412	Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study. International Journal of Endocrinology, 2013, 2013, 1-7.	0.6	15
413	Increased apolipoprotein A-I levels mediate the development of prehypertension among Turks. Anatolian Journal of Cardiology, 2013, 13, 306-14.	0.4	11
414	Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidenceâ€Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 1675-1683.	6.7	22
415	Identification of a Novel Polymorphism in X-Linked Sterol-4-Alpha-Carboxylate 3-Dehydrogenase (Nsdhl) Associated with Reduced High-Density Lipoprotein Cholesterol Levels in I/LnJ Mice. G3: Genes, Genomes, Genetics, 2013, 3, 1819-1825.	0.8	5
416	Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor. Anatolian Journal of Cardiology, 2013, 13, 543-51.	0.4	15
417	Mortality risk of triglyceride levels in patients with coronary artery disease. Heart, 2013, 99, 22-29.	1.2	40
418	Exercise Training in Patients with Chronic Heart Failure Promotes Restoration of High-Density Lipoprotein Functional Properties. Circulation Research, 2013, 113, 1345-1355.	2.0	70
419	Apolipoprotein C-III. Circulation Research, 2013, 112, 1405-1408.	2.0	59
420	The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans. Circulation: Cardiovascular Genetics, 2013, 6, 54-62.	5.1	53
421	High-density lipoprotein cholesterol raising. Current Opinion in Cardiology, 2013, 28, 464-474.	0.8	21
422	Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol. Current Opinion in Cardiology, 2013, 28, 389-398.	0.8	34
423	Update on the detection and treatment of atherogenic low-density lipoproteins. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 140-147.	1.2	14
424	Winner by points? â€“ LDL cholesterol as a target for therapeutic intervention. Current Opinion in Lipidology, 2013, 24, 277-278.	1.2	0
425	Postprandial lipaemia and vascular disease. Current Opinion in Cardiology, 2013, 28, 446-451.	0.8	27
426	Importance of high-density lipoprotein quality. Current Opinion in Nephrology and Hypertension, 2013, 22, 259-265.	1.0	14
427	Choice of medical therapy to lower triglycerides in those at risk of pancreatitis. Current Opinion in Lipidology, 2013, 24, 532-533.	1.2	2
428	Evidence of a Polygenic Origin of Extreme High-Density Lipoprotein Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1521-1528.	1.1	49

#	Article	IF	Citations
429	Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. Journal of Lipid Research, 2013, 54, 467-472.	2.0	52
430	Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease. Circulation, 2013, 127, 891-904.	1.6	303
431	Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events. Evidence-Based Medicine, 2013, 18, 73-74.	0.6	1
432	Prevalence and Management of Dyslipidemia in Korea: Korea National Health and Nutrition Examination Survey during 1998 to 2010. Diabetes and Metabolism Journal, 2013, 37, 433.	1.8	78
433	Triglycerides and cardiovascular risk. Heart, 2013, 99, 1-2.	1.2	15
434	Polymorphisms, de novo lipogenesis, and plasma triglyceride response following fish oil supplementation. Journal of Lipid Research, 2013, 54, 2866-2873.	2.0	20
435	Liver ABCA1 Deletion in LDLrKO Mice Does Not Impair Macrophage Reverse Cholesterol Transport or Exacerbate Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2288-2296.	1.1	35
436	Why Targeting HDL Should Work as a Therapeutic Tool, but Has Not. Journal of Cardiovascular Pharmacology, 2013, 62, 239-246.	0.8	30
437	New therapies to reduce low-density lipoprotein cholesterol. Current Opinion in Cardiology, 2013, 28, 452-457.	0.8	22
438	Within-person variability in calculated risk factors: Comparing the aetiological association of adiposity ratios with risk of coronary heart disease. International Journal of Epidemiology, 2013, 42, 849-859.	0.9	21
439	Comparable Incremental Value of Standard and Nonstandard Lipids for Coronary Heart Disease Risk Assessment in Elderly Adults: The Three City Study. Journal of the American Geriatrics Society, 2013, 61, 1234-1236.	1.3	0
440	High-density lipoprotein impedes glycation of low-density lipoprotein. Diabetes and Vascular Disease Research, 2013, 10, 152-160.	0.9	27
441	HDL, Atherosclerosis, and Emerging Therapies. Cholesterol, 2013, 2013, 1-18.	1.6	70
442	Journey Through Cholesteryl Ester Transfer Protein Inhibition. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 360-366.	0.9	11
443	The inverse relation of HDL antiâ€oxidative functionality with serum amyloid a is lost in metabolic syndrome subjects. Obesity, 2013, 21, 361-366.	1.5	27
444	Cardiorespiratory Fitness and Cardiovascular Risk in Patients With Ankylosing Spondylitis: A Crossâ€Sectional Comparative Study. Arthritis Care and Research, 2013, 65, 969-976.	1.5	13
445	Nonâ€<scp>HDL</scp> cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the <scp>EPIC</scp>â€Norfolk prospective population study. European Journal of Clinical Investigation, 2013, 43, 1009-1015.	1.7	27
446	The impact of gender and serum estradiol levels on <scp>HDL</scp>â€mediated reverse cholesterol transport. European Journal of Clinical Investigation, 2013, 43, 317-323.	1.7	28

#	Article	IF	Citations
447	Impaired HDL function in obese adolescents: Impact of lifestyle intervention and bariatric surgery. Obesity, 2013, 21, E687-95.	1.5	28
448	Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial. Diabetes Care, 2013, 36, 422-428.	4.3	43
449	High density lipoprotein structure, function, and metabolism: a new Thematic Series. Journal of Lipid Research, 2013, 54, 2031-2033.	2.0	16
450	Dyslipidemia Is Associated With Tunneledâ€Cuffed Catheterâ€Related Central Venous Thrombosis in Hemodialysis Patients: A Retrospective, Multicenter Study. Artificial Organs, 2013, 37, E155-61.	1.0	8
451	High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study. Journal of Rheumatology, 2013, 40, 825-830.	1.0	24
452	Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease. European Journal of Preventive Cardiology, 2013, 20, 89-97.	0.8	17
454	Cardiovascular Disease Epidemiology in Asia. Circulation Journal, 2013, 77, 1646-1652.	0.7	217
455	High-Density Lipoproteins. Circulation Journal, 2013, 77, 2432-2448.	0.7	143
456	Low bone mineral density is associated with dyslipidemia in South Korean men: The 2008â€“2010 Korean National Health and Nutrition Examination Survey. Endocrine Journal, 2013, 60, 1179-1189.	0.7	28
457	The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. Clinical Lipidology, 2013, 8, 243-256.	0.4	2
458	Cardiovascular disease and hypertriglyceridemia: a report from the hypertriglyceridemia registry of the Spanish Atherosclerosis Society. Clinical Lipidology, 2013, 8, 525-532.	0.4	4
459	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vascular Health and Risk Management, 2013, 9, 617.	1.0	71
460	Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. Vascular Health and Risk Management, 2013, 9, 671.	1.0	28
461	The involvement of multiple thrombogenic and atherogenic markers in premature coronary artery disease. Clinics, 2013, 68, 1502-1508.	0.6	7
462	Management of Hypertriglyceridemia for Prevention of Cardiovascular Diseases. Journal of Lipid and Atherosclerosis, 2013, 2, 53.	1.1	2
463	High Density Lipoprotein Cholesterol in Coronary Artery Disease: When Higher Means Later. Journal of Atherosclerosis and Thrombosis, 2013, 20, 23-31.	0.9	5
464	Znf202 Affects High Density Lipoprotein Cholesterol Levels and Promotes Hepatosteatosis in Hyperlipidemic Mice. PLoS ONE, 2013, 8, e57492.	1.1	15
465	RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist. PLoS ONE, 2013, 8, e83190.	1.1	168

#	Article	IF	Citations
466	Dyslipidemia in women with polycystic ovary syndrome. Obstetrics and Gynecology Science, 2013, 56, 137.	0.6	117
467	Intercorrelations of lipoprotein subfractions and their covariation with lifestyle factors in healthy men. Journal of Clinical Biochemistry and Nutrition, 2014, 54, 174-180.	0.6	10
468	A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach. PLoS ONE, 2014, 9, e98368.	1.1	38
469	Psychological Changes following Weight Loss in Overweight and Obese Adults: A Prospective Cohort Study. PLoS ONE, 2014, 9, e104552.	1.1	31
470	Does fasting in Ramadan ameliorate Lipid profile? A prospective observational study. Pakistan Journal of Medical Sciences, 2014, 30, 708-11.	0.3	10
471	Dyslipidemia in women: etiology and management. International Journal of Women's Health, 2014, 6, 185.	1.1	57
472	Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease. Therapeutics and Clinical Risk Management, 2014, 10, 815.	0.9	31
473	Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?. World Journal of Diabetes, 2014, 5, 444.	1.3	588
474	Elevated Small Dense Low-Density Lipoprotein Cholesterol as a Predictor for Future Cardiovascular Events in Patients with Stable Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2014, 21, 755-767.	0.9	68
475	Trends in metabolic syndrome risk factors among adolescents in rural Crete between 1989 and 2011. Hormones, 2014, 13, 259-267.	0.9	5
476	High-density lipoprotein from patients with coronary heart disease loses anti-thrombotic effects on endothelial cells: impact on arterial thrombus formation. Thrombosis and Haemostasis, 2014, 112, 1024-1035.	1.8	27
477	Effect of CPAP Treatment for Obstructive Sleep Apnea Hypopnea Syndrome on Lipid Profile: A Meta-Regression Analysis. Journal of Clinical Sleep Medicine, 2014, 10, 1295-1302.	1.4	62
478	HDL particles â€“ more complex than we thought. Thrombosis and Haemostasis, 2014, 112, 857-857.	1.8	13
479	Effect of Obstructive Sleep Apnea Hypopnea Syndrome on Lipid Profile: A Meta-Regression Analysis. Journal of Clinical Sleep Medicine, 2014, 10, 475-489.	1.4	118
480	Utility of the Triglyceride Level for Predicting Incident Diabetes Mellitus According to the Fasting Status and Body Mass Index Category: The Ibaraki Prefectural Health Study. Journal of Atherosclerosis and Thrombosis, 2014, 21, 1152-1169.	0.9	16
481	High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 55-63.	0.9	56
483	Update on the NCEP ATP-III emerging cardiometabolic risk factors. BMC Medicine, 2014, 12, 115.	2.3	51
484	Risk prediction with triglycerides in patients with stable coronary disease on statin treatment. Clinical Research in Cardiology, 2014, 103, 984-997.	1.5	10

#	Article	IF	Citations
485	Genetically low vitamin D concentrations and increased mortality: mendelian randomisation analysis in three large cohorts. BMJ, The, 2014, 349, g6330-g6330.	3.0	238
486	Cholesterol Efflux Capacity, Carotid Atherosclerosis, and Cerebrovascular Symptomatology. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 921-926.	1.1	30
487	Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases. Pharmacogenomics, 2014, 15, 1931-1940.	0.6	7
488	Dysfunctional HDL: the journey from savior to slayer. Clinical Lipidology, 2014, 9, 49-59.	0.4	15
489	Fibrates and niacin: is there a place for them in clinical practice?. Expert Opinion on Pharmacotherapy, 2014, 15, 2673-2680.	0.9	11
490	The Impact of Lipoproteins on Wound Healing: Topical HDL Therapy Corrects Delayed Wound Healing in Apolipoprotein E Deficient Mice. Pharmaceuticals, 2014, 7, 419-432.	1.7	26
491	Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients. BioMed Research International, 2014, 2014, 1-11.	0.9	28
492	An In-Silico Model of Lipoprotein Metabolism and Kinetics for the Evaluation of Targets and Biomarkers in the Reverse Cholesterol Transport Pathway. PLoS Computational Biology, 2014, 10, e1003509.	1.5	35
493	Genomics and Pharmacogenomics of Lipid-Lowering Therapies. , 2014, , 715-746.		0
494	Different Risk Factor Profiles for Ischemic and Hemorrhagic Stroke in Type 1 Diabetes Mellitus. Stroke, 2014, 45, 2558-2562.	1.0	39
495	Association of the Apolipoprotein B/Apolipoprotein A-I Ratio, Metabolic Syndrome Components, Total Cholesterol, and Low-Density Lipoprotein Cholesterol with Insulin Resistance in the Population of Georgia. International Journal of Endocrinology, 2014, 2014, 1-8.	0.6	9
496	Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. Current Medical Research and Opinion, 2014, 30, 1957-1965.	0.9	5
497	The relationship of high-density lipoprotein cholesterol to new-onset diabetes: a review. Diabetes Management, 2014, 4, 355-365.	0.5	0
498	Dyslipidaemia in children on renal replacement therapy. Nephrology Dialysis Transplantation, 2014, 29, 594-603.	0.4	18
499	Integrated Care: Nonfasting Screening for Cardiovascular Risk Among Individuals Taking Second-Generation Antipsychotics. Psychiatric Services, 2014, 65, 573-576.	1.1	5
500	Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack. Neurosurgical Focus, 2014, 36, E10.	1.0	2
501	Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events. Circulation, 2014, 129, 553-561.	1.6	189
502	Is Nonâ€“High-Density Lipoprotein Cholesterol a Marker and Therapeutic Target for Dyslipidemia in Metabolic Syndrome?. Metabolic Syndrome and Related Disorders, 2014, 12, 451-453.	0.5	0

#	Article	IF	Citations
503	Pediatric Lipid Management. Endocrinology and Metabolism Clinics of North America, 2014, 43, 981-992.	1.2	13
504	Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. Journal of Lipid Research, 2014, 55, 2167-2177.	2.0	47
505	Evolving targets for lipidâ€modifying therapy. EMBO Molecular Medicine, 2014, 6, 1215-1230.	3.3	11
506	Heart Disease and Stroke Statisticsâ€”2014 Update. Circulation, 2014, 129, e28-e292.	1.6	4,522
507	Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. American Heart Journal, 2014, 168, 878-883.e1.	1.2	58
508	ApoAâ€mutations, L202P and K131del, in HDL from heterozygotes with low HDLâ€. Proteomics - Clinical Applications, 2014, 8, 241-250.	0.8	5
509	Nonâ€highâ€density lipoprotein cholesterol independently predicts new onset of nonâ€alcoholic fatty liver disease. Liver International, 2014, 34, e128-35.	1.9	48
510	Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2014, 64, 2525-2540.	1.2	192
511	Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. European Journal of Clinical Investigation, 2014, 44, 240-248.	1.7	42
512	Apolipoprotein B Attenuates Albuminuria-Associated Cardiovascular Disease in Prevention of Renal and Vascular Endstage Disease (PREVEND) Participants. Journal of the American Society of Nephrology: JASN, 2014, 25, 2906-2915.	3.0	16
513	Cardiovascular and cancer events in hyper-high-density lipoprotein cholesterolemic patients: a post hoc analysis of the MEGA study. Lipids in Health and Disease, 2014, 13, 133.	1.2	3
514	Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovascular Diabetology, 2014, 13, 135.	2.7	38
515	Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia. Clinical Lipidology, 2014, 9, 399-406.	0.4	3
516	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. European Journal of Preventive Cardiology, 2014, 21, 866-875.	0.8	18
517	Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Current Opinion in Lipidology, 2014, 25, 461-467.	1.2	61
518	Remnant cholesterol and ischemic heart disease. Current Opinion in Lipidology, 2014, 25, 266-273.	1.2	41
519	Newer Therapeutic Strategies to Alter High-Density Lipoprotein Level and Function. Cardiology in Review, 2014, 22, 17-24.	0.6	1
520	High-Density Lipoprotein Functionality in Coronary Artery Disease. American Journal of the Medical Sciences, 2014, 347, 504-508.	0.4	34

#	Article	IF	Citations
521	Blood Lipids and the Incidence of Atrial Fibrillation: The Multiâ€Ethnic Study of Atherosclerosis and the Framingham Heart Study. Journal of the American Heart Association, 2014, 3, e001211.	1.6	99
522	Anacetrapib. Cardiology in Review, 2014, 22, 253-261.	0.6	3
523	Treatment options for low high-density lipoproteins. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 134-139.	1.2	12
524	A comparative analysis of risk factors for stroke in blacks and whites: the Atherosclerosis Risk in Communities study. Ethnicity and Health, 2014, 19, 601-616.	1.5	14
525	Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study. Circulation, 2014, 129, 1821-1831.	1.6	445
526	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD â€“ Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	0.9	173
527	Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease. Diabetes and Vascular Disease Research, 2014, 11, 53-59.	0.9	2
528	The association between Mediterranean Diet Score and glucokinase regulatory protein gene variation on the markers of cardiometabolic risk: an analysis in the European Prospective Investigation into Cancer (EPIC)-Norfolk study. British Journal of Nutrition, 2014, 112, 122-131.	1.2	17
529	The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. European Heart Journal, 2014, 35, 1792-1800.	1.0	76
530	Impact of Genetic Variants in Human Scavenger Receptor Class B Type I (SCARB1) on Plasma Lipid Traits. Circulation: Cardiovascular Genetics, 2014, 7, 838-847.	5.1	16
531	Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovascular Diabetology, 2014, 13, 159.	2.7	135
532	Serum TG-lowering properties of plant sterols and stanols are associated with decreased hepatic VLDL secretion. Journal of Lipid Research, 2014, 55, 2554-2561.	2.0	30
533	Postprandial hypertriglyceridemia as a coronary risk factor. Clinica Chimica Acta, 2014, 431, 131-142.	0.5	157
534	HDL does not influence the polarization of human monocytes toward an alternative phenotype. International Journal of Cardiology, 2014, 172, 179-184.	0.8	23
535	Non-High-Density Lipoprotein Cholesterol and Coronary Artery Calcium Progression in a Multiethnic US Population. American Journal of Cardiology, 2014, 113, 471-474.	0.7	7
536	High-density lipoprotein cholesterol and risk of cardiovascular events in octogenarian patients with acute coronary syndrome: Long-term follow-up study. International Journal of Cardiology, 2014, 174, 133-134.	0.8	3
537	Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease. , 2014, 24, 65-71.		7
538	The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol. Clinica Chimica Acta, 2014, 433, 34-38.	0.5	32

#	Article	IF	Citations
539	Utility of post-mortem lipid levels in fatal premature CAD: An autopsy study. International Journal of Cardiology, 2014, 174, 212-214.	0.8	1
540	Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: A cross sectional study. Indian Heart Journal, 2014, 66, 280-288.	0.2	40
541	Strategies for vascular disease prevention: The role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a)). Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 281-294.	2.2	23
542	Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: The ARIC Study. Atherosclerosis, 2014, 234, 42-46.	0.4	42
543	Flow-mediated dilation, carotid wall thickness and HDL function in subjects with hyperalphalipoproteinemia. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 777-783.	1.1	28
544	Pleiotropic genes for metabolic syndrome and inflammation. Molecular Genetics and Metabolism, 2014, 112, 317-338.	0.5	107
545	Differential Metabolic Actions of Specific Statins: Clinical and Therapeutic Considerations. Antioxidants and Redox Signaling, 2014, 20, 1286-1299.	2.5	20
546	Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk. Journal of Medicinal Chemistry, 2014, 57, 1-17.	2.9	42
547	Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes. Current Diabetes Reports, 2014, 14, 482.	1.7	43
548	Novel Therapies Focused on the High-Density Lipoprotein Particle. Circulation Research, 2014, 114, 193-204.	2.0	34
549	High-Density Lipoproteins and Cerebrovascular Integrity in Alzheimerâ€™s Disease. Cell Metabolism, 2014, 19, 574-591.	7.2	76
550	Genome-wide association studies identified novel loci for non-high-density lipoprotein cholesterol and its postprandial lipemic response. Human Genetics, 2014, 133, 919-930.	1.8	10
551	Identification of the molecular genetic basis of the low palmitic acid seed oil trait in soybean mutant line RG3 and association analysis of molecular markers with elevated seed stearic acid and reduced seed palmitic acid. Molecular Breeding, 2014, 34, 447-455.	1.0	11
552	The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 45-53.	2.6	110
553	Residual macrovascular risk in 2013: what have we learned?. Cardiovascular Diabetology, 2014, 13, 26.	2.7	149
554	Effects of Native and Myeloperoxidase-Modified Apolipoprotein A-I on Reverse Cholesterol Transport and Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 779-789.	1.1	120
555	Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. Contemporary Diabetes, 2014, , 373-398.	0.0	0
556	Joint British Societiesâ€™ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart, 2014, 100, ii1-ii67.	1.2	441

#	Article	IF	Citations
557	Screening Strategies for Cardiovascular Disease in Asymptomatic Adults. Primary Care - Clinics in Office Practice, 2014, 41, 371-397.	0.7	36
558	Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins. Journal of Proteomics, 2014, 106, 181-190.	1.2	61
559	GuÃa de prÃ¡ctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciÃ³n con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	0.6	15
560	Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia. American Journal of Medicine, 2014, 127, 36-44.e1.	0.6	62
561	High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm. Clinical Pharmacology and Therapeutics, 2014, 96, 48-56.	2.3	60
562	Serum lipid concentrations among persons with spinal cord injury â€“ A systematic review and meta-analysis of the literature. Atherosclerosis, 2014, 232, 305-312.	0.4	53
563	Treatment of periodontitis improves the atherosclerotic profile: a systematic review and metaâ€analysis. Journal of Clinical Periodontology, 2014, 41, 70-79.	2.3	241
564	Effects of bioactive lipids and lipoproteins on bone. Trends in Endocrinology and Metabolism, 2014, 25, 53-59.	3.1	64
565	Cardioprotective functions of HDLs. Journal of Lipid Research, 2014, 55, 168-179.	2.0	237
566	Inhibition of Arthritis in the Lewis Rat by Apolipoprotein A-I and Reconstituted High-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 543-551.	1.1	34
567	High-Density Lipoprotein. Circulation Research, 2014, 114, 171-182.	2.0	236
568	High-Density Lipoprotein Mediated Cellular Cholesterol Efflux in Acute Coronary Syndromes. American Journal of Cardiology, 2014, 113, 249-255.	0.7	51
569	Dyslipidemia, Coronary Artery Calcium, and Incident Atherosclerotic Cardiovascular Disease. Circulation, 2014, 129, 77-86.	1.6	212
570	Guidelines for the Primary Prevention of Stroke. Stroke, 2014, 45, 3754-3832.	1.0	1,621
571	Tolerability, pharmacokinetics and pharmacodynamics of <scp>TA</scp>â€8995, a selective cholesteryl ester transfer protein (<scp>CETP</scp>) inhibitor, in healthy subjects. British Journal of Clinical Pharmacology, 2014, 78, 498-508.	1.1	27
572	Macrophage phenotypes in atherosclerosis. Immunological Reviews, 2014, 262, 153-166.	2.8	454
573	Cardiovascular Disease Risk Prediction in Women: Is There a Role for Novel Biomarkers?. Clinical Chemistry, 2014, 60, 88-97.	1.5	19
575	The Ratio of Highâ€Density Lipoprotein Cholesterol to Apolipoprotein Aâ€I Predicts Myocardial Injury Following Elective Percutaneous Coronary Intervention. Clinical Cardiology, 2014, 37, 558-565.	0.7	7

#	Article	IF	Citations
576	Prevalence of adiposity and associated cardiometabolic risk factors in the samoan genomeâ€wide association study. American Journal of Human Biology, 2014, 26, 491-501.	0.8	72
577	Longitudinal changes in highâ€density lipoprotein cholesterol and cardiovascular events in older adults. Clinical Endocrinology, 2014, 80, 662-670.	1.2	6
578	The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis, 2014, 237, 287-300.	0.4	57
579	Cardiovascular risk factors in a treatment-naÃ¯ve, human immunodeficiency virus-infected rural population in Dikgale, South Africa. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2014, 56, 190-195.	0.2	3
580	Multiple Associated Variants Increase the Heritability Explained for Plasma Lipids and Coronary Artery Disease. Circulation: Cardiovascular Genetics, 2014, 7, 583-587.	5.1	29
581	Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Farâ€"Is This the End for Statins?. Clinical Pharmacology and Therapeutics, 2014, 96, 192-205.	2.3	20
582	Common Genetic Variants Contribute to Primary Hypertriglyceridemia Without Differences Between Familial Combined Hyperlipidemia and Isolated Hypertriglyceridemia. Circulation: Cardiovascular Genetics, 2014, 7, 814-821.	5.1	36
583	Treating low high-density lipoprotein cholesterol: what is the evidence?. Therapeutic Advances in Endocrinology and Metabolism, 2014, 5, 10-17.	1.4	8
584	Secondary Prevention of Stroke in the Elderly: Focus on Drug Therapy. Drugs and Aging, 2014, 31, 721-730.	1.3	16
585	HDL and coronary heart diseaseâ€"novel insights. Nature Reviews Cardiology, 2014, 11, 559-560.	6.1	9
586	Novel metabolic biomarkers of cardiovascular disease. Nature Reviews Endocrinology, 2014, 10, 659-672.	4.3	85
587	Cardiovascular preventionâ€"end of the road for niacin?. Nature Reviews Endocrinology, 2014, 10, 646-647.	4.3	9
588	A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. Nature Communications, 2014, 5, 4871.	5.8	62
589	Behavioral Cardiology. Journal of the American College of Cardiology, 2014, 64, 100-110.	1.2	138
590	Haemostatic factors, lipoproteins and long-term mortality in a multi-ethnic population of Gujarati, African-Caribbean and European origin. Atherosclerosis, 2014, 236, 62-72.	0.4	4
591	Metrological traceability in mass spectrometry-based targeted protein quantitation: A proof-of-principle study for serum apolipoproteins A-I and B100. Journal of Proteomics, 2014, 109, 143-161.	1.2	31
592	Low Nonfasting Triglycerides and Reduced All-Cause Mortality: A Mendelian Randomization Study. Clinical Chemistry, 2014, 60, 737-746.	1.5	147
593	MR_predictor: a simulation engine for Mendelian Randomization studies. Bioinformatics, 2014, 30, 3432-3434.	1.8	7

#	Article	IF	Citations
594	Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1498-1512.	1.2	25
595	Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides. Atherosclerosis, 2014, 236, 244-250.	0.4	42
596	Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovascular Research, 2014, 103, 395-404.	1.8	92
597	High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovascular Research, 2014, 103, 350-361.	1.8	83
598	Triglycerides and cardiovascular disease. Lancet, The, 2014, 384, 626-635.	6.3	1,005
599	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation, 2014, 129, S49-73.	1.6	2,823
600	Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: The Circulatory Risk in Communities Study (CIRCS). Atherosclerosis, 2014, 237, 361-368.	0.4	83
601	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2014, 45, 2160-2236.	1.0	3,891
602	Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease. Clinical and Experimental Nephrology, 2014, 18, 247-250.	0.7	14
603	Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine, 2014, 371, 203-212.	13.9	1,367
604	High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovascular Research, 2014, 103, 362-371.	1.8	115
605	HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nature Communications, 2014, 5, 3292.	5.8	343
606	Lipid-lowering therapy and mortality post-MI: is it just about the LDL?. Heart, 2014, 100, 825-826.	1.2	0
607	Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality. Circulation, 2014, 130, 546-553.	1.6	118
608	Emerging Therapeutic Approaches to Treat Dyslipidemia. Current Cardiology Reports, 2014, 16, 506.	1.3	6
609	Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis. Drugs, 2014, 74, 513-520.	4.9	0
610	Deletions of the SACPD-C locus elevate seed stearic acid levels but also result in fatty acid and morphological alterations in nitrogen fixing nodules. BMC Plant Biology, 2014, 14, 143.	1.6	47
611	Impact of admission triglyceride for early outcome in diabetic patients with stable coronary artery disease. Lipids in Health and Disease, 2014, 13, 73.	1.2	9

#	Article	IF	Citations
612	Loss-of-Function Mutations inAPOC3and Risk of Ischemic Vascular Disease. New England Journal of Medicine, 2014, 371, 32-41.	13.9	749
613	Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia. International Journal of Cardiology, 2014, 176, 696-702.	0.8	45
614	Understanding high-density lipoprotein function in disease: Recent advances in proteomics unravel the complexity of its composition and biology. Progress in Lipid Research, 2014, 56, 36-46.	5.3	96
615	Mendelian Disorders of High-Density Lipoprotein Metabolism. Circulation Research, 2014, 114, 124-142.	2.0	43
616	Lipoprotein Particle Concentrations in Children and Adults following Kawasaki Disease. Journal of Pediatrics, 2014, 165, 727-731.	0.9	16
617	APOC3, Coronary Disease, and Complexities of Mendelian Randomization. Cell Metabolism, 2014, 20, 387-389.	7.2	34
618	Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults. Journal of Clinical Lipidology, 2014, 8, 501-509.	0.6	11
619	Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammationâ€“lipid interactions. Annals of the Rheumatic Diseases, 2014, 73, 1495-1499.	0.5	26
620	Racial differences in levels of serum lipids and effects of exposure to persistent organic pollutants on lipid levels in residents of Anniston, Alabama. Environment International, 2014, 73, 216-223.	4.8	20
621	Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant recipients. Journal of Heart and Lung Transplantation, 2014, 33, 499-506.	0.3	13
622	Simvastatin treatment upregulates intestinal lipid secretion pathways in a rodent model of the metabolic syndrome. Atherosclerosis, 2014, 232, 141-148.	0.4	24
623	HDL-C, triglycerides and carotid IMT: A meta-analysis of 21,000 patients with automated edge detection IMT measurement. Atherosclerosis, 2014, 232, 65-71.	0.4	41
624	2013 ACC/AHA Guideline on the Assessment ofÂCardiovascular Risk. Journal of the American College of Cardiology, 2014, 63, 2935-2959.	1.2	3,277
625	Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management. Revista Espanola De Cardiologia (English Ed), 2014, 67, 36-44.	0.4	7
626	Mining the genome for lipid genes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1993-2009.	1.8	35
627	The ABCG5/8 Cholesterol Transporter and Myocardial Infarction Versus Gallstone Disease. Journal of the American College of Cardiology, 2014, 63, 2121-2128.	1.2	45
628	Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogÃ©nica. Revista Espanola De Cardiologia, 2014, 67, 36-44.	0.6	26
629	Dietary modulators of statin efficacy in cardiovascular disease and cognition. Molecular Aspects of Medicine, 2014, 38, 1-53.	2.7	13

#	Article	IF	Citations
630	Serum paraoxonase-1 activity is more closely related to HDL particle concentration and large HDL particles than to HDL cholesterol in Type 2 diabetic and non-diabetic subjects. Clinical Biochemistry, 2014, 47, 1022-1027.	0.8	39
631	Interleukin-1 Revisited. Journal of the American College of Cardiology, 2014, 63, 1735-1738.	1.2	2
632	Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. , 2014, 141, 358-367.		167
633	Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 860-864.	1.0	5
634	Tragopogon porrifolius improves serum lipid profile and increases short-term satiety in rats. Appetite, 2014, 72, 1-7.	1.8	10
635	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology,the, 2014, 2, 655-666.	5.5	473
636	High-density lipoprotein, beta cells, and diabetes. Cardiovascular Research, 2014, 103, 384-394.	1.8	93
637	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements, 2014, 15, 1-15.	1.2	83
638	Treatment of dyslipidemia. F1000prime Reports, 2014, 6, 17.	5.9	10
639	Lipid-modifying Therapy: The Clinicianâ€™s Perspective. Clinical Therapeutics, 2015, 37, 2712-2715.	1.1	0
640	Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A caseâ€“control study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 187-193.	1.4	4
641	Consumption of Fructose and High Fructose Corn Syrup Increase Postprandial Triglycerides, LDL-Cholesterol, and Apolipoprotein-B in Young Men and Women. , 2015, , 63-84.		0
642	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan â€“ 2015. Endocrine Practice, 2015, 21, 1-87.	1.1	443
644	A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention: TableÂ1. Evidence-Based Medicine, 2015, 20, 162-169.	0.6	7
645	The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids in Health and Disease, 2015, 14, 127.	1.2	22
646	Lipoprotein heterogeneity in persons with Spinal Cord Injury: a model of prolonged sitting and restricted physical activity. Lipids in Health and Disease, 2015, 14, 81.	1.2	17
647	Improving the odds: ezetimibe and cardiovascular disease. International Journal of Clinical Practice, 2015, 69, 390-395.	0.8	2
648	Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC Cancer, 2015, 15, 913.	1.1	22

#	Article	IF	Citations
649	Weight loss therapy for clinical management of patients with some atherosclerotic diseases: a randomized clinical trial. Nutrition Journal, 2015, 14, 120.	1.5	3
650	Screening for cardiovascular disease risk factors beginning in childhood. Public Health Reviews, 2015, 36, 9.	1.3	31
651	Assessing the Impact of Analytical Error on Perceived Disease Severity. Archives of Pathology and Laboratory Medicine, 2015, 139, 1295-1301.	1.2	1
652	Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology, 2015, 26, 484-491.	1.2	35
653	New worldwide lipid guidelines. Current Opinion in Cardiology, 2015, 30, 447-453.	0.8	4
654	The dual and opposite role of the TM6SF2â€rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A metaâ€analysis. Hepatology, 2015, 62, 1742-1756.	3.6	135
655	HDL-cholesterol and cardiovascular disease. Current Opinion in Cardiology, 2015, 30, 536-542.	0.8	59
656	Prioritizing health outcomes in a limited world. Current Opinion in Lipidology, 2015, 26, 188-194.	1.2	2
657	Non-high-density lipoprotein cholesterol. Current Opinion in Lipidology, 2015, 26, 502-510.	1.2	69
658	Mendelian randomization studies. Current Opinion in Lipidology, 2015, 26, 566-571.	1.2	56
659	Low-Normal Thyroid Function and Novel Cardiometabolic Biomarkers. Nutrients, 2015, 7, 1352-1377.	1.7	39
660	Beneficial Effect of Higher Dietary Fiber Intake on Plasma HDL-C and TC/HDL-C Ratio among Chinese Rural-to-Urban Migrant Workers. International Journal of Environmental Research and Public Health, 2015, 12, 4726-4738.	1.2	40
661	Potential of PCSK9 as a new target for the management of LDL cholesterol. Research Reports in Clinical Cardiology, 0, , 73.	0.2	6
662	Association between Serum C-Peptide as a Risk Factor for Cardiovascular Disease and High-Density Lipoprotein Cholesterol Levels in Nondiabetic Individuals. PLoS ONE, 2015, 10, e112281.	1.1	18
663	Apolipoprotein B48, the Structural Component of Chylomicrons, Is Sufficient to Antagonize Staphylococcus aureus Quorum-Sensing. PLoS ONE, 2015, 10, e0125027.	1.1	18
664	Biphasic Regulation of Lipid Metabolism: A Meta-Analysis of Icodextrin in Peritoneal Dialysis. BioMed Research International, 2015, 2015, 1-11.	0.9	1
665	Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics. Cholesterol, 2015, 2015, 1-22.	1.6	30
666	Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	4

#	Article	IF	Citations
667	High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1515-1519.	1.1	83
668	Novel methodologies for biomarker discovery in atherosclerosis. European Heart Journal, 2015, 36, 2635-2642.	1.0	174
669	Multivariable Mendelian Randomization: The Use of Pleiotropic Genetic Variants to Estimate Causal Effects. American Journal of Epidemiology, 2015, 181, 251-260.	1.6	909
670	Cholesterol Efflux Capacity as a Novel Biomarker for Incident Cardiovascular Events. Circulation Research, 2015, 116, 1646-1648.	2.0	6
671	HDLs, Diabetes, and Metabolic Syndrome. Handbook of Experimental Pharmacology, 2015, 224, 405-421.	0.9	44
672	Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials. European Journal of Pharmacology, 2015, 763, 48-63.	1.7	44
673	Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals inÂHungary. Atherosclerosis, 2015, 241, 62-68.	0.4	18
674	Twenty-five years of statins: where do we go from here?. Clinical Lipidology, 2015, 10, 33-45.	0.4	2
675	CETP genotype and changes in lipid levels in response to weight-loss diet intervention in the POUNDS LOST and DIRECT randomized trials. Journal of Lipid Research, 2015, 56, 713-721.	2.0	39
676	Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. Journal of the American College of Cardiology, 2015, 65, 2267-2275.	1.2	210
677	Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. Atherosclerosis Supplements, 2015, 18, 109-111.	1.2	37
678	Lipoproteins and Cardiovascular Disease Risk. Contemporary Endocrinology, 2015, , 57-65.	0.3	0
679	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2015, 3, 507-513.	5.5	389
680	Protective Effects of the Mediterranean Diet on Type 2 Diabetes and Metabolic Syndrome. Journal of Nutrition, 2016, 146, 920S-927S.	1.3	155
681	A Change in Inflammatory Footprint Precedes Plaque Instability: A Systematic Evaluation of Cellular Aspects of the Adaptive Immune Response in Human Atherosclerosis. Journal of the American Heart Association, 2015, 4, .	1.6	89
682	Infusion of Reconstituted Highâ€Ðensity Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. Journal of the American Heart Association, 2015, 4, e002171.	1.6	89
683	Lipids and Cerebrovascular Disease. Stroke, 2015, 46, 3322-3328.	1.0	116
684	Biochemistry laboratories should routinely report non-HDL-cholesterol. Annals of Clinical Biochemistry, 2015, 52, 629-631.	0.8	4

#	Article	IF	Citations
685	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. Journal of the American College of Cardiology, 2015, 66, 2201-2210.	1.2	105
686	Lipoprotein profiles in human heterozygote carriers of a functional mutation P297S in scavenger receptor class B1. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 1587-1595.	1.2	14
687	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Journal of Clinical Lipidology, 2015, 9, 511-518.e5.	0.6	5
688	Reproducibility and biological variability of HDL's vascular functional assays. Atherosclerosis, 2015, 241, 588-594.	0.4	9
689	Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease?. Cardiology, 2015, 131, 225-227.	0.6	14
690	Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough. BMJ Open, 2015, 5, e008678.	0.8	5
691	Hypertriglyceridemia in the Genomic Era: A New Paradigm. Endocrine Reviews, 2015, 36, 131-147.	8.9	118
692	Relation Between Paradoxical Decrease in High-Density Lipoprotein Cholesterol Levels After Statin Therapy and Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction. American Journal of Cardiology, 2015, 115, 411-416.	0.7	10
693	HDL particle number measured on the VanteraÂ®, the first clinical NMR analyzer. Clinical Biochemistry, 2015, 48, 148-155.	0.8	51
694	Effect of pistachio consumption on plasma lipoprotein subclasses in pre-diabetic subjects. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 396-402.	1.1	27
695	Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor. Cardiovascular Research, 2015, 105, 372-382.	1.8	11
696	High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in Japanese men. Atherosclerosis, 2015, 239, 444-450.	0.4	18
698	Sex differences in cardiovascular risk factors and disease prevention. Atherosclerosis, 2015, 241, 211-218.	0.4	399
699	Predictive value of serum apolipoprotein B/apolipoprotein A-I ratio in metabolic syndrome risk: a Chinese cohort study. Endocrine, 2015, 49, 404-414.	1.1	6
700	Cholesterol-Overloaded HDL Particles Are Independently Associated With Progression of Carotid Atherosclerosis in a Cardiovascular Disease-Free Population. Journal of the American College of Cardiology, 2015, 65, 355-363.	1.2	74
701	Effects of high fructose and salt feeding on systematic metabonome probed via ¹H NMR spectroscopy. Magnetic Resonance in Chemistry, 2015, 53, 295-303.	1.1	10
702	Dissecting the proteome of lipoproteins: New biomarkers for cardiovascular diseases?. Translational Proteomics, 2015, 7, 30-39.	1.2	18
703	Early investigational drugs targeting PPAR-Î± for the treatment of metabolic disease. Expert Opinion on Investigational Drugs, 2015, 24, 611-621.	1.9	41

#	Article	IF	Citations
704	Heart Disease and Stroke Statisticsâ€"2015 Update. Circulation, 2015, 131, e29-322.	1.6	5,963
705	High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart, 2015, 101, 356-362.	1.2	39
706	Isolated low-HDL cholesterol in Japanese patients with type 2 diabetes. Diabetology International, 2015, 6, 290-299.	0.7	0
707	A novel compound 4010B-30 upregulates apolipoprotein A-I gene expression through activation of PPARÎ³ in HepG2 cells. Atherosclerosis, 2015, 239, 589-598.	0.4	7
708	Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy. Cardiovascular Drugs and Therapy, 2015, 29, 41-50.	1.3	16
709	Association of apolipoprotein B, LDL-C and vascular stiffness in adolescents with type 1 diabetes. Acta Diabetologica, 2015, 52, 611-619.	1.2	12
710	Contributions of risk factors and medical care to cardiovascular mortality trends. Nature Reviews Cardiology, 2015, 12, 508-530.	6.1	243
711	New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E177-E190.	1.8	38
712	Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. Vascular Pharmacology, 2015, 74, 80-86.	1.0	9
713	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. Circulation, 2015, 132, 423-432.	1.6	24
714	Association between cardiometabolic index and atherosclerotic progression in patients with peripheral arterial disease. Clinica Chimica Acta, 2015, 446, 231-236.	0.5	35
715	Relation of Combined Nonâ€"High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis inÂAdults With Type 1 Diabetes Mellitus. American Journal of Cardiology, 2015, 116, 1057-1062.	0.7	16
716	Vascular function and cardiovascular risk factors in women with severe flushing. Maturitas, 2015, 80, 379-383.	1.0	17
717	The evolving role of CETP inhibition: beyond HDL cholesterol. Lancet, The, 2015, 386, 412-414.	6.3	11
718	Metabolic alterations, HFE gene mutations and atherogenic lipoprotein modifications in patients with primary iron overload. Clinical Science, 2015, 128, 609-618.	1.8	7
719	LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?. Current Cardiology Reports, 2015, 17, 610.	1.3	11
720	Use of Lipoprotein Particle Measures for Assessing Coronary Heart Disease Risk Post-American Heart Association/American College of Cardiology Guidelines. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 448-454.	1.1	29
721	Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3. Drug Design, Development and Therapy, 2015, 9, 2129.	2.0	12

#	Article	IF	Citations
722	La mayor adherencia a un patrÃ³n de dieta mediterrÃ¡nea se asocia a una mejora del perfil lipÃdico plasmÃ¡tico: la cohorte del Aragon Health Workers Study. Revista Espanola De Cardiologia, 2015, 68, 290-297.	0.6	46
723	LDL cholesterol still a problem in old age? A Mendelian randomization study. International Journal of Epidemiology, 2015, 44, 604-612.	0.9	42
724	Genome-Wide Linkage and Positional Association Analyses Identify Associations of Novel AFF3 and NTM Genes with Triglycerides: The GenSalt Study. Journal of Genetics and Genomics, 2015, 42, 107-117.	1.7	13
725	Genetic Risk Factors and Mendelian Randomization in Cardiovascular Disease. Current Cardiology Reports, 2015, 17, 33.	1.3	11
726	High-density lipoproteins at the interface between central nervous system and plasma lipoprotein metabolism. Clinical Lipidology, 2015, 10, 69-81.	0.4	2
727	Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia. Journal of Clinical Lipidology, 2015, 9, 360-367.	0.6	22
728	A dose-response study of consuming high-fructose corn syrupâ€“sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. American Journal of Clinical Nutrition, 2015, 101, 1144-1154.	2.2	214
729	The mechanism by which moderate alcohol consumption influences coronary heart disease. Nutrition Journal, 2015, 14, 33.	1.5	31
730	How do high glycemic load diets influence coronary heart disease?. Nutrition and Metabolism, 2015, 12, 6.	1.3	13
731	Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis. Heart, 2015, 101, 847-853.	1.2	15
732	System responses to chronic cold stress probed via¹H NMR spectroscopy in plasma and urine matrices. Molecular BioSystems, 2015, 11, 1425-1433.	2.9	7
733	Hypertriglyceridemia in an outpatient department â€“ Significance as an atherosclerotic risk factor. Atherosclerosis Supplements, 2015, 18, 146-153.	1.2	1
734	Effect of Naturally Random Allocation toÂLower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms inÂNPC1L1, HMGCR, or Both. Journal of the American College of Cardiology, 2015, 65, 1552-1561.	1.2	324
735	Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes and Endocrinology,the, 2015, 3, 243-253.	5.5	115
736	Mendelian randomization of blood lipids for coronary heart disease. European Heart Journal, 2015, 36, 539-550.	1.0	567
737	HDL and Atherothrombotic Vascular Disease. Handbook of Experimental Pharmacology, 2015, 224, 369-403.	0.9	24
738	Dysfunctional HDL: From Structure-Function-Relationships to Biomarkers. Handbook of Experimental Pharmacology, 2015, 224, 337-366.	0.9	45
739	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. Journal of Clinical Lipidology, 2015, 9, 129-169.	0.6	632

#	Article	IF	Citations
740	HDL cholesterol, leptin and interleukin-6 predict high risk coronary anatomy assessed by CT angiography in patients with stable chest pain. Atherosclerosis, 2015, 241, 55-61.	0.4	37
741	Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2015, 191, 138-148.	0.8	39
742	High prevalence of cardiovascular disease in South Asians: Central role for brown adipose tissue?. Critical Reviews in Clinical Laboratory Sciences, 2015, 52, 150-157.	2.7	16
743	Atherosclerosis: Recent trials, new targets and future directions. International Journal of Cardiology, 2015, 192, 72-81.	0.8	28
744	Cholesterol Efflux and Reverse Cholesterol Transport. Handbook of Experimental Pharmacology, 2015, 224, 181-206.	0.9	109
745	Cholesterol-lowering therapy: Old evidence, new guidelines â€“ Which one to follow? A critical appraisal. Atherosclerosis Supplements, 2015, 18, 176-179.	1.2	1
746	Greater Adherence to a Mediterranean Dietary Pattern Is Associated With Improved Plasma Lipid Profile: the Aragon Health Workers Study Cohort. Revista Espanola De Cardiologia (English Ed), 2015, 68, 290-297.	0.4	23
749	Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. European Heart Journal, 2015, 36, 39-50.	1.0	65
750	Apolipoprotein C-III. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 119-125.	1.2	87
751	HDL particle subpopulations: Focus on biological function. BioFactors, 2015, 41, 67-77.	2.6	47
752	Genetically Determined Height and Coronary Artery Disease. New England Journal of Medicine, 2015, 372, 1608-1618.	13.9	220
753	Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Journal of the American College of Cardiology, 2015, 66, 1657-1668.	1.2	389
754	Circulating nonâ€“HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease. Journal of Clinical Lipidology, 2015, 9, 794-800.	0.6	18
755	Nonstatin Low-Density Lipoproteinâ€“Lowering Therapy and Cardiovascular Risk Reductionâ€”Statement From ATVB Council. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2269-2280.	1.1	58
756	The Association of Elevated HDL Levels With Carotid Atherosclerosis in Middle-Aged Women With Untreated Essential Hypertension. Angiology, 2015, 66, 904-910.	0.8	10
757	Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. Journal of Lipid Research, 2015, 56, 2085-2093.	2.0	27
758	HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity. Journal of Lipid Research, 2015, 56, 2002-2009.	2.0	39
759	Intake of grape procyanidins during gestation and lactation impairs reverse cholesterol transport and increases atherogenic risk indexes in adult offspring. Journal of Nutritional Biochemistry, 2015, 26, 1670-1677.	1.9	21

#	Article	IF	Citations
760	Elevated Triglycerides, Atherosclerosis and Adverse Clinical Events. , 2015, , 55-67.		0
761	Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. Journal of Lipid Research, 2015, 56, 703-712.	2.0	73
762	Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ, The, 2015, 351, h3576.	3.0	664
763	Low-density lipoprotein-cholesterol (LDL-C) greater than 100â€‰mg/dL as a quality indicator: locating risk in person, place and time. Journal of Evaluation in Clinical Practice, 2015, 21, 735-739.	0.9	3
764	Identification of the Best Anthropometric Predictors of Serum High- and Low-Density Lipoproteins Using Machine Learning. IEEE Journal of Biomedical and Health Informatics, 2015, 19, 1747-1756.	3.9	13
765	Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy. Current Medical Research and Opinion, 2015, 31, 2273-2285.	0.9	9
766	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrateâ€“statin combination therapy. Atherosclerosis Supplements, 2015, 19, 1-12.	1.2	66
767	Lean-seafood intake reduces cardiovascular lipid risk factors in healthy subjects: results from a randomized controlled trial with a crossover design. American Journal of Clinical Nutrition, 2015, 102, 582-592.	2.2	66
768	Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis. International Journal of Cardiology, 2015, 201, 20-29.	0.8	33
769	Cardiovascular risk assessment and lipid modification: NICE guideline. British Journal of General Practice, 2015, 65, 378-380.	0.7	42
770	Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2015, 42, 1652-1660.	1.0	22
771	Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis, 2015, 241, 539-546.	0.4	60
772	Serum Non-High-Density Lipoprotein Cholesterol Levels and the Incidence of Ischemic Stroke in a Japanese Population. Asia-Pacific Journal of Public Health, 2015, 27, NP535-NP543.	0.4	11
773	New and Emerging Biomarkers in Cardiovascular Disease. Current Diabetes Reports, 2015, 15, 88.	1.7	16
774	Secondary hypertriglyceridemia in children and adolescents. Journal of Clinical Lipidology, 2015, 9, S29-S40.	0.6	27
775	Insights into blood lipids from rare variant discovery. Current Opinion in Genetics and Development, 2015, 33, 25-31.	1.5	4
776	Poultry Femoral Head Separation and Necrosis: A Review. Avian Diseases, 2015, 59, 349-354.	0.4	29
777	Effects of change in high-density lipoprotein cholesterol by statin switching on glucose metabolism and renal function in hypercholesterolemia. Journal of Clinical Lipidology, 2015, 9, 709-715.	0.6	8

#	Article	IF	Citations
778	Myocardial infarction in a 36-year-old man with combined ABCA1 and APOA-1 deficiency. Journal of Clinical Lipidology, 2015, 9, 396-399.	0.6	5
779	Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?. Clinical Therapeutics, 2015, 37, 2716-2731.	1.1	27
780	Hypercholesterolemia Abolishes High-Density Lipoproteinâ€“Related Cardioprotective Effects in the Setting of Myocardial Infarction. Journal of the American College of Cardiology, 2015, 66, 2469-2470.	1.2	33
781	Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(tri (BMS-795311). Journal of Medicinal Chemistry, 2015, 58, 9010-9026.	2.9	11
782	Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials. American Journal of Clinical Nutrition, 2015, 102, 1347-1356.	2.2	265
783	Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and caseâ€“control study. Metabolic Brain Disease, 2015, 30, 1319-1330.	1.4	35
784	Palmitateâ€Stimulated Monocytes Induce Adhesion Molecule Expression in Endothelial Cells via ILâ€1 Signaling Pathway. Journal of Cellular Physiology, 2015, 230, 732-742.	2.0	26
785	Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions. Handbook of Experimental Pharmacology, 2015, 224, 455-482.	0.9	37
786	Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis, 2015, 238, 213-219.	0.4	23
787	Preterm birth and long-term maternal cardiovascular health. Annals of Epidemiology, 2015, 25, 40-45.	0.9	45
788	Inflammation modulation and cardiovascular disease prevention. European Journal of Preventive Cardiology, 2015, 22, 719-733.	0.8	47
789	Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol: Cohort Norway. European Journal of Preventive Cardiology, 2015, 22, 872-881.	0.8	19
790	Ten years cardiovascular risk estimation according to Framingham score and non HDL-cholesterol in blood donors. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2015, 9, 24-27.	1.8	4
791	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysis, 2015, 28, 35-47.	0.7	49
792	Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography. Journal of Thrombosis and Thrombolysis, 2015, 39, 15-22.	1.0	13
793	Exercise training improves high-density lipoprotein-mediated transcription of proangiogenic microRNA in endothelial cells. European Journal of Preventive Cardiology, 2015, 22, 899-903.	0.8	34
794	Advanced Atherogenic Index for the Assessment of Consolidated Lipid Risk in Premature Coronary Artery Disease Patients in India. Journal of Laboratory Physicians, 2016, 8, 077-084.	0.4	5
795	Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond. Archives of Medical Science, 2016, 6, 1302-1307.	0.4	14

#	Article	IF	Citations
796	Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol. Korean Circulation Journal, 2016, 46, 324.	0.7	10
797	Common and Rare Variant Association Study for Plasma Lipids and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2016, 23, 241-256.	0.9	15
798	Role of Conventional Risk Factors in Genetic Susceptibility to Cardiovascular Diseases. , 2016, , 159-176.		0
799	Impact of admission serum total cholesterol level on in-hospital mortality in patients with acute aortic dissection. Pakistan Journal of Medical Sciences, 2016, 32, 939-43.	0.3	5
800	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vascular Health and Risk Management, 2016, 12, 171.	1.0	166
801	Hypertriglyceridemia and Cardiovascular Diseases: Revisited. Korean Circulation Journal, 2016, 46, 135.	0.7	39
802	Genetics of Dyslipidemia. Arquivos Brasileiros De Cardiologia, 2016, 106, 434-8.	0.3	22
803	Hypertriglyceridemia and Cardiovascular Outcomes. American Journal of Therapeutics, 2016, 23, e862-e870.	0.5	6
804	Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say. International Journal of Clinical Practice, 2016, 70, 142-146.	0.8	0
805	HDLs in crises. Current Opinion in Lipidology, 2016, 27, 264-273.	1.2	29
806	The TyG index may predict the development of cardiovascular events. European Journal of Clinical Investigation, 2016, 46, 189-197.	1.7	294
807	Lipidâ€Free Apolipoprotein Aâ€I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio. Journal of the American Heart Association, 2016, 5, .	1.6	19
808	Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. British Journal of Sports Medicine, 2016, 50, 496-504.	3.1	463
809	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	1.5	28
810	The effect of Chinese herbs and its effective components on coronary heart disease through PPARs-PGC1Î± pathway. BMC Complementary and Alternative Medicine, 2016, 16, 514.	3.7	22
812	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
813	Variants inANGPTL4and the Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2303-2306.	13.9	18
814	Associations of genetic variants for adult lipid levels with lipid levels in children. The Generation R Study. Journal of Lipid Research, 2016, 57, 2185-2192.	2.0	9

#	Article	IF	Citations
815	Dyslipidemia and its risk factors among urban middle-aged Iranians: A population-based study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016, 10, 149-156.	1.8	22
816	Clinical significance of serum apolipoproteins as a predictor of coronary heart disease risk in Korean men. Clinical Endocrinology, 2016, 84, 63-71.	1.2	4
817	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. Journal of the American College of Cardiology, 2016, 67, 2578-2589.	1.2	723
818	Emerging Risk Factors for Stroke. Stroke, 2016, 47, 1673-1678.	1.0	21
819	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpointsâ€"A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry, 2016, 62, 930-946.	1.5	145
820	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37, 2315-2381.	1.0	5,370
821	Nonâ€"high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf. Journal of Clinical Lipidology, 2016, 10, 368-377.	0.6	14
822	Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. Current Cardiology Reports, 2016, 18, 65.	1.3	13
823	Relationship between serum triglyceride levels and endothelial function in a large community-based study. Atherosclerosis, 2016, 249, 70-75.	0.4	36
824	VariantASGR1Associated with a Reduced Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 374, 2131-2141.	13.9	137
825	Cholesterol Efflux Capacity. Journal of the American College of Cardiology, 2016, 67, 2488-2491.	1.2	5
826	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nature Reviews Endocrinology, 2016, 12, 467-484.	4.3	28
827	Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. Translational Research, 2016, 173, 30-57.	2.2	75
828	Scavenger receptor class B1 â€" a target to reduce CHD risk?. Nature Reviews Cardiology, 2016, 13, 249-250.	6.1	0
829	Diabetes Dyslipidemia. Diabetes Therapy, 2016, 7, 203-219.	1.2	259
830	Biochemistry of Statins. Advances in Clinical Chemistry, 2016, 73, 127-168.	1.8	38
831	Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy. Journal of Clinical Lipidology, 2016, 10, 116-123.	0.6	3
832	Association between Lp (a) and atherosclerosis in menopausal women without metabolic syndrome. Biomarkers in Medicine, 2016, 10, 397-402.	0.6	20

#	Article	IF	Citations
833	Nonfasting for Routine Lipid Testing. JAMA Internal Medicine, 2016, 176, 1005.	2.6	38
834	Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature Genetics, 2016, 48, 634-639.	9.4	214
835	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association, 2016, 5, .	1.6	121
836	Serum Calcium Increase Correlates With Worsening of Lipid Profile. Medicine (United States), 2016, 95, e2774.	0.4	28
837	Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases â€“ Some answers and still many questions. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 370-378.	2.7	41
838	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 2016, 253, 281-344.	0.4	1,189
839	Commentary: Nonfasting remnant cholesterol simplifies triglyceride-rich lipoproteins for clinical use, and metabolomic phenotyping ignites scientific curiosity. International Journal of Epidemiology, 2016, 45, 1379-1385.	0.9	4
840	Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. Journal of Clinical Lipidology, 2016, 10, 1137-1144.e3.	0.6	26
841	Is High-Density Lipoprotein Cholesterol Causally Related to Kidney Function?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2252-2258.	1.1	21
842	Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes. Cardiovascular Diabetology, 2016, 15, 137.	2.7	25
843	High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study. Archives of Cardiovascular Diseases, 2016, 109, 607-617.	0.7	7
844	Utility of high density lipoprotein particle concentration in predicting future major adverse cardiovascular events among patients undergoing angiography. Clinical Biochemistry, 2016, 49, 1122-1126.	0.8	8
846	The TromsÃ¸ study 1974â€“2016: 40 years of cardiovascular research. Scandinavian Cardiovascular Journal, 2016, 50, 276-281.	0.4	25
847	Disentangling the Causal Association of Plasma Lipid Traits and Type 2 Diabetes Using Human Genetics. JAMA Cardiology, 2016, 1, 631.	3.0	3
848	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. Journal of Clinical Lipidology, 2016, 10, 1248-1258.	0.6	29
849	Cholesterol Guidelines: More Similar Than Different. Progress in Cardiovascular Diseases, 2016, 59, 190-199.	1.6	2
850	Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology, 2016, 40, 304-314.	0.6	4,142
851	High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training. Integrative Medicine Research, 2016, 5, 212-215.	0.7	49

#	Article	IF	Citations
852	Low-Density Lipoprotein Cholesterol, Nonâ€“High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease. American Journal of Cardiology, 2016, 118, 804-810.	0.7	23
853	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	1.0	2,393
854	Interaction Between Peroxisome Proliferator Activated Receptor Î´ and Epithelial Membrane Protein 2 Polymorphisms Influences HDLâ€C Levels in the Chinese Population. Annals of Human Genetics, 2016, 80, 282-293.	0.3	1
855	Non-HDL Cholesterol and Triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2220-2228.	1.1	119
856	Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia. JAMA - Journal of the American Medical Association, 2016, 316, 634.	3.8	75
857	Hypertension Canadaâ€™s 2016 Canadian Hypertension Education Program guidelines for pharmacists. Canadian Pharmacists Journal, 2016, 149, 337-344.	0.4	6
859	Traditional Cardiovascular Risk Factors for Incident Atrial Fibrillation. Circulation Journal, 2016, 80, 2415-2422.	0.7	22
860	Non-HDL-C is a Better Predictor for the Severity of Coronary Atherosclerosis Compared with LDL-C. Heart Lung and Circulation, 2016, 25, 975-981.	0.2	43
861	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.4	415
862	Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, The, 2016, 388, 2532-2561.	6.3	1,399
863	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	0.8	775
864	Relationship of non-cardiac biomarkers with periprocedural myocardial injury in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2016, 221, 726-733.	0.8	5
865	Drug-loaded particles: â€œTrojan horsesâ€•in the therapy of atherosclerosis. Atherosclerosis, 2016, 251, 528-530.	0.4	3
866	Serum levels of Lp(a) are related to waist circumference in NAFLD patients with low prevalence of co-morbidities. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 544-552.	0.6	3
867	Cholesteryl ester transfer protein (CETP) I405V polymorphism and cardiovascular disease in eastern European Caucasians â€“ a cross-sectional study. BMC Geriatrics, 2016, 16, 144.	1.1	9
868	Loss of Transcription Factor CREBH Accelerates Diet-Induced Atherosclerosis in Ldlr ^{â^'/â^'} Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1772-1781.	1.1	21
869	Impact of Dietary and Metabolic Risk Factors on Cardiovascular and Diabetes Mortality in South Asia: Analysis From the 2010 Global Burden of Disease Study. American Journal of Public Health, 2016, 106, 2113-2125.	1.5	22
871	GW27-e0609 The effect of Chinese herbs and its effective components on coronary heart disease through PPARs-PGC1Î± pathway. Journal of the American College of Cardiology, 2016, 68, C60.	1.2	0

#	Article	IF	Citations
872	An APOC3 3â€²UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site. Scientific Reports, 2016, 6, 32700.	1.6	21
873	Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study. BMC Medicine, 2016, 14, 125.	2.3	24
874	Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2133-2135.	1.1	83
875	Reductions in Atherogenic Lipids and Major Cardiovascular Events. Circulation, 2016, 134, 1931-1943.	1.6	110
876	Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study. Scientific Reports, 2016, 6, 27367.	1.6	53
877	Mind the gap - surviving in the modern world. International Journal of Clinical Practice, 2016, 70, 517-519.	0.8	0
878	Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation. Current Opinion in Lipidology, 2016, 27, 459-472.	1.2	25
879	Using Mendelian Randomization Studies to Assess Causality and Identify New Therapeutic Targets in Cardiovascular Medicine. Current Genetic Medicine Reports, 2016, 4, 207-212.	1.9	4
880	Genetic susceptibility to dyslipidemia and incidence of cardiovascular disease depending on a diet quality index in the MalmÃ¶ Diet and Cancer cohort. Genes and Nutrition, 2016, 11, 20.	1.2	6
881	HDL infusion for the management of atherosclerosis. Current Opinion in Lipidology, 2016, 27, 592-596.	1.2	12
882	Prediction of future development of cardiovascular disease with an equation to estimate apolipoprotein B. Medicine (United States), 2016, 95, e3644.	0.4	7
883	Renal denervation, adjusted drugs, or combined therapy for resistant hypertension. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ove	0.4	9
884	CETP Inhibition: Past Failures and Future Hopes. Clinical Medicine Insights: Cardiology, 2016, 10, CMC.S32667.	0.6	65
885	Comparison between the triglycerides standardization of routine methods used in Japan and the chromotropic acid reference measurement procedure used by the CDC Lipid Standardization Programme. Annals of Clinical Biochemistry, 2016, 53, 632-639.	0.8	22
886	HDL mimetic CER-001 targets atherosclerotic plaques in patients. Atherosclerosis, 2016, 251, 381-388.	0.4	51
887	Association of elevated triglycerides and acute myocardial infarction in young Hispanics. Cardiovascular Revascularization Medicine, 2016, 17, 510-514.	0.3	7
888	Relationship between non-high-density lipoprotein cholesterol and the long-term mortality of cardiovascular diseases: NIPPON DATA 90. International Journal of Cardiology, 2016, 220, 262-267.	0.8	29
889	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-pointsâ€"a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 2016, 37, 1944-1958.	1.0	542

#	Article	IF	Citations
890	The Association Between Air Pollution Exposure and Glucose and Lipids Levels. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2460-2467.	1.8	111
892	Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib. European Journal of Clinical Pharmacology, 2016, 72, 563-572.	0.8	0
893	Severe hypertriglyceridemia does not protect from ischemic brain injury in gene-modified hypertriglyceridemic mice. Brain Research, 2016, 1639, 161-173.	1.1	4
894	HDL functionality in South Asians as compared to white Caucasians. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 697-705.	1.1	13
895	Multiple apolipoprotein kinetics measured in human HDL by high-resolution/accurate mass parallel reaction monitoring. Journal of Lipid Research, 2016, 57, 714-728.	2.0	35
896	Beneficial effects of rice endosperm protein intake in Japanese men with risk factors for metabolic syndrome: a randomized, crossover clinical trial. BMC Nutrition, 2016, 2, .	0.6	3
897	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	0.8	683
898	Design, synthesis and biological evaluation of N,N-3-phenyl-3-benzylaminopropanamide derivatives as novel cholesteryl ester transfer protein inhibitor. Bioorganic and Medicinal Chemistry, 2016, 24, 1589-1597.	1.4	9
899	Heart Disease and Stroke Statisticsâ€"2016 Update. Circulation, 2016, 133, e38-360.	1.6	5,447
900	Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification. Journal of the American College of Cardiology, 2016, 67, 193-201.	1.2	120
901	Niacin: old habits die hard. Heart, 2016, 102, 170-171.	1.2	1
902	Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. Circulation, 2016, 133, 256-264.	1.6	80
903	Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circulation Research, 2016, 118, 579-585.	2.0	131
904	Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study. Indian Heart Journal, 2016, 68, 646-654.	0.2	6
905	A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 23-29.	1.4	61
906	High-density lipoprotein cholesterol on a roller coaster: where will the ride end?. Kidney International, 2016, 89, 747-749.	2.6	12
907	New Era of Lipid-Lowering Drugs. Pharmacological Reviews, 2016, 68, 458-475.	7.1	45
908	Promoting high-density lipoprotein function via intravenous infusion: the rebirth of apoA-I Milano?. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 30-31.	1.4	6

#	Article	IF	Citations
909	Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. Journal of Clinical Lipidology, 2016, 10, 905-914.	0.6	54
910	Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circulation Research, 2016, 118, 535-546.	2.0	936
911	Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis. Atherosclerosis, 2016, 247, 161-169.	0.4	34
912	Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. Circulation Research, 2016, 118, 547-563.	2.0	701
913	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes and Endocrinology,the, 2016, 4, 403-410.	5.5	133
914	New Therapeutic Approaches to the Treatment of Dyslipidemia. Cell Metabolism, 2016, 23, 405-412.	7.2	67
915	Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 285-294.	1.1	17
916	Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 994-1002.	1.1	32
917	Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 817-824.	1.1	61
918	Slippery Slope of Triglycerides. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 97-99.	0.9	4
919	Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2016, 30, 580-585.	1.2	29
920	Pharmacometabolomics Meets Genetics. Journal of the American College of Cardiology, 2016, 67, 1211-1213.	1.2	11
921	Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 100-108.	0.9	138
922	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
923	Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. American Journal of Clinical Nutrition, 2016, 103, 965-978.	2.2	437
924	The High-Density Lipoprotein Puzzle. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 777-782.	1.1	42
925	Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting. Clinical Drug Investigation, 2016, 36, 225-233.	1.1	12
926	Management of residual risk after statin therapy. Atherosclerosis, 2016, 245, 161-170.	0.4	71

#	Article	IF	Citations
927	HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target. Current Atherosclerosis Reports, 2016, 18, 2.	2.0	46
928	Healthy lifestyle and heart rate variability in young adults. European Journal of Preventive Cardiology, 2016, 23, 1037-1044.	0.8	34
929	Itinerary of high density lipoproteins in endothelial cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 98-107.	1.2	19
930	Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation. Vascular Pharmacology, 2016, 82, 1-10.	1.0	38
931	Serum Lipoproteins Are Critical for Pulmonary Innate Defense against Staphylococcus aureus Quorum Sensing. Journal of Immunology, 2016, 196, 328-335.	0.4	21
932	Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer and Prostatic Diseases, 2016, 19, 57-62.	2.0	35
933	Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 156-165.	1.1	69
934	Monocyte adhesion to the endothelium is an initial stage of atherosclerosis development. Cor Et Vasa, 2016, 58, e419-e425.	0.1	79
935	ESR1 polymorphisms and statin therapy: a sex-specific approach. Pharmacogenomics Journal, 2016, 16, 507-513.	0.9	14
936	Association of Cholesteryl Ester Transfer Protein and Endothelial Nitric Oxide Synthase Gene Polymorphisms With Coronary Artery Disease in the Multi-Ethnic Malaysian Population. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 581-588.	0.7	4
937	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. European Journal of Preventive Cardiology, 2016, 23, 474-485.	0.8	12
938	Serum Lipid Levels in Pseudoexfoliation Syndrome. Seminars in Ophthalmology, 2017, 32, 281-284.	0.8	9
939	A New Predictor for Obstructive Sleep Apnea Syndrome: Monocyte to HDL Ratio. Indian Journal of Otolaryngology and Head and Neck Surgery, 2017, 69, 142-146.	0.3	10
940	Associations between hypo-HDL cholesterolemia and cardiometabolic risk factors in middle-aged men and women: Independence of habitual alcohol drinking, smoking and regular exercise. Obesity Research and Clinical Practice, 2017, 11, 324-334.	0.8	4
941	Effects of Neuroprotectants Before and After Stroke: Statins and Anti-hypertensives. Springer Series in Translational Stroke Research, 2017, , 349-399.	0.1	3
942	Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy. Canadian Journal of Cardiology, 2017, 33, 872-882.	0.8	34
943	Cerebral disease in a nationwide Dutch pseudoxanthoma elasticum cohort with a systematic review of the literature. Journal of the Neurological Sciences, 2017, 373, 167-172.	0.3	26
944	Biomarkers of Calcific Aortic Valve Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 623-632.	1.1	63

#	Article	IF	Citations
945	Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease. Lipids in Health and Disease, 2017, 16, 7.	1.2	22
946	Usefulness of Nonâ€“High-Density Lipoprotein Cholesterol as a Predictor of Cardiovascular Disease Mortality in Men in 22-Year Follow-Up. American Journal of Cardiology, 2017, 119, 1193-1198.	0.7	36
947	Short-term, high-fat overfeeding impairs glycaemic control but does not alter gut hormone responses to a mixed meal tolerance test in healthy, normal-weight individuals. British Journal of Nutrition, 2017, 117, 48-55.	1.2	31
948	Heart Disease and Stroke Statisticsâ€”2017 Update: A Report From the American Heart Association. Circulation, 2017, 135, e146-e603.	1.6	7,085
949	Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. Diabetes Care, 2017, 40, 529-537.	4.3	224
950	Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias. Revista Espanola De Cardiologia (English Ed), 2017, 70, 72-77.	0.4	5
951	High-density lipoproteins and adrenal steroidogenesis: A population-based study. Journal of Clinical Lipidology, 2017, 11, 469-476.	0.6	5
952	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Current Cardiology Reports, 2017, 19, 19.	1.3	19
953	Optical Properties of Europium Tetracycline Complexes in the Presence of High-Density Lipoproteins (HDL) Subfractions. Applied Spectroscopy, 2017, 71, 1560-1567.	1.2	0
954	Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study. BMJ Open Diabetes Research and Care, 2017, 5, e000335.	1.2	16
956	Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)â€”A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. American Heart Journal, 2017, 187, 182-190.	1.2	66
958	â€˜Mendelian randomizationâ€™: an approach for exploring causal relations in epidemiology. Public Health, 2017, 145, 113-119.	1.4	59
959	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. Journal of Diabetes and Its Complications, 2017, 31, 918-927.	1.2	72
960	Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology, 2017, 6, 8-16.	0.8	109
961	Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. European Heart Journal, 2017, 38, 2478-2486.	1.0	447
962	Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in Blacks. Journal of the American Heart Association, 2017, 6, .	1.6	9
963	Increasing HDL-C levels with medication. Current Opinion in Lipidology, 2017, 28, 361-366.	1.2	12
964	High density lipoprotein from coronary artery disease patients caused abnormal expression of long non-coding RNAs in vascular endothelial cells. Biochemical and Biophysical Research Communications, 2017, 487, 552-559.	1.0	13

#	Article	IF	Citations
965	Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor Î± modulator (SPPARMÎ±), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis, 2017, 261, 144-152.	0.4	101
966	A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist. European Journal of Internal Medicine, 2017, 41, 10-17.	1.0	14
967	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1206-1212.	1.1	56
968	Meta-analysis of serum non-high-density lipoprotein cholesterol and risk of coronary heart disease in the general population. Clinica Chimica Acta, 2017, 471, 23-28.	0.5	17
969	The Role of Emerging Risk Factors in Cardiovascular Outcomes. Current Atherosclerosis Reports, 2017, 19, 28.	2.0	43
970	Do triglyceride-lowering drugs decrease risk of cardiovascular disease?. Current Opinion in Lipidology, 2017, 28, 374-379.	1.2	12
971	The CHADS 2 and CHA 2 DS 2 -VASc scores predict atrial fibrillation in dyslipidemic individuals: Role of incorporating low high-density lipoprotein cholesterol levels. International Journal of Cardiology, 2017, 241, 194-199.	0.8	20
972	Human genetic insights into lipoproteins and risk of cardiometabolic disease. Current Opinion in Lipidology, 2017, 28, 113-119.	1.2	12
973	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation, 2017, 136, e1-e23.	1.6	884
974	Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk. American Journal of Epidemiology, 2017, 186, 736-744.	1.6	28
975	HDL cholesterol concentration or HDL function: which matters?. European Heart Journal, 2017, 38, 2487-2489.	1.0	31
976	Effect of a Diet Enriched with Fresh Coconut Saturated Fats on Plasma Lipids and Erythrocyte Fatty Acid Composition in Normal Adults. Journal of the American College of Nutrition, 2017, 36, 330-334.	1.1	10
977	Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice. European Journal of Preventive Cardiology, 2017, 24, 71-76.	0.8	15
978	Lipid levels and risk of venous thrombosis: results from the MEGA-study. European Journal of Epidemiology, 2017, 32, 669-681.	2.5	35
979	High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: A potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein. Journal of Clinical Lipidology, 2017, 11, 1043-1054.e2.	0.6	35
980	Downregulation of cholesteryl ester transfer protein by glucocorticoids: a randomised study on <scp>HDL</scp>. European Journal of Clinical Investigation, 2017, 47, 494-503.	1.7	15
981	Comprehensive qualification and quantification of triacylglycerols with specific fatty acid chain composition in horse adipose tissue, human plasma and liver tissue. Talanta, 2017, 172, 206-214.	2.9	17
982	Triglycerides Revisited to the Serial. Advances in Clinical Chemistry, 2017, 80, 1-44.	1.8	7

#	Article	IF	Citations
983	New perspectives on biological HDL-targeted therapies. Expert Opinion on Biological Therapy, 2017, 17, 793-796.	1.4	8
984	Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia. Pediatric Infectious Disease Journal, 2017, 36, 53-60.	1.1	9
985	Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nature Reviews Cardiology, 2017, 14, 577-590.	6.1	443
987	Lipid control in patients with coronary artery disease in a healthcare area in CÃ¡ceres (Spain): LIPICERES study. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2017, 29, 13-19.	0.1	0
989	Recent trends in epidemiology of dyslipidemias in India. Indian Heart Journal, 2017, 69, 382-392.	0.2	85
990	Triglycerides: A reappraisal. Trends in Cardiovascular Medicine, 2017, 27, 428-432.	2.3	12
991	Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III. Journal of Lipid Research, 2017, 58, 1196-1203.	2.0	16
992	Associations between dietary patterns and serum lipids, apo and C-reactive protein in an adult population: evidence from a multi-city cohort in South America. British Journal of Nutrition, 2017, 117, 548-555.	1.2	29
993	Association of very Low-density Lipoprotein Cholesterol with All-cause and Cardiovascular Mortality in Peritoneal Dialysis. Kidney and Blood Pressure Research, 2017, 42, 52-61.	0.9	14
994	Association of the FADS gene cluster with coronary artery disease and plasma lipid concentrations in the northern Chinese Han population. Prostaglandins Leukotrienes and Essential Fatty Acids, 2017, 117, 11-16.	1.0	8
995	HDL cholesterol: reappraisal of its clinical relevance. Clinical Research in Cardiology, 2017, 106, 663-675.	1.5	186
996	The polymorphic <scp>CAG</scp> repeat in exon 1 of androgen receptor is associated with level of <scp>HDL</scp> cholesterol and hypertension in Chinese middleâ€aged and elderly men. Clinical Endocrinology, 2017, 87, 29-34.	1.2	1
997	Hypertriglyceridaemia and risk of coronary artery disease. Nature Reviews Cardiology, 2017, 14, 401-411.	6.1	257
998	2016 European Guidelines on cardiovascular disease prevention in clinical practice. International Journal of Behavioral Medicine, 2017, 24, 321-419.	0.8	84
999	Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography. Journal of Clinical Lipidology, 2017, 11, 646-656.	0.6	14
1000	Serum Levels of Apolipoproteins and Incident Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care, 2017, 40, 346-351.	4.3	40
1001	The Changing Face of HDL and the Best Way to Measure It. Clinical Chemistry, 2017, 63, 196-210.	1.5	86
1002	Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. Journal of Human Genetics, 2017, 62, 453-458.	1.1	15

#	Article	IF	Citations
1003	Lipoprotein profiling methodology based on determination of apolipoprotein concentration. Bioanalysis, 2017, 9, 9-19.	0.6	2
1004	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. Advances in Therapy, 2017, 34, 300-323.	1.3	37
1005	Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/RÂ+ÂDasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infectious Diseases and Therapy, 2017, 6, 515-529.	1.8	28
1006	Extending the MRâ€Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy. Statistics in Medicine, 2017, 36, 4705-4718.	0.8	261
1007	Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study. Journal of Clinical Lipidology, 2017, 11, 1458-1470.e4.	0.6	14
1008	Association between modifiable lifestyle and the prevalence of atrial fibrillation in a Chinese population: Based on the cardiovascular health score. Clinical Cardiology, 2017, 40, 1061-1067.	0.7	18
1009	Association between plant-based diets and plasma lipids: a systematic review and meta-analysis. Nutrition Reviews, 2017, 75, 683-698.	2.6	230
1010	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine, 2017, 377, 1217-1227.	13.9	780
1011	Macronutrients and cardiovascular risk in a global context. Lancet Diabetes and Endocrinology,the, 2017, 5, 758-759.	5.5	3
1012	Economic insecurity during the Great Recession and metabolic, inflammatory and liver function biomarkers: analysis of the UK Household Longitudinal Study. Journal of Epidemiology and Community Health, 2017, 71, 1005-1013.	2.0	16
1013	A Test in Context: Lipid Profile, FastingÂVersus Nonfasting. Journal of the American College of Cardiology, 2017, 70, 1637-1646.	1.2	145
1014	Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 3038-3048.	1.8	14
1015	Association of high-density lipoprotein cholesterol concentration with different types of stroke and coronary heart disease: The Japan Public Health Center-based prospective (JPHC) study. Atherosclerosis, 2017, 265, 147-154.	0.4	43
1016	Dyslipidemia. Physician Assistant Clinics, 2017, 2, 633-650.	0.1	3
1017	Effects of Low-density Lipoprotein Cholesterol on Coronary Artery Calcification Progression According to High-density Lipoprotein Cholesterol Levels. Archives of Medical Research, 2017, 48, 284-291.	1.5	5
1018	Impact of physical activity on the association between lipid profiles and mortality among older people. Scientific Reports, 2017, 7, 8399.	1.6	21
1019	Alirocumab Treatment and Achievement of Nonâ€Highâ€Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. Journal of the American Heart Association, 2017, 6, .	1.6	14
1020	Prevalence and risk factors associated with stroke in middle-aged and older Chinese: A community-based cross-sectional study. Scientific Reports, 2017, 7, 9501.	1.6	26

#	Article	IF	Citations
1021	Effects of Myricetinâ€Containing Ethanol Solution on Highâ€Fat Diet Induced Obese Rats. Journal of Food Science, 2017, 82, 1947-1952.	1.5	10
1022	Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Alimentary Pharmacology and Therapeutics, 2017, 46, 599-604.	1.9	42
1023	Apolipoprotein B is associated with carotid atherosclerosis progression independent of individual cholesterol measures in a 9-year prospective study of Multi-Ethnic Study of Atherosclerosis participants. Journal of Clinical Lipidology, 2017, 11, 1181-1191.e1.	0.6	21
1024	ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Scientific Reports, 2017, 7, 2312.	1.6	47
1025	Stress, Religious Involvement, and Cholesterol: Is It Better to Give than to Receive?. Journal of Applied Biobehavioral Research, 2017, 22, e12064.	2.0	1
1026	Association of Highâ€Density Lipoproteinâ€Cholesterol Versus Apolipoprotein Aâ€I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancerâ€Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. Journal of the American Heart Association, 2017, 6, .	1.6	13
1029	How cholesteryl ester transfer protein can also be a potential triglyceride transporter. Scientific Reports, 2017, 7, 6159.	1.6	9
1030	Statin Effects on Metabolic Profiles. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	18
1031	ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. Current Atherosclerosis Reports, 2017, 19, 62.	2.0	41
1032	HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics. Current Cardiology Reports, 2017, 19, 132.	1.3	85
1033	Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia. Current Opinion in Lipidology, 2017, 28, 427-433.	1.2	7
1034	Coffee Drinking and Mortality in 10 European Countries. Annals of Internal Medicine, 2017, 167, 236-247.	2.0	168
1035	Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. Current Cardiology Reports, 2017, 19, 61.	1.3	12
1036	Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?. Diabetology and Metabolic Syndrome, 2017, 9, 22.	1.2	46
1037	Association between high-density lipoprotein-cholesterol and hypertension in relation to circulating CD34-positive cell levels. Journal of Physiological Anthropology, 2017, 36, 26.	1.0	24
1038	Atherosclerosis. Advances in Experimental Medicine and Biology, 2017, 1003, 121-144.	0.8	61
1039	Assessment of the Validity and Reproducibility of a Novel Standardized Test Meal for the Study of Postprandial Triacylglycerol Concentrations. Lipids, 2017, 52, 675-686.	0.7	13
1040	Role of Niacin in Current Clinical Practice: A Systematic Review. American Journal of Medicine, 2017, 130, 173-187.	0.6	66

#	Article	IF	Citations
1041	Sex-specific incidence rates and risk factors of premature cardiovascular disease. A long term follow up of the Tehran Lipid and Glucose Study. International Journal of Cardiology, 2017, 227, 826-832.	0.8	31
1042	Plaque imaging to refine indications for emerging lipid-lowering drugs. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 58-67.	1.4	26
1044	High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. Canadian Journal of Cardiology, 2017, 33, 325-333.	0.8	41
1045	Prognostic value of non-high-density lipoprotein cholesterol for mortality in patients with coronary heart disease: A systematic review and meta-analysis. International Journal of Cardiology, 2017, 227, 950-955.	0.8	22
1046	Cholesteryl Ester Transfer Protein Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 99-104.	1.0	11
1047	Improvement of Highâ€Ðensity Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. Arthritis and Rheumatology, 2017, 69, 46-57.	2.9	48
1048	Atherogenic index of plasma may be strong predictor of subclinical atherosclerosis in patients with BehÃ§et disease. Zeitschrift Fur Rheumatologie, 2017, 76, 259-266.	0.5	27
1049	The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Report, 2017, 22, 51-73.	1.4	154
1050	Association of high-density lipoprotein cholesterol with non-fatal cardiac and non-cardiac events: a CANHEART substudy. Open Heart, 2017, 4, e000731.	0.9	3
1051	Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPICâ€“Heidelberg cohort. BMC Medicine, 2017, 15, 218.	2.3	78
1052	Risk Factors. , 2017, , 383-392.		0
1053	The integrated effect of moderate exercise on coronary heart disease. Cardiovascular Journal of Africa, 2017, 28, 125-133.	0.2	4
1054	Obesity and Anesthesia Management. , 0, , .		3
1055	Review: Biomarkers and Role in the Prediction and Detection of Type 2 Diabetes and Its Complications. Biomarkers Journal, 2017, 3, .	0.2	2
1056	Economic insecurity during the Great Recession and metabolic, inflammatory and liver function biomarkers: analysis of the UK Household Longitudinal Study. Journal of Epidemiology and Community Health, 2017, 71, 1005-1013.	2.0	14
1057	Stable ischemic heart disease in women: current perspectives. International Journal of Women's Health, 2017, Volume 9, 701-709.	1.1	7
1058	Determination of Sphingosine-1-Phosphate in Human Plasma Using Liquid Chromatography Coupled with Q-Tof Mass Spectrometry. International Journal of Molecular Sciences, 2017, 18, 1800.	1.8	9
1059	Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics. International Journal of Molecular Sciences, 2017, 18, 2550.	1.8	73

#	Article	IF	Citations
1060	Design, Synthesis and Biological Evaluation of N,N-Substituted Amine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors. Molecules, 2017, 22, 1658.	1.7	1
1061	Transglycosylated Starch Improves Insulin Response and Alters Lipid and Amino Acid Metabolome in a Growing Pig Model. Nutrients, 2017, 9, 291.	1.7	18
1062	Vitamin D Deficiency: A Potential Modifiable Risk Factor for Cardiovascular Disease in Children with Severe Obesity. Children, 2017, 4, 80.	0.6	14
1063	Apolipoprotein C-I Polymorphism and Its Association with Serum Lipid Levels and Longevity in the Bama Population. International Journal of Environmental Research and Public Health, 2017, 14, 505.	1.2	4
1064	Daily Consumption of Virgin Coconut Oil Increases High-Density Lipoprotein Cholesterol Levels in Healthy Volunteers: A Randomized Crossover Trial. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-8.	0.5	36
1065	Association between Knowledge-Attitude-Practices and Control of Blood Glucose, Blood Pressure, and Blood Lipids in Patients with Type 2 Diabetes in Shanghai, China: A Cross-Sectional Study. Journal of Diabetes Research, 2017, 2017, 1-9.	1.0	15
1066	Sphingosine-1-Phosphate and HDL Metabolism. , 2017, , 153-170.		1
1067	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.4	70
1068	Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 yearsâ€"The Australian Positive & Peers Longevity Evaluation Study (APPLES). PLoS ONE, 2017, 12, e0184583.	1.1	28
1069	The association between the apolipoprotein B/A-I ratio and coronary calcification may differ depending on kidney function in a healthy population. PLoS ONE, 2017, 12, e0185522.	1.1	8
1070	MicroRNA Regulation of HDL Homeostasis. , 2017, , 209-229.		0
1071	Etiologic effects and optimal intakes of foods and nutrients for risk of cardiovascular diseases and diabetes: Systematic reviews and meta-analyses from the Nutrition and Chronic Diseases Expert Group (NutriCoDE). PLoS ONE, 2017, 12, e0175149.	1.1	287
1072	Childhood obesity and adult cardiovascular disease risk factors: a systematic review with meta-analysis. BMC Public Health, 2017, 17, 683.	1.2	347
1073	The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovascular Diabetology, 2017, 16, 132.	2.7	71
1074	The 23-year tracking of blood lipids from adolescence to adulthood in Korea: the Kangwha study. Lipids in Health and Disease, 2017, 16, 221.	1.2	14
1075	High-density lipoproteins suppress AÎ²-induced PBMC adhesion to human endothelial cells in bioengineered vessels and in monoculture. Molecular Neurodegeneration, 2017, 12, 60.	4.4	35
1076	Association between high-density lipoprotein cholesterol level and pulmonary function in healthy Korean adolescents: the JS high school study. BMC Pulmonary Medicine, 2017, 17, 190.	0.8	11
1078	Early markers of cardiovascular disease are associated with occupational exposure to polycyclic aromatic hydrocarbons. Scientific Reports, 2017, 7, 9426.	1.6	71

#	Article	IF	Citations
1079	Lipid Lowering Therapy to Modify Plaque Microstructures:. Journal of Atherosclerosis and Thrombosis, 2017, 24, 360-372.	0.9	7
1081	ASSOCIATION OF LIPID FRACTIONS LEVELS WITH CARDIOVASCULAR DISEASE. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10, 180.	0.3	2
1082	Potential Association of Triglyceride Glucose Index with Cardiac Autonomic Neuropathy in Type 2 Diabetes Mellitus Patients. Journal of Korean Medical Science, 2017, 32, 1131.	1.1	10
1083	Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis. Archives of Medical Science, 2017, 1, 210-214.	0.4	4
1084	Cholesterol and Lipids. , 2017, , 9-21.		0
1085	Circulating miRNA-21 is a promising biomarker for heart failure. Molecular Medicine Reports, 2017, 16, 7766-7774.	1.1	55
1086	Cholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances in Reverse Cholesterol Transport. Annals of Hepatology, 2017, 16, S27-S42.	0.6	172
1087	Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?. Current Atherosclerosis Reports, 2018, 20, 14.	2.0	11
1088	Is It Time for New Thinking About High-Density Lipoprotein?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 484-486.	1.1	21
1089	HDL in CKDâ€"The Devil Is in the Detail. Journal of the American Society of Nephrology: JASN, 2018, 29, 1356-1371.	3.0	65
1090	Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease. Heart, 2018, 104, 1455-1460.	1.2	23
1091	Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease. European Heart Journal, 2018, 39, 2172-2178.	1.0	53
1092	High-Density Lipoproteins. Cardiology Clinics, 2018, 36, 317-327.	0.9	14
1093	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 2018, 138, 770-781.	1.6	126
1094	Preventive Cardiology. , 2018, , 269-289.		0
1095	Reprint of: Proteomics in cardiovascular diseases: Unveiling sex and gender differences in the era of precision medicine. Journal of Proteomics, 2018, 178, 57-72.	1.2	9
1096	Risk of major adverse cardiovascular events in subjects with asymptomatic mild carotid artery stenosis. Scientific Reports, 2018, 8, 4700.	1.6	22
1097	Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599â€ˆ912 current drinkers in 83 prospective studies. Lancet, The, 2018, 391, 1513-1523.	6.3	858

#	Article	IF	Citations
1098	Colesterol no-HDL como marcador de riesgo y objetivo terapÃ©utico. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 72-73.	0.4	0
1099	Insights from population-based analyses of plasma lipids across the allele frequency spectrum. Current Opinion in Genetics and Development, 2018, 50, 1-6.	1.5	9
1100	Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. European Heart Journal, 2018, 39, 354-359.	1.0	43
1101	Genetics, Lifestyle, and Low-Density Lipoprotein Cholesterol in Young and Apparently Healthy Women. Circulation, 2018, 137, 820-831.	1.6	30
1102	Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. Journal of Clinical Lipidology, 2018, 12, 488-497.	0.6	15
1103	Oral Delivery of Highly Lipophilic, Poorly Water-Soluble Drugs: Self-Emulsifying Drug Delivery Systems to Improve Oral AbsorptionÂand Enable High-Dose Toxicology Studies of a CholesterylÂEster Transfer Protein Inhibitor in Preclinical Species. Journal of Pharmaceutical Sciences, 2018, 107, 1352-1360.	1.6	14
1104	Challenges in Interpreting Multivariable Mendelian Randomization: Might â€œGood Cholesterolâ€•Be Good After All?. American Journal of Kidney Diseases, 2018, 71, 149-153.	2.1	15
1105	Update on the laboratory investigation of dyslipidemias. Clinica Chimica Acta, 2018, 479, 103-125.	0.5	38
1106	Lipids, Lipoproteins, and Metabolites andÂRisk of Myocardial Infarction andÂStroke. Journal of the American College of Cardiology, 2018, 71, 620-632.	1.2	294
1107	A rare missense variant in NR1H4 associates with lower cholesterol levels. Communications Biology, 2018, 1, 14.	2.0	6
1108	From High-Density Lipoprotein Cholesterol to Measurements of Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 487-499.	1.1	94
1109	Persistently high psychological well-being predicts better HDL cholesterol and triglyceride levels: findings from the midlife in the U.S. (MIDUS) longitudinal study. Lipids in Health and Disease, 2018, 17, 1.	1.2	126
1110	Heart Disease and Stroke Statisticsâ€”2018 Update: A Report From the American Heart Association. Circulation, 2018, 137, e67-e492.	1.6	5,228
1111	Causal associations between risk factors and common diseases inferred from GWAS summary data. Nature Communications, 2018, 9, 224.	5.8	629
1112	Paraoxonase-1 is a better indicator than HDL of Atherosclerosis â€“ A pilot study in North Indian population. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 275-278.	1.8	8
1113	HDL-C, ApoA1 and VLDL-TG as biomarkers for the carotid plaque presence in patients with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 175-179.	1.8	13
1114	Maternal lipid profile 6 years after a gestational hypertensive disorder. Journal of Clinical Lipidology, 2018, 12, 428-436.e4.	0.6	11
1115	Modified risk associations of lipoproteins and apolipoproteins by chronic low-grade inflammation. Expert Review of Cardiovascular Therapy, 2018, 16, 39-48.	0.6	4

#	Article	IF	Citations
1116	A randomized study of dietary composition during weight-loss maintenance: Rationale, study design, intervention, and assessment. Contemporary Clinical Trials, 2018, 65, 76-86.	0.8	12
1117	Discordance between lipoprotein particle number and cholesterol content: an update. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 130-136.	1.2	32
1118	Hypothetical interventions to prevent stroke: an application of the parametric g-formula to a healthy middle-aged population. European Journal of Epidemiology, 2018, 33, 557-566.	2.5	14
1119	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs, 2018, 78, 215-229.	4.9	33
1120	High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals. Atherosclerosis, 2018, 269, 92-99.	0.4	11
1121	Association between triglyceride glucose index and arterial stiffness in Korean adults. Cardiovascular Diabetology, 2018, 17, 41.	2.7	169
1122	Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia. Circulation Journal, 2018, 82, 1387-1395.	0.7	8
1123	Pharmacogenomics of blood lipid regulation. Pharmacogenomics, 2018, 19, 651-665.	0.6	3
1124	Rational application of macrophage-specific LXR agonists avoids the pitfalls of SREBP-induced lipogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5051-5053.	3.3	9
1125	Control of serum triglyceride levels by the apolipoprotein C3 gene and its relationship to cardiovascular disease. Current Opinion in Lipidology, 2018, 29, 271-272.	1.2	2
1126	Clinical features and outcomes of severe, very severe, and extreme hypertriglyceridemia in a regional health service. Journal of Clinical Lipidology, 2018, 12, 928-936.	0.6	23
1127	Non-HDL-C goals based on the distribution of population percentiles in ELSA-Brasil: Is it time to change?. Atherosclerosis, 2018, 274, 243-250.	0.4	5
1128	New antihyperglycaemic agents and cardiovascular disease. Current Opinion in Cardiology, 2018, 33, 444-454.	0.8	4
1129	Lipids and Lipoproteins in Risk Prediction. Cardiology Clinics, 2018, 36, 213-220.	0.9	7
1130	The Pros and Cons of Mendelian Randomization Studies to Evaluate Emerging Cardiovascular Risk Factors. Current Cardiovascular Risk Reports, 2018, 12, 1.	0.8	1
1131	Loss of LCAT activity in the golden Syrian hamster elicits pro-atherogenic dyslipidemia and enhanced atherosclerosis. Metabolism: Clinical and Experimental, 2018, 83, 245-255.	1.5	26
1132	An update on trials of novel lipid-lowering drugs. Current Opinion in Cardiology, 2018, 33, 416-422.	0.8	5
1133	Determination of quality markers of Xuezhiling tablet for hyperlipidemia treatment. Phytomedicine, 2018, 44, 231-238.	2.3	19

#	Article	IF	Citations
1134	Highâ€Density Lipoprotein Subspecies Defined by Apolipoprotein Câ€III and Subclinical Atherosclerosis Measures: MESA (The Multiâ€Ethnic Study of Atherosclerosis). Journal of the American Heart Association, 2018, 7, .	1.6	19
1135	The relationship between migraine and lipid sub-fractions among individuals without cardiovascular disease: A cross-sectional evaluation in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Cephalalgia, 2018, 38, 528-542.	1.8	9
1136	Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a metaâ€analysis of randomised placeboâ€control human clinical trials. Journal of Human Nutrition and Dietetics, 2018, 31, 67-84.	1.3	90
1137	Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis, 2018, 268, 196-206.	0.4	81
1138	Nonfasting Triglycerides, Low-Density Lipoprotein Cholesterol, and Heart Failure Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 464-472.	1.1	56
1139	High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts. Circulation, 2018, 137, 1364-1373.	1.6	85
1140	Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. Clinical Therapeutics, 2018, 40, 83-94.	1.1	23
1141	Triglycerides and glycated hemoglobin for screening insulin resistance in obese patients. Clinical Biochemistry, 2018, 53, 8-12.	0.8	8
1142	Proteomics in cardiovascular diseases: Unveiling sex and gender differences in the era of precision medicine. Journal of Proteomics, 2018, 173, 62-76.	1.2	21
1143	Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals. Journal of Human Genetics, 2018, 63, 213-230.	1.1	35
1144	Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk: A community-based cohort study. Journal of Clinical Lipidology, 2018, 12, 89-98.e2.	0.6	20
1145	Dynamic changes of the composition of plasma <scp>HDL</scp> particles in patients with cardiac disease: Spotlight on sphingosineâ€1â€phosphate/serum amyloid A ratio. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 319-325.	0.9	3
1146	Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults. JAMA Cardiology, 2018, 3, 34.	3.0	54
1147	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	2.6	32
1148	SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux. Annual Review of Physiology, 2018, 80, 95-116.	5.6	257
1149	Association Between Blood Lipid Profiles and Atrial Fibrillation: A Case-Control Study. Medical Science Monitor, 2018, 24, 3903-3908.	0.5	25
1150	Determinants of the aortic pulse wave velocity index in hypertensive and diabetic patients. Journal of Hypertension, 2018, 36, 2324-2332.	0.3	22
1151	Lipid Measurements. , 2018, , 88-97.		0

#	Article	IF	Citations
1152	The impact of periodontal treatment on inflammatory markers and cellular parameters associated with atherosclerosis in patients after myocardial infarction. Central-European Journal of Immunology, 2018, 43, 442-452.	0.4	2
1153	Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. Journal of Thoracic Disease, 2018, 10, 6137-6146.	0.6	122
1154	Genetic associations in community context: a mixed model approach identifies a functional variant in the RBP4 gene associated with HDL-C dyslipidemia. BMC Medical Genetics, 2018, 19, 205.	2.1	3
1155	Gender-Associated Biomarkers in Metabolic Syndrome. , 0, , .		4
1156	BMP1 5â€²UTRâ€‰+â€‰104ÂT/C gene variation: can be a predictive marker for serum HDL and apoprotein A1 levels in male patients with coronary heart disease. Molecular Biology Reports, 2018, 45, 1269-1276.	1.0	3
1157	OBSOLETE: Risk Factors for Cardiovascular Disease. , 2018, , .		0
1158	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circulation Journal, 2018, 48, 1097.	0.7	15
1159	The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity. Cardiovascular Diabetology, 2018, 17, 142.	2.7	19
1160	Lipid disorders among Black Africans non-users of lipid-lowering medication. Archives of Endocrinology and Metabolism, 2018, 62, 552-559.	0.3	5
1161	Altered High Density Lipoprotein Composition in Behavioral Variant Frontotemporal Dementia. Frontiers in Neuroscience, 2018, 12, 847.	1.4	16
1162	Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?. World Journal of Gastroenterology, 2018, 24, 4617-4621.	1.4	31
1163	Health Benefits of Nut Consumption. , 2018, , .		6
1164	Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk. Journal of Thoracic Disease, 2018, 10, 109-112.	0.6	23
1165	Bivariate Genome-Wide Association Scan Identifies 6 Novel Loci Associated With Lipid Levels and Coronary Artery Disease. Circulation Genomic and Precision Medicine, 2018, 11, e002239.	1.6	26
1166	Highâ€efficient bacterial production of human ApoAâ€Ⅰ amyloidogenic variants. Protein Science, 2018, 27, 2101-2109.	3.1	7
1167	Association of Serum Triglycerides With Arterial Stiffness in Subjects With Low Levels of Low-Density Lipoprotein Cholesterol. Circulation Journal, 2018, 82, 3052-3057.	0.7	7
1168	Associations between Socioeconomic Status and the Prevalence and Treatment of Hypercholesterolemia in a General Japanese Population: NIPPON DATA2010. Journal of Atherosclerosis and Thrombosis, 2018, 25, 606-620.	0.9	17
1169	Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: A prospective cohort study. Atherosclerosis, 2018, 278, 190-196.	0.4	60

#	Article	IF	Citations
1170	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nature Genetics, 2018, 50, 1514-1523.	9.4	497
1171	Plasma oxidized high-density lipoprotein and glycated apolipoprotein A-I concentrations in ST-segment elevation myocardial infarction patients with stress hyperglycaemia or high thrombus burden. Upsala Journal of Medical Sciences, 2018, 123, 158-166.	0.4	4
1172	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	1.2	276
1173	Lipidomics in Carotid Artery Stenosis: Further Understanding of Pathology and Treatment. Translational Bioinformatics, 2018, , 55-72.	0.0	0
1174	Genetics of Coronary Atherosclerosis. , 2018, , 33-44.		0
1175	Nonstatin Therapy for Dyslipidemia. Circulation Research, 2018, 123, 1036-1038.	2.0	3
1176	Commentary on High-density Lipoprotein Versus Low-density Lipoprotein Therapy and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes by Nikolaos Papageorgiou et al.. Current Cardiology Reviews, 2018, 14, 301-302.	0.6	0
1177	Purified Phlorizin from Docynla Indica (Wall.) Decne by HSCCC, Compared with Whole Extract, Phlorizin and Non-Phlorizin Fragment Ameliorate Obesity, Insulin Resistance, and Improves Intestinal Barrier Function in High-Fat-Diet-Fed Mice. Molecules, 2018, 23, 2701.	1.7	11
1178	Recent Highlights of ATVB. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e185-e197.	1.1	3
1179	Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease. Molecules, 2018, 23, 2730.	1.7	33
1180	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	4.1	153
1181	Identification of the first Tangier disease patient in Lebanon carrying a new pathogenic variant in ABCA1. Journal of Clinical Lipidology, 2018, 12, 1374-1382.	0.6	6
1182	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. Journal of the American Heart Association, 2018, 7, e009778.	1.6	67
1183	Does pregnancy alter life-course lipid trajectories? Evidence from the HUNT Study in Norway. Journal of Lipid Research, 2018, 59, 2403-2412.	2.0	14
1184	Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infectious Diseases and Therapy, 2018, 7, 473-484.	1.8	7
1185	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 683-697.	1.1	19
1186	Does pattern mixture modelling reduce bias due to informative attrition compared to fitting a mixed effects model to the available cases or data imputed using multiple imputation?: a simulation study. BMC Medical Research Methodology, 2018, 18, 89.	1.4	4
1187	Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population. Lipids in Health and Disease, 2018, 17, 208.	1.2	9

#	Article	IF	Citations
1188	Lipids: a personal view of the past decade. Hormones, 2018, 17, 461-478.	0.9	5
1189	Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease. PLoS ONE, 2018, 13, e0202682.	1.1	10
1190	A robust method to estimate regional polygenic correlation under misspecified linkage disequilibrium structure. Genetic Epidemiology, 2018, 42, 636-647.	0.6	3
1191	Lipidomic differentiation of Gravesâ€™ ophthalmopathy in plasma and urine from Gravesâ€™ disease patients. Analytical and Bioanalytical Chemistry, 2018, 410, 7121-7133.	1.9	10
1192	Diabetes alters the association between high-density lipoprotein subfractions and carotid intima-media thickness: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Diabetes and Vascular Disease Research, 2018, 15, 541-547.	0.9	6
1193	Acute phase reactant proteins, anthropometric and dyslipidaemic changes associated with type 2 diabetic mellitus among Nigerian population. Ife Journal of Science, 2018, 20, 557.	0.1	0
1194	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry, 2018, 64, 1006-1033.	1.5	189
1195	Further options for treating lipids in people with diabetes: targeting <scp>LDL</scp>â€cholesterol and beyond. Diabetic Medicine, 2018, 35, 1173-1180.	1.2	3
1196	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. Journal of Lipid Research, 2018, 59, 1266-1275.	2.0	62
1197	Genetic-Driven Druggable Target Identification and Validation. Trends in Genetics, 2018, 34, 558-570.	2.9	44
1198	Plasma cytokines and risk of coronary heart disease in the PROCARDIS study. Open Heart, 2018, 5, e000807.	0.9	24
1199	Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. Journal of the Endocrine Society, 2018, 2, 497-512.	0.1	19
1200	Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy. Journal of the American Heart Association, 2018, 7, .	1.6	3
1201	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. Clinical Pharmacology and Therapeutics, 2018, 104, 244-256.	2.3	14
1202	Delayed postprandial TAG peak after intake of SFA compared with PUFA in subjects with and without familial hypercholesterolaemia: a randomised controlled trial. British Journal of Nutrition, 2018, 119, 1142-1150.	1.2	8
1203	Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in familial combined hyperlipidemia. Atherosclerosis, 2018, 277, 204-210.	0.4	39
1204	Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naÃ¯ve dyslipidemic patients. Indian Heart Journal, 2018, 70, S64-S67.	0.2	2
1205	The MR-Base platform supports systematic causal inference across the human phenome. ELife, 2018, 7, .	2.8	3,639

#	Article	IF	Citations
1206	Stable Angina Pectoris. , 2018, , 157-200.		0
1207	On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease â€“ The multi-center T-SPARCLE registry study. Journal of the Formosan Medical Association, 2018, 117, 814-824.	0.8	9
1208	Using an atlas of gene regulation across 44 human tissues to inform complex disease- and trait-associated variation. Nature Genetics, 2018, 50, 956-967.	9.4	389
1209	The Correlation of Dyslipidemia with the Extent of Coronary Artery Disease in the Multiethnic Study of Atherosclerosis. Journal of Lipids, 2018, 2018, 1-9.	1.9	26
1210	Postprandial Hyperchylomicronemia and Thin-Cap Fibroatheroma in Nonculprit Lesions. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1940-1947.	1.1	9
1211	Association of High-Density Lipoprotein Subclasses with Carotid Intima-Media Thickness: Shimane CoHRE Study. Journal of Atherosclerosis and Thrombosis, 2018, 25, 42-54.	0.9	10
1212	Impact of a one-year lifestyle modification program on cholesterol efflux capacities in men with abdominal obesity and dyslipidemia. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E460-E468.	1.8	19
1213	Long-term moderately elevated LDL-cholesterol and blood pressure and risk of coronary heart disease. PLoS ONE, 2018, 13, e0200017.	1.1	19
1214	Pediatric reference intervals for calculated LDL cholesterol, non-HDL cholesterol, and remnant cholesterol in the healthy CALIPER cohort. Clinica Chimica Acta, 2018, 486, 129-134.	0.5	8
1215	Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3019-3027.	1.8	74
1216	High risk of subclinical atherosclerosis in COPD exacerbator phenotype. Respiratory Medicine, 2018, 141, 165-171.	1.3	8
1217	Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ: British Medical Journal, 2018, 362, k601.	2.4	1,880
1218	Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA). Cardiovascular Diabetology, 2018, 17, 77.	2.7	25
1219	Interaction between endothelial nitric oxide synthase rs1799983, cholesteryl ester-transfer protein rs708272 and angiopoietin-like protein 8 rs2278426 gene variants highly elevates the risk of type 2 diabetes mellitus and cardiovascular disease. Cardiovascular Diabetology, 2018, 17, 97.	2.7	18
1220	LDLâ€Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk. Clinical Pharmacology and Therapeutics, 2018, 104, 235-238.	2.3	10
1221	Regulation of apolipoprotein A-I gene expression by the histamine H1 receptor: Requirement for NF-ÎºB. Life Sciences, 2018, 208, 102-110.	2.0	5
1222	Unravelling HDLâ€"Looking beyond the Cholesterol Surface to the Quality Within. International Journal of Molecular Sciences, 2018, 19, 1971.	1.8	51
1223	Effect of a public health center-based nutrition education program for hypertension in women older than 50 years of age. Journal of Nutrition and Health, 2018, 51, 228.	0.2	2

#	Article	IF	Citations
1224	Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. Atherosclerosis, 2018, 276, 39-43.	0.4	45
1225	The art of cardiovascular risk assessment. Clinical Cardiology, 2018, 41, 677-684.	0.7	28
1226	High-density lipoprotein 3 cholesterol is a predictive factor for arterial stiffness: a community-based 4.8-year prospective study. Lipids in Health and Disease, 2018, 17, 5.	1.2	15
1227	Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study. Biomarkers, 2018, 23, 647-653.	0.9	20
1228	Relations of lipid parameters, other variables with carotid intima-media thickness and plaque in the general Chinese adults: an observational study. Lipids in Health and Disease, 2018, 17, 107.	1.2	28
1229	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. Current Cardiology Reports, 2018, 20, 88.	1.3	18
1230	A critical appraisal of the measurement of serum â€˜cholesterol efflux capacityâ€™ and its use as surrogate marker of risk of cardiovascular disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 1257-1273.	1.2	18
1231	Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk. Journal of Lipid Research, 2018, 59, 1987-2000.	2.0	19
1232	Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. Nature Communications, 2018, 9, 3391.	5.8	140
1233	No-HDL-cholesterol as risk marker and therapeutic goal. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2018, 30, 72-73.	0.1	0
1234	The effect of omentectomy added to bariatric surgery on metabolic outcomes: a systematic review and meta-analysis of randomized controlled trials. Surgery for Obesity and Related Diseases, 2018, 14, 1766-1782.	1.0	6
1235	Clinical Characteristics and Sequelae of Severe Hypertriglyceridemia in Pediatrics. Endocrine Practice, 2018, 24, 789-795.	1.1	6
1236	Establishing a threshold to predict risk of cardiovascular disease from the serum triglyceride and high-density lipoprotein concentrations in persons with spinal cord injury. Spinal Cord, 2018, 56, 1051-1058.	0.9	14
1237	Relationship between Cardiorespiratory Fitness and Non-High-Density Lipoprotein Cholesterol: A Cohort Study. Journal of Atherosclerosis and Thrombosis, 2018, 25, 1196-1205.	0.9	15
1238	Relationship between serum lipid concentrations and posttraumatic stress symptoms in the bereaved after the Sewol ferry disaster: A prospective cohort study. Psychiatry Research, 2018, 266, 132-137.	1.7	8
1239	Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study. International Journal of Cardiology, 2018, 270, 21-27.	0.8	16
1240	HDL-cholesterol, genetics, and coronary artery disease: the myth of the â€˜good cholesterolâ€™?. European Heart Journal, 2018, 39, 2179-2182.	1.0	15
1241	Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance. BMJ: British Medical Journal, 2018, 361, k2139.	2.4	213

#	Article	IF	Citations
1242	Inverse Association Between Serum Nonâ€“Highâ€Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. Journal of the American Heart Association, 2018, 7, .	1.6	20
1243	Risk Factors for Cardiovascular Disease. , 2018, , 307-314.		2
1244	APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in Apoe atherosclerotic mice. International Journal of Cardiology, 2018, 271, 233-239.	0.8	11
1245	Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. JAMA Cardiology, 2018, 3, 619.	3.0	428
1246	Antiâ€ApoAâ€I IgG antibodies are not associated with carotid artery disease progression and firstâ€time cardiovascular events in middleâ€aged individuals. Journal of Internal Medicine, 2019, 285, 49-58.	2.7	4
1247	Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy. Familial Cancer, 2019, 18, 19-27.	0.9	6
1248	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. Clinical Pharmacology and Therapeutics, 2019, 105, 568-581.	2.3	6
1249	Probabilistic Quantitative Assessment of Coronary Heart Disease Risk From Dietary Exposure to Industrially Produced Trans-Fatty Acids in Partially Hydrogenated Oils. Toxicological Sciences, 2019, 172, 213-224.	1.4	5
1250	Cholesterol Insights and Controversies From the UK Biobank Study. Circulation, 2019, 140, 553-555.	1.6	8
1251	Atherosclerosis. Nature Reviews Disease Primers, 2019, 5, 56.	18.1	1,601
1252	HDL Cholesterol Level and Mortality Occurrence in the Elderly: Is the Good Cholesterol Always Good?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4114-4116.	1.8	6
1253	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. Current Cardiology Reports, 2019, 21, 110.	1.3	24
1254	Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?. Current Medicinal Chemistry, 2019, 26, 1512-1524.	1.2	17
1255	A Metabolic Obesity Profile Is Associated With Decreased Gray Matter Volume in Cognitively Healthy Older Adults. Frontiers in Aging Neuroscience, 2019, 11, 202.	1.7	23
1256	Cardiometabolic comorbidities inÂRAÂand PsA: lessons learned andÂfuture directions. Nature Reviews Rheumatology, 2019, 15, 461-474.	3.5	95
1257	Age-related and gender-stratified differences in the association between high triglyceride and risk of hyperuricemia. Lipids in Health and Disease, 2019, 18, 147.	1.2	11
1258	Powerful three-sample genome-wide design and robust statistical inference in summary-data Mendelian randomization. International Journal of Epidemiology, 2019, 48, 1478-1492.	0.9	121
1259	Repeated measures of extremely high levels of high-density lipoprotein cholesterol and subsequent all-cause mortality and cardiovascular events: A longitudinal study. Atherosclerosis, 2019, 288, 17-25.	0.4	11

#	Article	IF	Citations
1260	The Australian Aboriginal Birth Cohort study: socioâ€economic status at birth and cardiovascular risk factors to 25 years of age. Medical Journal of Australia, 2019, 211, 265-270.	0.8	3
1261	Rounding the corner on residual risk: Implications of REDUCEâ€IT for omegaâ€3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. Clinical Cardiology, 2019, 42, 829-838.	0.7	13
1262	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. International Journal of Molecular Sciences, 2019, 20, 3151.	1.8	58
1263	Goals of non-high density lipoprotein cholesterol need to be adjusted in Chinese acute coronary syndrome patients: Findings from the CCC-ACS project. Clinica Chimica Acta, 2019, 496, 48-54.	0.5	10
1264	Atherogenic indices in pseudoexfoliation syndrome. Eye, 2019, 33, 1911-1915.	1.1	3
1265	Cholesteryl Ester Transfer Protein Genetic Variants Associated with Risk for Type 2 Diabetes and Diabetic Kidney Disease in Taiwanese Population. Genes, 2019, 10, 782.	1.0	6
1266	Association between high-density lipoprotein cholesterol and all-cause mortality in the general population of northern China. Scientific Reports, 2019, 9, 14426.	1.6	25
1267	Apolipoproteins and cancer. Cancer Medicine, 2019, 8, 7032-7043.	1.3	86
1268	TriglycÃ©rides et risque cardiovasculaire. Medecine Des Maladies Metaboliques, 2019, 13, 123-128.	0.1	2
1269	FTIR, Raman and AFM characterization of the clinically valid biochemical parameters of the thrombi in acute ischemic stroke. Scientific Reports, 2019, 9, 15475.	1.6	27
1270	Apolipoprotein B Particles and Cardiovascular Disease. JAMA Cardiology, 2019, 4, 1287.	3.0	299
1271	Lower than average HDL cholesterol efflux capacity in Lithuanian population. Lipids in Health and Disease, 2019, 18, 186.	1.2	1
1272	The impact of monocyte to high-density lipoprotein ratio on reduced renal function: insights from a large population. Biomarkers in Medicine, 2019, 13, 773-783.	0.6	12
1273	APOE polymorphism is associated with blood lipid and serum uric acid metabolism in hypertension or coronary heart disease in a Chinese population. Pharmacogenomics, 2019, 20, 1021-1031.	0.6	19
1274	Circulating microRNAs as predictive biomarkers of myocardial infarction: Evidence from the HUNT study. Atherosclerosis, 2019, 289, 1-7.	0.4	42
1275	World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. The Lancet Global Health, 2019, 7, e1332-e1345.	2.9	554
1276	Risks of ischaemic heart disease and stroke in meat eaters, fish eaters, and vegetarians over 18 years of follow-up: results from the prospective EPIC-Oxford study. BMJ: British Medical Journal, 2019, 366, l4897.	2.4	115
1277	Investigating potential associations between O3 exposure and lipid profiles: A longitudinal study of older adults in Beijing. Environment International, 2019, 133, 105135.	4.8	19

#	Article	IF	Citations
1278	The gut microbiome and cardiovascular disease: current knowledge and clinical potential. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H923-H938.	1.5	82
1279	Physical Activity, Sedentary Leisure Time, Circulating Metabolic Markers, and Risk of Major Vascular Diseases. Circulation Genomic and Precision Medicine, 2019, 12, 386-396.	1.6	24
1280	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1381.	3.8	144
1281	Ratio of triglyceride to high-density lipoprotein cholesterol and risk of major cardiovascular events in kidney transplant recipients. Clinical and Experimental Nephrology, 2019, 23, 1407-1417.	0.7	5
1282	Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4848-4856.	1.8	14
1283	Anti-Inflammatory Effects of HDL (High-Density Lipoprotein) in Macrophages Predominate Over Proinflammatory Effects in Atherosclerotic Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, e253-e272.	1.1	86
1284	Effects of Replacing Dietary Monounsaturated Fat With Carbohydrate on HDL (High-Density) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 507 and Vascular Biology, 2019, 39, 2411-2430.	1.1	15
1285	Effects of OSA Surgery on Leptin and Metabolic Profiles. Otolaryngology - Head and Neck Surgery, 2019, 161, 1048-1055.	1.1	9
1286	High triglyceride to highâ€density lipoprotein cholesterol ratio and arterial stiffness in postmenopausal Korean women. Journal of Clinical Hypertension, 2019, 21, 399-404.	1.0	21
1287	Cholesteryl Ester TransferÂProtein Inhibition for Preventing CardiovascularÂEvents. Journal of the American College of Cardiology, 2019, 73, 477-487.	1.2	102
1288	Formulation and Characterization of Quercetin-loaded Oil in Water Nanoemulsion and Evaluation of Hypocholesterolemic Activity in Rats. Nutrients, 2019, 11, 244.	1.7	31
1289	Heart Disease and Stroke Statisticsâ€”2019 Update: A Report From the American Heart Association. Circulation, 2019, 139, e56-e528.	1.6	6,192
1290	Thyroid Function and the Risk of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 97.	3.0	6
1291	The triglyceride paradox in the mortality of coronary artery disease. Lipids in Health and Disease, 2019, 18, 21.	1.2	17
1292	LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. Atherosclerosis, 2019, 282, 37-44.	0.4	38
1293	High-Density Lipoprotein Function and Dysfunction in Health and Disease. Cardiovascular Drugs and Therapy, 2019, 33, 207-219.	1.3	69
1294	The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	14
1295	The Impact of Physical Activity on the Health of Young Adult Survivors of Childhood Cancer: An Exploratory Analysis. Journal of Adolescent and Young Adult Oncology, 2019, 8, 602-609.	0.7	7

#	Article	IF	Citations
1296	New dual peroxisome proliferator activated receptor agonistâ€"Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovascular Diabetology, 2019, 18, 80.	2.7	90
1297	Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation, 2019, 140, 542-552.	1.6	118
1298	Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights. Current Cardiology Reports, 2019, 21, 68.	1.3	49
1299	Sex differences in postprandial responses to different dairy products on lipoprotein subclasses: a randomised controlled cross-over trial. British Journal of Nutrition, 2019, 122, 780-789.	1.2	5
1300	Urinary apolipoprotein AI in children with kidney disease. Pediatric Nephrology, 2019, 34, 2351-2360.	0.9	12
1301	High-Density Lipoprotein Cholesterol and All-Cause and Cause-Specific Mortality Among the Elderly. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3370-3378.	1.8	35
1302	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	2.7	104
1303	Egg Consumption and Risk of Total and Cause-Specific Mortality: An Individual-Based Cohort Study and Pooling Prospective Studies on Behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Journal of the American College of Nutrition, 2019, 38, 552-563.	1.1	31
1304	Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trialâ€"Lipid Lowering Arm. JAMA Internal Medicine, 2019, 179, 898.	2.6	46
1305	Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk. Atherosclerosis: X, 2019, 1, 100001.	0.0	3
1306	Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and Allâ€Cause Mortality: Observations From the Framingham Study Over 35 Years. Journal of the American Heart Association, 2019, 8, e011433.	1.6	98
1307	Assessing the performance of monocyte to high-density lipoprotein ratio for predicting ischemic stroke: insights from a population-based Chinese cohort. Lipids in Health and Disease, 2019, 18, 127.	1.2	32
1308	Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men. Journal of Lipid Research, 2019, 60, 1457-1464.	2.0	27
1309	Association of ABCA1 Haplotypes with Coronary Artery Disease. Laboratory Medicine, 2019, 51, 157-168.	0.8	4
1310	Effect of Food on the Pharmacokinetics of 2 Formulations of DRLâ€17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males. Clinical Pharmacology in Drug Development, 2019, 8, 1042-1052.	0.8	2
1311	Epimedium koreanum Extract and Its Flavonoids Reduced Atherosclerotic Risk via Suppressing Modification of Human HDL. Nutrients, 2019, 11, 1110.	1.7	15
1312	IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 702-711.	2.2	22
1313	Placental secretion of apolipoprotein A1 and E: the anti-atherogenic impact of the placenta. Scientific Reports, 2019, 9, 6225.	1.6	30

#	Article	IF	Citations
1314	Allele-specific enhancers mediate associations between LCAT and ABCA1 polymorphisms and HDL metabolism. PLoS ONE, 2019, 14, e0215911.	1.1	3
1315	Effects of a Novel Nutraceutical Combination (Aquilea ColesterolÂ®) on the Lipid Profile and Inflammatory Biomarkers: A Randomized Control Trial. Nutrients, 2019, 11, 949.	1.7	8
1316	Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opinion on Pharmacotherapy, 2019, 20, 1277-1288.	0.9	18
1317	Elevated triglycerides rather than other lipid parameters are associated with increased urinary albumin to creatinine ratio in the general population of China: a report from the REACTION study. Cardiovascular Diabetology, 2019, 18, 57.	2.7	13
1318	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2019, 31, 75-88.	0.1	6
1319	Genetic Association of Finger Photoplethysmography-Derived Arterial Stiffness Index With Blood Pressure and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1253-1261.	1.1	35
1320	Hepatocyte Deletion of Triglycerideâ€Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice. Hepatology, 2019, 70, 1972-1985.	3.6	75
1321	An updated review of lipidâ€modifying therapy. Medical Journal of Australia, 2019, 211, 87-92.	0.8	9
1322	Emerging Lipid-Lowering Therapies in Secondary Prevention. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	0
1323	Consumption of Meat, Fish, Dairy Products, and Eggs and Risk of Ischemic Heart Disease. Circulation, 2019, 139, 2835-2845.	1.6	103
1324	Residual cardiovascular risk among people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 28-38.	2.2	31
1325	Low plasma concentrations of apolipoprotein M are associated with disease activity and endothelial dysfunction in systemic lupus erythematosus. Arthritis Research and Therapy, 2019, 21, 110.	1.6	10
1326	Effect of Health Information Technologies on Cardiovascular Risk Factors among Patients with Diabetes. Current Diabetes Reports, 2019, 19, 28.	1.7	4
1327	Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovascular Diabetology, 2019, 18, 48.	2.7	76
1328	Association between plasma essential amino acids and atherogenic lipid profile in a Chinese population: A cross-sectional study. Atherosclerosis, 2019, 286, 7-13.	0.4	20
1329	Divergent effects of lipids on stroke. Nature Medicine, 2019, 25, 543-544.	15.2	3
1330	High-Density Lipoproteins and Inflammatory Diseases: Full Circle Ahead. Clinical Chemistry, 2019, 65, 607-608.	1.5	1
1331	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry, 2019, 56, 338-356.	0.8	27

#	Article	IF	Citations
1332	Cholesterol in Atherosclerosis and Cardiovascular Disease: The Role of Specific Dietary and Lifestyle Patterns. , 2019, , 145-169.		0
1333	Association between vegetarian diets and cardiovascular risk factors in non-Hispanic white participants of the Adventist Health Study-2. Journal of Nutritional Science, 2019, 8, e6.	0.7	44
1334	Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 1455-1463.	2.2	24
1335	A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function. Obesity Science and Practice, 2019, 5, 36-45.	1.0	14
1336	Associations of Genetic Variations in ABCA1 and Lifestyle Factors with Coronary Artery Disease in a Southern Chinese Population with Dyslipidemia: A Nested Case-Control Study. International Journal of Environmental Research and Public Health, 2019, 16, 786.	1.2	4
1337	Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nature Medicine, 2019, 25, 569-574.	15.2	200
1338	Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Preâ€specified analysis of the Chinese population from the BERSON clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 1464-1473.	2.2	21
1339	Association Between Serum Highâ€Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOWâ€CKD. Journal of the American Heart Association, 2019, 8, e011162.	1.6	32
1340	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocrine Reviews, 2019, 40, 537-557.	8.9	262
1341	Peripheral artery disease risk factors in Jeddah, Saudi Arabia: a retrospective study. International Journal of General Medicine, 2019, Volume 12, 49-54.	0.8	4
1342	Retinal Vein Occlusion is Associated with Low Blood High-Density Lipoprotein Cholesterol: AÂNationwide Cohort Study. American Journal of Ophthalmology, 2019, 205, 35-42.	1.7	23
1343	Apolipoprotein Aâ€I improves pancreatic Î²â€cell function independent of the ATPâ€binding cassette transporters ABCA1 and ABCG1. FASEB Journal, 2019, 33, 8479-8489.	0.2	17
1344	Serum Level of Total Lipids and Telomere Length in the Male Population: A Cross-Sectional Study. American Journal of Men's Health, 2019, 13, 155798831984297.	0.7	13
1345	Vaccination against atherosclerosis. Current Opinion in Immunology, 2019, 59, 15-24.	2.4	31
1346	Target of Triglycerides as Residual Risk for Cardiovascular Events in Patients With Coronary Artery Diseaseã€â€• Post Hoc Analysis of the FMD-J Study A â€•. Circulation Journal, 2019, 83, 1064-1071.	0.7	17
1347	Hypertriglyceridaemia predicts subsequent longâ€term risk of cardiovascular events in Chinese adults: 23â€year followâ€up of the Daqing Diabetes Study. Diabetes/Metabolism Research and Reviews, 2019, 35, e3163.	1.7	6
1348	Triglycerides as Residual Risk for Atherosclerotic Cardiovascular Disease. Circulation Journal, 2019, 83, 969-970.	0.7	9
1349	Relative effects of LDL-C on ischemic stroke and coronary disease. Neurology, 2019, 92, e1176-e1187.	1.5	40

#	Article	IF	Citations
1350	The APOE<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:msup><mml:mrow /><mml:mrow><mml:mo>â^—</mml:mo></mml:mrow></mml:msup></mml:math>3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis. Journal of Diabetes Research, 2019, 2019, 1-13.	1.0	8
1351	Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Caseâ€“Control Study. Metabolic Syndrome and Related Disorders, 2019, 17, 223-231.	0.5	9
1352	Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Annals of Neurology, 2019, 85, 550-559.	2.8	70
1353	Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H801-H827.	1.5	54
1354	Stroke Epidemiology and Prevention. , 2019, , 1-21.		2
1356	Statins and Cognitive Impairment. Journal of the American College of Cardiology, 2019, 74, 2569-2571.	1.2	5
1357	Time to review fibrate prescribing?. Drug and Therapeutics Bulletin, 2019, 57, 154-157.	0.3	2
1358	Genetic risk scores in lipid disorders. Current Opinion in Cardiology, 2019, 34, 406-412.	0.8	7
1359	Modulation of cholesterol efflux capacity in patients with myocardial infarction. Current Opinion in Cardiology, 2019, 34, 714-720.	0.8	4
1360	Childhood obesity leads to adult type 2 diabetes and coronary artery diseases. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	53
1361	Risk factor reduction in type 2 diabetes demands a multifactorial approach. European Journal of Preventive Cardiology, 2019, 26, 81-91.	0.8	13
1362	Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet, The, 2019, 394, 2173-2183.	6.3	177
1363	Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?. Cardiology in Review, 2019, 27, 242-248.	0.6	5
1364	Integrative genomic analysis identified common regulatory networks underlying the correlation between coronary artery disease and plasma lipid levels. BMC Cardiovascular Disorders, 2019, 19, 310.	0.7	9
1365	Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis. Lipids in Health and Disease, 2019, 18, 223.	1.2	82
1366	Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis. Scientific Reports, 2019, 9, 19178.	1.6	14
1367	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. Current Opinion in Lipidology, 2019, 30, 462-469.	1.2	18
1368	SPPARM alpha. Current Opinion in Lipidology, 2019, 30, 419-427.	1.2	11

#	Article	IF	Citations
1369	Dyslipidemias and cardiovascular risk scores in urban and rural populations in north-western Tanzania and southern Uganda. PLoS ONE, 2019, 14, e0223189.	1.1	7
1370	Associations between serum apolipoproteins, urinary albumin excretion rate, estimated glomerular filtration rate, and diabetic retinopathy in individuals with type 2 diabetes. Medicine (United States), 2019, 98, e15703.	0.4	9
1372	Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 109-116.	1.2	36
1373	Metabolic health in normal-weight and obese individuals. Diabetologia, 2019, 62, 558-566.	2.9	112
1374	Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?. European Journal of Preventive Cardiology, 2019, 26, 531-532.	0.8	5
1375	Riesgo cardiovascular residual de origen lipÃ¡dico. Componentes y aspectos fisiopatolÃ³gicos. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 75-88.	0.4	6
1376	Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology, 2019, 51, 148-154.	0.3	113
1377	Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 89-96.	1.1	91
1378	Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application. Journal of Atherosclerosis and Thrombosis, 2019, 26, 111-120.	0.9	20
1379	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019, 73, e285-e350.	1.2	1,550
1380	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1046-e1081.	1.6	361
1381	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1082-e1143.	1.6	2,380
1382	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology, 2019, 73, 3168-3209.	1.2	1,128
1383	Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. International Journal of Cardiology, 2019, 276, 242-247.	0.8	30
1384	Attainment of lipid goals and long-term mortality after coronary-artery bypass surgery. European Journal of Preventive Cardiology, 2019, 26, 401-408.	0.8	19
1385	Potential causal associations of serum 25-hydroxyvitamin D with lipids: a Mendelian randomization approach of the HUNT study. European Journal of Epidemiology, 2019, 34, 57-66.	2.5	11
1386	Organochlorine pesticides and polychlorinated biphenyls (PCBs) in early adulthood and blood lipids over a 23-year follow-up. Environmental Toxicology and Pharmacology, 2019, 66, 24-35.	2.0	17
1387	Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting. Neurology, 2019, 92, .	1.5	30

#	Article	IF	Citations
1388	Association Between Lipid Profiles and Arterial Stiffness in Chinese Patients With Hypertension: Insights From the CSPPT. Angiology, 2019, 70, 515-522.	0.8	33
1389	Small HDL subclass is associated with coronary plaque stability: An optical coherence tomography study in patients with coronary artery disease. Journal of Clinical Lipidology, 2019, 13, 326-334.e2.	0.6	4
1390	New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Current Atherosclerosis Reports, 2019, 21, 2.	2.0	87
1391	Non-traditional lipid profiles associated with ischemic stroke not hemorrhagic stroke in hypertensive patients: results from an 8.4â€‰years follow-up study. Lipids in Health and Disease, 2019, 18, 9.	1.2	19
1392	Sterol regulatory element binding protein (SREBP) -1 mediates oxidized low-density lipoprotein (oxLDL) induced macrophage foam cell formation through NLRP3 inflammasome activation. Cellular Signalling, 2019, 53, 316-326.	1.7	46
1393	Non-HDL cholesterol predictive factor of type 2 diabetes in the city of Tlemcen. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 518-521.	1.8	0
1394	Non-high-density lipoprotein cholesterol and risk of cardiovascular disease in the general population and patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2019, 147, 1-8.	1.1	18
1395	Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease. Clinical Cardiology, 2019, 42, 56-61.	0.7	25
1396	Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology, 2019, 51, 131-141.	0.3	112
1397	High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?. Cardiovascular Research, 2019, 115, 6-7.	1.8	3
1398	Kidney as modulator and target of â€œgood/badâ€•HDL. Pediatric Nephrology, 2019, 34, 1683-1695.	0.9	14
1399	Metaâ€•analysis of nonâ€•linear exposureâ€•outcome relationships using individual participant data: A comparison of two methods. Statistics in Medicine, 2019, 38, 326-338.	0.8	22
1400	Monocyte/HDL Ratio and Lymphocyte/Monocyte Ratio in Patients with Pseudoexfoliation Syndrome. Ocular Immunology and Inflammation, 2020, 28, 142-146.	1.0	21
1401	Utility of apolipoprotein measurements in predicting incident type 2 diabetes: A Chinese cohort study. Journal of the Formosan Medical Association, 2020, 119, 51-58.	0.8	12
1402	Non-High-Density Lipoprotein Cholesterol and Risk of Stroke Subtypes and Coronary Heart Disease: The Japan Public Health Center-Based Prospective (JPHC) Study. Journal of Atherosclerosis and Thrombosis, 2020, 27, 363-374.	0.9	30
1403	Effect of Statin on Stroke Recurrence Prevention at Different Infarction Locations: A Post Hoc Analysis of The J-STARS Study. Journal of Atherosclerosis and Thrombosis, 2020, 27, 524-533.	0.9	3
1404	PCSK9 inhibitors and cardiovascular outcomes. Expert Opinion on Biological Therapy, 2020, 20, 35-47.	1.4	26
1405	National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. International Journal of Epidemiology, 2020, 49, 173-192.	0.9	44

#	Article	IF	Citations
1406	Comparison of remnant cholesterol levels estimated by calculated and measured LDL-C levels in Chinese patients with coronary heart disease. Clinica Chimica Acta, 2020, 500, 75-80.	0.5	20
1407	Enrichment of HDL proteome and phospholipidome from human serum via IMAC/MOAC affinity. Biomedical Chromatography, 2020, 34, e4693.	0.8	3
1408	What Kind of Probucol Affects Normalizing Male Birth?. Journal of Atherosclerosis and Thrombosis, 2020, 27, 4-5.	0.9	0
1409	Blood lipid profiles and risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. Journal of Clinical Lipidology, 2020, 14, 133-142.e3.	0.6	38
1410	Advances in our understanding of the structure and functionality of edible fats and fat mimetics. Soft Matter, 2020, 16, 289-306.	1.2	87
1411	Retinol, Retinoic Acid, and Retinol-Binding Protein 4 are Differentially Associated with Cardiovascular Disease, Type 2 Diabetes, and Obesity: An Overview of Human Studies. Advances in Nutrition, 2020, 11, 644-666.	2.9	67
1412	Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults. JAMA Cardiology, 2020, 5, 13.	3.0	29
1413	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clinical Chemistry and Laboratory Medicine, 2020, 58, 496-517.	1.4	119
1414	Familial chylomicronemia syndrome: an underâ€recognized cause of severe hypertriglyceridaemia. Journal of Internal Medicine, 2020, 287, 340-348.	2.7	61
1415	Low High-Density Lipoprotein Cholesterol to Monitor Long-Term Average Increased Triglycerides. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1657-e1666.	1.8	24
1416	Role of Highâ€Ðensity Lipoproteins in Cholesterol Homeostasis and Glycemic Control. Journal of the American Heart Association, 2020, 9, e013531.	1.6	27
1417	Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals. Journal of Hematology and Oncology, 2020, 13, 129.	6.9	46
1418	Nanoparticle-based â€œTwo-prongedâ€•approach to regress atherosclerosis by simultaneous modulation of cholesterol influx and efflux. Biomaterials, 2020, 260, 120333.	5.7	27
1419	Hypertriglyceridemiaâ€”Causes, Significance, and Approaches to Therapy. Frontiers in Endocrinology, 2020, 11, 616.	1.5	29
1420	Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markers. Journal of Clinical Lipidology, 2020, 14, 825-836.	0.6	6
1421	Management of hypertriglyceridemia. BMJ, The, 2020, 371, m3109.	3.0	89
1422	Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2020, 32, 209-218.	0.1	2
1423	MR-LDP: a two-sample Mendelian randomization for GWAS summary statistics accounting for linkage disequilibrium and horizontal pleiotropy. NAR Genomics and Bioinformatics, 2020, 2, lqaa028.	1.5	27

#	Article	IF	Citations
1424	Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7		
1425	Roles for circulating polyunsaturated fatty acids in ischemic stroke and modifiable factors: a Mendelian randomization study. Nutrition Journal, 2020, 19, 70.	1.5	16
1426	VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins. Journal of the American College of Cardiology, 2020, 76, 2725-2735.	1.2	105
1427	Indoxyl sulfate and high-density lipoprotein cholesterol in early stages of chronic kidney disease. Renal Failure, 2020, 42, 1157-1163.	0.8	3
1428	Statin Treatment in Specific Patient Groups: Role for Improved Cardiovascular Risk Markers. Journal of Clinical Medicine, 2020, 9, 3748.	1.0	2
1429	Mendelian randomization and pleiotropy analysis. Quantitative Biology, 2021, 9, 122-132.	0.3	28
1430	Quantifying the contribution of established risk factors to cardiovascular mortality differences between Russia and Norway. Scientific Reports, 2020, 10, 20796.	1.6	3
1431	An iterative approach to detect pleiotropy and perform Mendelian Randomization analysis using GWAS summary statistics. Bioinformatics, 2021, 37, 1390-1400.	1.8	22
1432	High-Density Lipoprotein (HDL) in Allergy and Skin Diseases: Focus on Immunomodulating Functions. Biomedicines, 2020, 8, 558.	1.4	18
1433	A point mutation decouples the lipid transfer activities of microsomal triglyceride transfer protein. PLoS Genetics, 2020, 16, e1008941.	1.5	20
1434	The Role of Statins in Current Guidelines. Current Atherosclerosis Reports, 2020, 22, 50.	2.0	17
1435	HDL Cholesterol Efflux Capacity is Impaired in Severe Short-Term Hypothyroidism Despite Increased HDL Cholesterol. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3355-e3362.	1.8	13
1436	There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3â€“5. Scientific Reports, 2020, 10, 12749.	1.6	8
1437	Microarray analysis of long non-coding RNA expression profiles in low high-density lipoprotein cholesterol disease. Lipids in Health and Disease, 2020, 19, 175.	1.2	4
1438	Use of an Exposome Approach to Understand the Effects of Exposures From the Natural, Built, and Social Environments on Cardio-Vascular Disease Onset, Progression, and Outcomes. Frontiers in Public Health, 2020, 8, 379.	1.3	42
1439	Cardiovascular risk factors in women with previous gestational diabetes mellitus: A systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 729-761.	2.6	26
1440	Assessment of YKL-40, lipid profile, antioxidant status, and some trace elements in benign and malignant breast proliferation. Molecular Biology Reports, 2020, 47, 6973-6982.	1.0	5
1441	Association of Hypertriglyceridemia with Allâ€Cause Mortality and Atherosclerotic Cardiovascular Events in a Lowâ€Risk Italian Population: The TGâ€REAL Retrospective Cohort Analysis. Journal of the American Heart Association, 2020, 9, e015801.	1.6	38

#	Article	IF	Citations
1442	Apolipoprotein B Level and the Apolipoprotein B/Apolipoprotein A-I Ratio as a Harbinger of Ischemic Stroke: A Prospective Observation in Taiwan. Cerebrovascular Diseases, 2020, 49, 487-494.	0.8	5
1443	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3613-3682.	1.8	63
1444	Cholesterol and Inflammation in Atherosclerosis: An Immune-Metabolic Hypothesis. Nutrients, 2020, 12, 2444.	1.7	12
1445	Single nucleotide polymorphisms of ADIPOQ gene associated with cardiovascular disease risk factors in European adolescents: the Healthy Lifestyle in Europe by Nutrition in Adolescence study. Journal of Hypertension, 2020, 38, 1971-1979.	0.3	3
1446	Protein-Defined Subspecies of HDLs (High-Density Lipoproteins) and Differential Risk of Coronary Heart Disease in 4 Prospective Studies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2714-2727.	1.1	38
1447	A family of partial-linear single-index models for analyzing complex environmental exposures with continuous, categorical, time-to-event, and longitudinal health outcomes. Environmental Health, 2020, 19, 96.	1.7	6
1448	Antiâ€Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016507.	1.6	21
1449	Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment. Scientific Reports, 2020, 10, 21835.	1.6	5
1450	Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007â€“2014. American Journal of Preventive Cardiology, 2020, 3, 100087.	1.3	3
1451	Identification and characterization of a rare variant in apolipoprotein A-IV, p.(V336M), and evaluation of HDL functionality in a Greek cohort with extreme HDL cholesterol levels. Archives of Biochemistry and Biophysics, 2020, 696, 108655.	1.4	1
1452	TriglicÃ©ridos, colesterol HDL y dislipidemia aterogÃ©nica en la guÃa europea para el control de las dislipidemias 2019. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2020, 32, 209-218.	0.4	3
1453	Association of non-HDL-C/HDL-C ratio and its dynamic changes with incident type 2 diabetes mellitus: The Rural Chinese Cohort Study. Journal of Diabetes and Its Complications, 2020, 34, 107712.	1.2	7
1454	A Review of Lipidomics of Cardiovascular Disease Highlights the Importance of Isolating Lipoproteins. Metabolites, 2020, 10, 163.	1.3	71
1455	Plasma lipids in patients with inflammatory bowel disease. Wiener Klinische Wochenschrift, 2020, 132, 283-294.	1.0	4
1456	Age-related trends in lipid levels: a large-scale cross-sectional study of the general Chinese population. BMJ Open, 2020, 10, e034226.	0.8	45
1457	Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors. Diagnostics, 2020, 10, 314.	1.3	63
1458	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Frontiers in Cardiovascular Medicine, 2020, 7, 88.	1.1	82
1459	Repositioning of the global epicentre of non-optimal cholesterol. Nature, 2020, 582, 73-77.	13.7	138

#	Article	IF	Citations
1460	Causes and Consequences of Hypertriglyceridemia. Frontiers in Endocrinology, 2020, 11, 252.	1.5	122
1461	Association of High-Density Lipoprotein Cholesterol With Cognitive Function: Findings From the PROspective Study of Pravastatin in the Elderly at Risk. Journal of Aging and Health, 2020, 32, 1267-1274.	0.9	4
1462	Gender heterogeneity in dyslipidemia prevalence, trends with age and associated factors in middle age rural Chinese. Lipids in Health and Disease, 2020, 19, 135.	1.2	17
1463	Ethanol-mediated upregulation of APOA1 gene expression in HepG2 cells is independent of de novo lipid biosynthesis. Lipids in Health and Disease, 2020, 19, 144.	1.2	8
1464	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Current Atherosclerosis Reports, 2020, 22, 25.	2.0	38
1465	Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?. Current Cardiology Reports, 2020, 22, 67.	1.3	42
1466	Association Between an Acute, Drug-Induced Decrease in High-Density Lipoprotein Cholesterol Levels and Risk of Cardiovascular Events. Clinical Drug Investigation, 2020, 40, 747-754.	1.1	1
1467	In-depth Mendelian randomization analysis of causal factors for coronary artery disease. Scientific Reports, 2020, 10, 9208.	1.6	9
1468	Effects of eicosapentaenoic acid and docosahexaenoic acidversusÎ±-linolenic acid supplementation on cardiometabolic risk factors: a meta-analysis of randomized controlled trials. Food and Function, 2020, 11, 1919-1932.	2.1	16
1469	Polygenic Hyperlipidemias and Coronary Artery Disease Risk. Circulation Genomic and Precision Medicine, 2020, 13, e002725.	1.6	60
1470	Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Medicine, 2020, 17, e1003062.	3.9	470
1471	Minority-centric meta-analyses of blood lipid levels identify novel loci in the Population Architecture using Genomics and Epidemiology (PAGE) study. PLoS Genetics, 2020, 16, e1008684.	1.5	17
1472	Triglycerides and Cardiovascular Outcomesâ€"Can We REDUCE-ITâ€‰?. International Journal of Angiology, 2020, 29, 002-011.	0.2	5
1473	On the Chameleonic Behaviour of Cholesterol through a Fractal/Multifractal Model. Computational and Mathematical Methods in Medicine, 2020, 2020, 1-11.	0.7	0
1474	Association Between Atherosclerosis and Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes Mellitus . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1911-1920.	1.1	9
1475	Atherosclerotic diseases and lung cancer â€“ a ten-year cross-sectional study in Cyprus. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 72-78.	0.5	0
1476	Advanced Glycated apoA-IV Loses Its Ability to Prevent the LPS-Induced Reduction in Cholesterol Efflux-Related Gene Expression in Macrophages. Mediators of Inflammation, 2020, 2020, 1-11.	1.4	6
1477	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology, 2020, 27, 1663-1674.	0.8	9

#	Article	IF	Citations
1478	Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis. Journal of Biological Chemistry, 2020, 295, 4836-4848.	1.6	13
1479	Triglycerides and residual risk. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 95-103.	1.2	42
1480	High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. Metabolic Syndrome and Related Disorders, 2020, 18, 176-185.	0.5	76
1481	The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors. Circulation, 2020, 141, 803-814.	1.6	75
1482	Synthetic apolipoprotein A-I mimetic peptide 4F protects hearts and kidneys after myocardial infarction. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2020, 318, R529-R544.	0.9	9
1483	Association of cholesterol uptake capacity, a novel indicator for HDL functionality, and coronary plaque properties: An optical coherence tomography-based observational study. Clinica Chimica Acta, 2020, 503, 136-144.	0.5	10
1484	Heart Disease and Stroke Statisticsâ€”2020 Update: A Report From the American Heart Association. Circulation, 2020, 141, e139-e596.	1.6	5,545
1485	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis, 2020, 294, 46-61.	0.4	137
1486	Predictive value of metabolomic biomarkers for cardiovascular disease risk: a systematic review and meta-analysis. Biomarkers, 2020, 25, 101-111.	0.9	24
1487	Association of four lipid components with mortality, myocardial infarction, and stroke in statin-naÃ¯ve young adults: A nationwide cohort study. European Journal of Preventive Cardiology, 2020, 27, 870-881.	0.8	31
1488	The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?. Current Opinion in Lipidology, 2020, 31, 140-146.	1.2	29
1489	Lipid-Modifying Agents, FromÂStatinsÂtoÂPCSK9 Inhibitors. Journal of the American College of Cardiology, 2020, 75, 1945-1955.	1.2	47
1492	High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential. Frontiers in Cardiovascular Medicine, 2020, 7, 39.	1.1	52
1493	Correlation without a cause: an epidemiological odyssey. International Journal of Epidemiology, 2020, 49, 4-14.	0.9	45
1494	Association of Carotid Atherosclerosis With Lipid Components in Asymptomatic Low-Income Chinese: A Population-Based Cross-Sectional Study. Frontiers in Neurology, 2020, 11, 276.	1.1	10
1495	HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies. European Journal of Preventive Cardiology, 2020, 27, 1187-1203.	0.8	72
1496	Enrichment of Tc1 cells and T cell resistance to suppression are associated with dysglycemia in the visceral fat in human obesity. BMJ Open Diabetes Research and Care, 2020, 8, e000772.	1.2	7
1497	Determinants of carotid intima-media thickness in asymptomatic elders: a population-based cross-sectional study in rural China. Postgraduate Medicine, 2020, 132, 544-550.	0.9	1

#	Article	IF	Citations
1498	Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2020, 15, 147-157.	1.2	12
1499	To fast or not to fast: Lipid measurement and cardiovascular disease risk estimation in rural sub-Saharan Africa. Journal of Global Health, 2020, 10, 010407.	1.2	6
1500	Insights into gene expression responses to infections in teleosts using microarray data: a systematic review. Reviews in Aquaculture, 2021, 13, 18-42.	4.6	2
1501	HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. European Journal of Preventive Cardiology, 2021, 28, 166-173.	0.8	26
1502	The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease. International Journal of Cardiology, 2021, 322, 251-257.	0.8	13
1503	The association between ambient air pollution and blood lipids: A longitudinal study in Shijiazhuang, China. Science of the Total Environment, 2021, 752, 141648.	3.9	42
1504	Time-of-day and Meal Size Effects on Clinical Lipid Markers. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1373-e1379.	1.8	11
1505	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. Annual Review of Medicine, 2021, 72, 447-458.	5.0	12
1506	A homogeneous assay to determine high-density lipoprotein subclass cholesterol in serum. Analytical Biochemistry, 2021, 613, 114019.	1.1	4
1507	Lipid temporal trends in normal-weight youth. American Heart Journal, 2021, 231, 68-72.	1.2	5
1508	Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study. Journal of Lipid Research, 2021, 62, 100044.	2.0	32
1509	Association between metabolic syndrome and gestational diabetes mellitus in women and their children: a systematic review and meta-analysis. Endocrine, 2021, 71, 310-320.	1.1	27
1510	Update on Lipids and Lipoproteinsâ€"Reply. JAMA - Journal of the American Medical Association, 2021, 325, 400.	3.8	1
1511	The Risk of Fasting Triglycerides and its Related Indices for Ischemic Cardiovascular Diseases in Japanese Community Dwellers: the Suita Study. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1275-1288.	0.9	17
1512	Diabetes Mellitus Modifies the Association of Serum Triglycerides with Ischemic Cardiovascular Disease Mortality: The Ibaraki Prefectural Health Study (IPHS). Journal of Atherosclerosis and Thrombosis, 2021, , .	0.9	1
1513	Lipoprotein and Lipid Metabolism. , 2021, , 235-278.		2
1514	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Laboratornaya Sluzhba, 2021, 10, 45.	0.0	1
1515	EvaluaciÃ³n de lÃpidos en suero, Â¿estÃ¡ hecho todo?. , 2021, 32, 179-181.		0

#	Article	IF	Citations
1516	Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK Biobank. Wellcome Open Research, 2020, 5, 222.	0.9	26
1517	What HaveWe Learned fromGWAS?. , 2021, , 159-183.		0
1519	Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1020-1030.	0.9	2
1520	Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	11
1521	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red) Tj ETQq0 0 1.7 rgBT /Overlock 10		0
1523	Biomarkers. , 2021, , 31-64.		0
1524	Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. European Journal of Preventive Cardiology, 2022, 29, e53-e64.	0.8	15
1525	Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. PLoS Medicine, 2021, 18, e1003498.	3.9	95
1526	Impact of Dyslipidemia on Ischemic Stroke. Stroke Revisited, 2021, , 23-41.	0.2	0
1527	Angiopoietinâ€like protein 4 and clinical outcomes in ischemic stroke patients. Annals of Clinical and Translational Neurology, 2021, 8, 687-695.	1.7	5
1528	Heart Disease and Stroke Statisticsâ€”2021 Update. Circulation, 2021, 143, e254-e743.	1.6	3,444
1529	Development and Validation of a Predictive Model for Coronary Artery Disease Using Machine Learning. Frontiers in Cardiovascular Medicine, 2021, 8, 614204.	1.1	9
1530	APOA1: a Protein with Multiple Therapeutic Functions. Current Atherosclerosis Reports, 2021, 23, 11.	2.0	72
1531	Alcohol consumption and risk of cardiovascular disease, cancer and mortality: a prospective cohort study. Nutrition Journal, 2021, 20, 13.	1.5	23
1532	A Pilot Study Comparing the Effects of Consuming 100% Orange Juice or Sucrose-Sweetened Beverage on Risk Factors for Cardiometabolic Disease in Women. Nutrients, 2021, 13, 760.	1.7	3
1533	Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure. Scientific Reports, 2021, 11, 3141.	1.6	20
1534	Triglycerides and risk of atherosclerotic cardiovascular disease: An update. Archives of Cardiovascular Diseases, 2021, 114, 132-139.	0.7	39
1535	The Association between HDL-C and Subclinical Atherosclerosis Depends on CETP Plasma Concentration: Insights from the IMPROVE Study. Biomedicines, 2021, 9, 286.	1.4	7

#	Article	IF	Citations
1538	The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes. Current Atherosclerosis Reports, 2021, 23, 23.	2.0	21
1539	High prevalence of dyslipidaemia subtypes and their associated personal and clinical attributes in Malaysian adults: the REDISCOVER study. BMC Cardiovascular Disorders, 2021, 21, 149.	0.7	17
1540	Apolipoprotein E4 Moderates the Association Between Vascular Risk Factors and Brain Pathology. Alzheimer Disease and Associated Disorders, 2021, 35, 223-229.	0.6	3
1541	Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-TreatedÂPatients. Journal of the American College of Cardiology, 2021, 77, 1439-1450.	1.2	144
1542	UNDERSTANDING THE METABOLIC RISK FACTOR CLUSTERING: ITS ASSOCIATION WITH OXIDATIVE STRESS AND DIABETES MELLITUS. , 2021, , 200-202.		0
1544	Which diagnostic criteria of metabolic syndrome are predictors of cardiovascular diseases in elderly populations?. Journal of Clinical and Translational Endocrinology, 2021, 23, 100248.	1.0	1
1545	Compatibility between an overnight fasting and random cholesterol tests in Asians. Scientific Reports, 2021, 11, 6478.	1.6	3
1546	The difference between fasting and non-fasting lipid measurements is not related to statin treatment. Annals of Translational Medicine, 2021, 9, 386-386.	0.7	8
1547	Cardiovascular Risk Assessment in the Older Athlete. Sports Health, 2021, 13, 622-629.	1.3	3
1548	Triglycerides and cardiovascular disease. Current Opinion in Cardiology, 2021, 36, 469-477.	0.8	19
1549	Role of Short Chain Fatty Acids and Apolipoproteins in the Regulation of Eosinophilia-Associated Diseases. International Journal of Molecular Sciences, 2021, 22, 4377.	1.8	10
1550	Family history of esophageal cancer modifies the association of serum lipids and malignant esophageal lesions: a nested case-control study from the â€œEndoscopic Screening for Esophageal Cancer in Chinaâ€•trial. Chinese Medical Journal, 2021, 134, 1079-1086.	0.9	2
1551	A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease. ELife, 2021, 10, .	2.8	25
1552	Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart, 2021, 107, 1369-1375.	1.2	53
1553	Improvement of serum lipid parameters in consumers of Mexican Wagyuâ€Cross beef: A randomized controlled trial. Journal of Food Science, 2021, 86, 2713-2726.	1.5	3
1554	Causal Language in Observational Orthopaedic Research. Journal of Bone and Joint Surgery - Series A, 2021, 103, e76.	1.4	12
1555	Large HDL2 combined with inflammatory factors as superior predictors for coronary artery disease than small HDL3. Annals of Translational Medicine, 2021, 9, 672-672.	0.7	1
1556	HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review. International Journal of Molecular Sciences, 2021, 22, 4547.	1.8	28

#	Article	IF	Citations
1557	High serum high-density lipoprotein and low serum triglycerides in Kratom users: A study of Kratom users in Thailand. Heliyon, 2021, 7, e06931.	1.4	7
1558	Ceramide Scores Predict Cardiovascular Risk in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1558-1569.	1.1	29
1559	Total cholesterol/HDL-C ratio versus non-HDL-C as predictors for ischemic heart disease: a 17-year follow-up study of women in southern Sweden. BMC Cardiovascular Disorders, 2021, 21, 163.	0.7	27
1560	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	2.3	56
1561	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. Cells, 2021, 10, 1061.	1.8	23
1562	An Update on Cardiovascular Risk Factors After Kawasaki Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 671198.	1.1	15
1563	Update on smoking. Alternatives for the management of patients with cardiovascular risk. Hipertension Y Riesgo Vascular, 2021, 38, 178-185.	0.3	2
1564	High Density Lipoproteins and Diabetes. Cells, 2021, 10, 850.	1.8	34
1565	The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity. Atherosclerosis, 2021, 323, 44-53.	0.4	17
1566	Role of dyslipidemia in early vascular aging syndrome. Turkish Journal of Medical Sciences, 2021, 51, 727-734.	0.4	10
1567	New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e208-e223.	1.1	26
1568	ANGPTL3 Variants Associate with Lower Levels of Irisin and C-Peptide in a Cohort of Arab Individuals. Genes, 2021, 12, 755.	1.0	0
1569	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.4	83
1570	General Perspectives for the Treatment of Atherosclerosis. Letters in Drug Design and Discovery, 2021, 18, 314-324.	0.4	0
1571	Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies. Cardiovascular Research, 2022, 118, 1330-1343.	1.8	24
1572	The role of HDL cholesterol as a measure of 10-year cardiovascular risk should be re-evaluated. European Journal of Preventive Cardiology, 2021, , .	0.8	0
1573	Sex and Racial Differences in High-Density Lipoprotein Levels in Acute Coronary Syndromes. American Journal of the Medical Sciences, 2021, 362, 435-441.	0.4	2
1574	Associations between High-Density Lipoprotein Functionality and Major Adverse Cardiovascular Events in Patients Who Have Undergone Coronary Computed Tomography Angiography. Journal of Clinical Medicine, 2021, 10, 2431.	1.0	3

#	Article	IF	Citations
1575	Lower triglyceride levels are associated with better endothelial function. Journal of Clinical Lipidology, 2021, 15, 500-511.	0.6	10
1576	Serum lipids are novel predictors for thyroid autoimmunity in the general population with normal TSH levels from a cross-sectional study. Endocrine, 2021, 73, 331-338.	1.1	6
1577	Association Between Renal Dysfunction and Low HDL Cholesterol Among the Elderly in China. Frontiers in Cardiovascular Medicine, 2021, 8, 644208.	1.1	7
1578	Discordance Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Progression of Coronary Artery Calcification in Middle Age. Circulation Journal, 2021, 85, 900-907.	0.7	7
1579	SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies. Biomedicines, 2021, 9, 612.	1.4	20
1580	Alterations in the lipid profile associate with a dysregulated inflammatory, prothrombotic, anti-fibrinolytic state and development of severe acute kidney injury in coronavirus disease 2019 (COVID-19): A study from Cincinnati, USA. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 863-868.	1.8	8
1581	Erectile Dysfunction Is a Hallmark of Cardiovascular Disease: Unavoidable Matter of Fact or Opportunity to Improve Menâ€™s Health?. Journal of Clinical Medicine, 2021, 10, 2221.	1.0	17
1582	High-Density Lipoprotein Cholesterol and the Risk of First Ischemic Stroke in a Chinese Hypertensive Population. Clinical Interventions in Aging, 2021, Volume 16, 801-810.	1.3	8
1583	Hipertrigliceridemia familiar/hipertrigliceridemia poligÃ©nica. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 37-42.	0.4	3
1584	Prevalence of High HDL Cholesterol and Its Associated Factors Among Tunisian Women of Childbearing Age: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2021, 18, 5461.	1.2	1
1585	Association of Early Renal Dysfunction with Lipid Profile Parameters among Hypertensives in Kazakhstan. Diagnostics, 2021, 11, 871.	1.3	4
1586	Evaluation of nonâ€invasive arterial stiffness parameters and their relationship with physical activity, anthropometric indices and lipid profiles in healthy middleâ€aged adults: Results of the PERSIAN cohort study. International Journal of Clinical Practice, 2021, 75, e14275.	0.8	4
1587	Peripheral Artery Disease and Abdominal Aortic Aneurysm: The Forgotten Diseases in COVID-19 Pandemic. Results from an Observational Study on Real-World Management. Medicina (Lithuania), 2021, 57, 672.	0.8	1
1588	Atherosclerotic cardiovascular disease events among statin eligible individuals with and without long-term healthy arterial aging. Atherosclerosis, 2021, 326, 56-62.	0.4	13
1589	The Genetic Basis of Hypertriglyceridemia. Current Atherosclerosis Reports, 2021, 23, 39.	2.0	17
1590	Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3. Circulation Genomic and Precision Medicine, 2021, 14, e003232.	1.6	3
1591	Statins in Healthy Adults: A Meta-Analysis. Medicina (Lithuania), 2021, 57, 585.	0.8	0
1592	Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats. Turkish Journal of Medical Sciences, 2021, 51, 1571-1577.	0.4	1

#	Article	IF	Citations
1593	Consumption of soy products and cardiovascular mortality in people with and without cardiovascular disease: a prospective cohort study of 0.5 million individuals. European Journal of Nutrition, 2021, 60, 4429-4438.	1.8	5
1594	Primary cardiovascular risk prediction by LDL-cholesterol in Caucasian middle-aged and older adults: a joint analysis of three cohorts. European Journal of Preventive Cardiology, 2022, 29, e128-e137.	0.8	9
1595	Predicting the probability of death using proteomics. Communications Biology, 2021, 4, 758.	2.0	10
1596	Nonâ€“High-Density Lipoprotein Cholesterol Predicts Adverse Outcomes in Acute Ischemic Stroke. Stroke, 2021, 52, 2035-2042.	1.0	12
1597	Managing dyslipidemia in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2221-2234.	0.9	14
1598	Atherogenic indices in non-arteritic ischemic optic neuropathy. International Journal of Ophthalmology, 2021, 14, 1041-1046.	0.5	4
1599	Abdominal and gluteofemoral fat depots show opposing associations with postprandial lipemia. American Journal of Clinical Nutrition, 2021, 114, 1467-1475.	2.2	9
1600	The significances and clinical implications of cholesterol components in human breast cancer. Science Progress, 2021, 104, 003685042110283.	1.0	8
1601	White Blood Cell Counts to High-Density Lipoprotein Cholesterol Ratio, as a Novel Predictor of Long-Term Adverse Outcomes in Patients After Percutaneous Coronary Intervention: A Retrospective Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 616896.	1.1	4
1602	LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker. Indian Heart Journal, 2021, 73, 544-548.	0.2	22
1603	Picky Eating in School-Aged Children: Sociodemographic Determinants and the Associations with Dietary Intake. Nutrients, 2021, 13, 2518.	1.7	8
1604	HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. Cells, 2021, 10, 1869.	1.8	46
1605	Research on the distribution spectrum of atherosclerotic plaques in patients with suspected coronary artery disease and the noninvasive screening model for coronary atherosclerosis burden. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3274-3285.	1.1	2
1606	Narrative review of the influence of diabetes mellitus and hyperglycemia on colorectal cancer risk and oncological outcomes. Translational Oncology, 2021, 14, 101089.	1.7	37
1607	MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, Highâ€Đensity Lipoprotein, and Lowâ€Đensity Lipoprotein Receptorâ€“Mediated Reverse Cholesterol Transport. Journal of the American Heart Association, 2021, 10, e014572.	1.6	18
1608	The challenge of choosing in cardiovascular risk management. Netherlands Heart Journal, 2022, 30, 47-57.	0.3	5
1609	Associations Between Macronutrients From Different Dietary Sources and Serum Lipids in 24 639 UK Biobank Study Participants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2190-2200.	1.1	11
1610	Familial Hypercholesterolemia: Do HDL Play a Role?. Biomedicines, 2021, 9, 810.	1.4	11

#	Article	IF	Citations
1611	Unraveling the Complexity of HDL Remodeling: On the Hunt to Restore HDL Quality. Biomedicines, 2021, 9, 805.	1.4	5
1612	A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT). Disease Markers, 2021, 2021, 1-10.	0.6	13
1613	Is a High HDL-Cholesterol Level Always Beneficial?. Biomedicines, 2021, 9, 1083.	1.4	22
1614	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	1.0	2,517
1615	Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, e631-e640.	0.8	0
1616	Functional diversity of high-density lipoproteins: finding the golden mean. , 2021, 17, 61-71.	0.0	3
1618	Comprehensive Use of Routine Clinical Parameters to Identify Patients at Risk of New-Onset Atrial Fibrillation in Acute Myocardial Infarction. Journal of Clinical Medicine, 2021, 10, 3622.	1.0	5
1619	HDL-C, longitudinal change and risk of mortality in a Chinese cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2669-2677.	1.1	5
1620	Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans. Nutrients, 2021, 13, 2706.	1.7	14
1621	Digital Technology Tools to Examine Patient Adherence to a Prescription-Only Omega-3 Polyunsaturated Fatty Acid Therapy To Mitigate Cardiovascular Risk: Protocol for a Prospective Observational Study and Preliminary Demographic Analysis. JMIR Research Protocols, 2021, 10, e29061.	0.5	3
1622	Inflammation Alters Relationship Between Highâ€Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients With Chronic Kidney Disease: Results From KNOWâ€CKD. Journal of the American Heart Association, 2021, 10, e021731.	1.6	9
1623	Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis. Biomedicines, 2021, 9, 985.	1.4	13
1624	Diabetic dyslipidaemia. Practical Laboratory Medicine, 2021, 26, e00248.	0.6	14
1625	Lower High-Density Lipoprotein Cholesterol Concentration Is Independently Associated with Greater Future Accumulation of Intra-Abdominal Fat. Endocrinology and Metabolism, 2021, 36, 835-844.	1.3	2
1626	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	0.8	220
1627	Association of pre-pandemic high-density lipoprotein cholesterol with risk of COVID-19 hospitalisation and death: The UK Biobank cohort study. Preventive Medicine Reports, 2021, 23, 101461.	0.8	13
1628	Is it Time for Single-Pill Combinations in Dyslipidemia?. American Journal of Cardiovascular Drugs, 2022, 22, 239-249.	1.0	4
1629	Renal function and lipid metabolism are major predictors of circumpapillary retinal nerve fiber layer thicknessâ€"the LIFE-Adult Study. BMC Medicine, 2021, 19, 202.	2.3	16

#	Article	IF	Citations
1630	Age dependent association between remnant cholesterol and cardiovascular disease. Atherosclerosis Plus, 2021, 45, 18-18.	0.3	2
1631	Relationship between serum lipid levels and ischemic stroke in patients with atrial fibrillation: a nested caseâ€“control study based on the China Atrial Fibrillation Registry. BMC Cardiovascular Disorders, 2021, 21, 424.	0.7	7
1632	Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study. Clinical Therapeutics, 2021, 43, 1735-1747.	1.1	7
1633	A lifestyle intervention with an energy-restricted Mediterranean diet and physical activity enhances HDL function: a substudy of the PREDIMED-Plus randomized controlled trial. American Journal of Clinical Nutrition, 2021, 114, 1666-1674.	2.2	15
1634	Association between Dietary Patterns and Low HDL-C among Community-Dwelling Elders in North China. Nutrients, 2021, 13, 3308.	1.7	8
1635	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	1.0	303
1636	Association between low-density cholesterol change and outcomes in acute ischemic stroke patients who underwent reperfusion therapy. BMC Neurology, 2021, 21, 360.	0.8	4
1637	Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack. Stroke, 2022, 53, 79-86.	1.0	11
1638	Are patients recovering from Kawasaki disease at increased risk for accelerated atherosclerosis? A meta-analysis. World Journal of Pediatrics, 2021, 17, 476-483.	0.8	5
1640	Mediation of the APOE associations with Alzheimerâ€™s and coronary heart diseases through body mass index and lipids. GeroScience, 2022, 44, 1141-1156.	2.1	8
1641	Urine Albumin-Creatinine ratio is associated with prognosis in patients with diabetic foot osteomyelitis. Diabetes Research and Clinical Practice, 2021, 180, 109043.	1.1	7
1642	Postprandial plasma lipidome responses to a high-fat meal among healthy women. Journal of Nutritional Biochemistry, 2021, 97, 108809.	1.9	3
1643	Impact of common cardio-metabolic risk factors on fatal and non-fatal cardiovascular disease in Latin America and the Caribbean: an individual-level pooled analysis of 31 cohort studies. The Lancet Regional Health Americas, 2021, 4, 100068.	1.5	1
1644	Lipoproteins in chronic kidney disease: from bench to bedside. European Heart Journal, 2021, 42, 2170-2185.	1.0	32
1645	Shifting perspectives â€“ interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals. World Journal of Hepatology, 2021, 13, 80-93.	0.8	1
1648	Insights into the prognosis of lipidomic dysregulation for death risk in patients with coronary artery disease. Clinical and Translational Medicine, 2020, 10, e189.	1.7	14
1649	Genetic Disorders of HDL Metabolism. Contemporary Endocrinology, 2015, , 221-233.	0.3	1
1650	High-Density Lipoprotein: Structural and Functional Changes Under Uremic Conditions and the Therapeutic Consequences. Handbook of Experimental Pharmacology, 2015, 224, 423-453.	0.9	7

#	Article	IF	Citations
1651	Lipid-Modifying Drugs: Pharmacology and Perspectives. Advances in Experimental Medicine and Biology, 2020, 1177, 133-148.	0.8	6
1652	Recent Advances in the Critical Role of the Sterol Efflux Transporters ABCG5/G8 in Health and Disease. Advances in Experimental Medicine and Biology, 2020, 1276, 105-136.	0.8	14
1653	Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080.		5
1654	The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease. , 2011, , 230-251.		1
1655	An examination of the relationship between discrimination, depression, and hypertension in Native Hawaiians.. Asian American Journal of Psychology, 2019, 10, 249-257.	0.7	10
1656	Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL. Clinical Science, 2019, 133, 2221-2235.	1.8	24
1657	Serum cholesterol as a risk factor for coronary heart disease revisited. South African Journal of Clinical Nutrition, 2015, 28, 34-37.	0.3	3
1658	Standardized secondary prevention in patients with ST-elevation myocardial infarction. European Journal of Preventive Cardiology, 2020, , .	0.8	4
1659	Ischemic Heart Disease in Women: A Review for Primary Care Physicians. Southern Medical Journal, 2011, 104, 200-204.	0.3	8
1665	Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. Journal of Clinical Investigation, 2011, 121, 2693-2708.	3.9	464
1666	Pro-neurotensin/neuromedin N and risk of ischemic stroke: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Vascular Medicine, 2020, 25, 534-540.	0.8	7
1667	Triglyceride-containing lipoprotein sub-fractions and risk of coronary heart disease and stroke: A prospective analysis in 11,560 adults. European Journal of Preventive Cardiology, 2020, 27, 1617-1626.	0.8	19
1668	Assessment of apolipoprotein B/apolipoprotein A-I ratio in non-ST segment elevation acute coronary syndrome patients. Egyptian Heart Journal, 2020, 72, 27.	0.4	8
1669	Is the ratio of apoB/apoA-1 the best predictor for the severity of coronary artery lesions in Chinese diabetics with stable angina pectoris? An assessment based on Gensini scores. Journal of Geriatric Cardiology, 2015, 12, 402-9.	0.2	12
1671	Epidemiology and Primary Prevention of Stroke. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 260-267.	0.4	27
1672	Non-HDL cholesterol is better than LDL-c at predicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A report from a Venezuelan population. F1000Research, 0, 7, 504.	0.8	4
1673	Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK Biobank. Wellcome Open Research, 2020, 5, 222.	0.9	27
1674	The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers. Journal of Lipid and Atherosclerosis, 2019, 8, 173.	1.1	19

#	Article	IF	Citations
1675	State of the Science on Cardiometabolic Risk After Spinal Cord Injury: Recap of the 2013 ASIA Pre-Conference on Cardiometabolic Disease. Topics in Spinal Cord Injury Rehabilitation, 2014, 20, 105-112.	0.8	6
1676	Inferring causal direction between two traits in the presence of horizontal pleiotropy with GWAS summary data. PLoS Genetics, 2020, 16, e1009105.	1.5	18
1677	The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled Analysis. PLoS ONE, 2013, 8, e65174.	1.1	496
1678	Trends in Prevalence of Dyslipidaemias and the Risk of Mortality in Lithuanian Urban Population Aged 45â€“64 in Relation to the Presence of the Dyslipidaemias and the Other Cardiovascular Risk Factors. PLoS ONE, 2014, 9, e100158.	1.1	10
1679	Diabetes Mellitus and Risk of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e108196.	1.1	70
1680	Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions. PLoS ONE, 2014, 9, e108891.	1.1	86
1681	A Snack Dietary Pattern Increases the Risk of Hypercholesterolemia in Northern Chinese Adults: A Prospective Cohort Study. PLoS ONE, 2015, 10, e0134294.	1.1	23
1682	Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. PLoS ONE, 2016, 11, e0145719.	1.1	13
1683	Cholestasis-associated glucocorticoid overexposure does not increase atherogenesis. Journal of Endocrinology, 2019, 242, 1-12.	1.2	7
1684	Investigation of the Predictive Values of Triglyceride/HDL Cholesterol Ratio and Whole Blood Viscosity with Regard to Severe Peripheral or Carotid Artery Disease in Patients Scheduled for Coronary Bypass. Heart Surgery Forum, 2020, 23, E310-E314.	0.2	9
1685	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. European Cardiology Review, 2020, 15, 1-9.	0.7	38
1686	Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science. European Cardiology Review, 2020, 15, e56.	0.7	10
1687	Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes. US Cardiology Review, 2019, 13, 49-53.	0.5	6
1688	Dyslipidemia and the risk of incident hypertension in a population of community-dwelling Brazilian elderly: the BambuÃ-cohort study of aging. Cadernos De Saude Publica, 2011, 27, s351-s359.	0.4	10
1689	Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.2	40
1690	Atheromarkers of high-density lipoproteins. Part 1. High-density lipoproteins: Structure, composition, physicochemical and physiological antiatherogenic properties, their mechanisms and markers (a) Tj ETQq1 1 0.784314 rgBT /Overlock	3.4	
1691	Apolipoprotein B/AI ratio as an independent risk factor for intracranial atherosclerotic stenosis. Aging, 2019, 11, 6851-6862.	1.4	7
1692	Association of genetic variations in the lipid regulatory pathway genes FBXW7 and SREBPs with coronary artery disease among Han Chinese and Uygur Chinese populations in Xinjiang, China. Oncotarget, 2017, 8, 88199-88210.	0.8	2

#	Article	IF	Citations
1693	The Role of Triglyceride in Cardiovascular Disease in Asian Patients with Type 2 Diabetes - A Systematic Review. Review of Diabetic Studies, 2013, 10, 101-109.	0.5	28
1694	Low Levels of High-Density Lipoprotein Cholesterol Do Not Predict the Incidence of Type 2 Diabetes in an Iranian High-Risk Population: The Isfahan Diabetes Prevention Study. Review of Diabetic Studies, 2016, 13, 187-196.	0.5	1
1695	Re-assessing the role of non-fasting lipids; a change in perspective. Annals of Translational Medicine, 2016, 4, 431-431.	0.7	16
1696	HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling. Current Medicinal Chemistry, 2019, 26, 1544-1575.	1.2	13
1697	Biological Consequences of Dysfunctional HDL. Current Medicinal Chemistry, 2019, 26, 1644-1664.	1.2	65
1698	Cardiovascular Risk in Perimenopausal Women. Current Vascular Pharmacology, 2019, 17, 591-594.	0.8	35
1699	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Current Vascular Pharmacology, 2019, 17, 498-514.	0.8	38
1700	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice. Current Diabetes Reviews, 2020, 16, 949-956.	0.6	2
1701	Bioinformatics Study on Serum Triglyceride Levels for Analysis of a Potential Risk Factor Affecting Blood Pressure Variability. Current Bioinformatics, 2019, 14, 376-385.	0.7	6
1702	Imaging of Coronary Arteries Aid in Prevention of Atherosclerosis and Clinical Coronary Heart Disease. The Open Epidemiology Journal, 2011, 4, 152-164.	1.0	4
1703	Role of niacin in current clinical practice. Minerva Medica, 2019, 110, 79-83.	0.3	8
1704	The Diagnosis and Treatment of Hypertriglyceridemia. Deutsches Ärzteblatt International, 2019, 116, 825-832.	0.6	50
1705	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technology Assessment, 2015, 19, 1-402.	1.3	30
1706	Correlation of Lipid Parameters and Markers of Insulin Resistance: Does Smoking Make a Difference?. Physiological Research, 2014, 63, S387-S393.	0.4	6
1707	Lipids and Lipid Mediators Associated with the Risk and Pathology of Ischemic Stroke. International Journal of Molecular Sciences, 2020, 21, 3618.	1.8	40
1708	THE EFFECTS OF A LOW-CARBOHYDRATE HIGH-FAT DIET AND PHYSICAL EXERCISE ON TYPE 2 DIABETIC PATIENTS: A REVIEW. Journal of Applied Sports Sciences, 2018, 1, 70-87.	0.5	1
1709	Impact of Isolated Low HDL Cholesterolemia on the Risk of Coronary Artery Disease: A 4-Year Community-Based Prospective Study. Korean Journal of Medicine, 2013, 84, 229.	0.1	1
1710	Les maladies chroniquesÂ: tendances rÃ©centes, enjeux et perspectives dâ€™Ã©volution. Sante Publique, 2015, S1, 189-197.	0.0	6

#	Article	IF	Citations
1711	Lipids, Blood Pressure, Kidney-what was New in 2012?. International Journal of Pharmacology, 2012, 8, 659-678.	0.1	9
1712	Is it time to abandon fasting for routine lipid testing?. Cleveland Clinic Journal of Medicine, 2017, 84, 919-922.	0.6	6
1713	Lifeâ€™s Simple 7 Approach to Atrial Fibrillation Prevention. Journal of Atrial Fibrillation, 2018, 11, 2051.	0.5	6
1714	Two-Sample Mendelian Randomization Study of Lipid levels and Ischemic Heart Disease. Korean Circulation Journal, 2020, 50, 940.	0.7	14
1715	Triglyceride and cardiovascular risk: A critical appraisal. Indian Journal of Endocrinology and Metabolism, 2016, 20, 418.	0.2	29
1716	The Importance of Non High Density Lipoprotein Cholesterol in Dyslipidaemia Management. Journal of Diabetes & Metabolism, 2015, 6, .	0.2	3
1717	Peripheral arterial disease, type 2 diabetes and postprandial lipidaemia: Is there a link?. World Journal of Diabetes, 2014, 5, 577.	1.3	18
1718	High density lipoprotein and cardiovascular diseases. World Journal of Cardiology, 2013, 5, 210.	0.5	19
1719	Testing lipid markers as predictors of all-cause morbidity, cardiac disease, and mortality risk in captive western lowland gorillas (<i>Gorilla gorilla gorilla</i>). Primate Biology, 2020, 7, 41-59.	0.6	3
1720	The HDL paradox: what does it mean and how to manage low serum HDL cholesterol level?. Kardiologia Polska, 2014, 72, 681-686.	0.3	5
1721	Combination Low Carbohydrate, High Fat Diet and Physical Activity Intervention on Lipoprotein-Lipids in Type 2 Diabetics. Asian Journal of Sports Medicine, 2019, In Press, .	0.1	3
1722	Non-HDL cholesterol is a good predictor of the risk of increased arterial stiffness in postmenopausal women in an urban Brazilian population. Clinics, 2017, 72, 106-110.	0.6	22
1723	A systematic review of population-based studies on lipid profiles in Latin America and the Caribbean. ELife, 2020, 9, .	2.8	13
1724	The association between serum lipids and risk of premature mortality in Latin America: a systematic review of population-based prospective cohort studies. PeerJ, 2019, 7, e7856.	0.9	1
1725	Atherogenesis in Psoriasis: Evaluation of the Serum Activities of Non-high-density Lipoprotein Cholesterol and Other Lipids Among Newly Diagnosed Psoriasis Patients. Cureus, 2019, 11, e4203.	0.2	2
1726	Cardiovascular prevention: Frontiers in lipid guidelines. Clinical Medicine, 2020, 20, 36-42.	0.8	6
1727	Cardiovascular Impact of Metabolic Abnormalities. ISGE Series, 2021, , 205-215.	0.2	0
1728	Association of Cigarette Smoking with Hyperlipidemia in Male Individuals. Food and Nutrition Sciences (Print), 2021, 12, 937-949.	0.2	2

#	Article	IF	Citations
1729	Serum lipid profile based on the prandial state among adult subjects. African Journal of Biochemistry Research, 2021, 15, 15-21.	0.2	0
1730	Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature Communications, 2021, 12, 5640.	5.8	57
1731	Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor. Global Cardiology Science & Practice, 2021, 2021, e202119.	0.3	2
1732	Assessing the Causal Role of Selenium in Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study. Frontiers in Genetics, 2021, 12, 724903.	1.1	5
1733	HDL (High-Density Lipoprotein) Subspecies, Prevalent Covert Brain Infarcts, and Incident Overt Ischemic Stroke: Cardiovascular Health Study. Stroke, 2022, 53, 1292-1300.	1.0	6
1734	Trajectories of Energy Intake Distribution and Risk of Dyslipidemia: Findings from the China Health and Nutrition Survey (1991â€“2018). Nutrients, 2021, 13, 3488.	1.7	8
1735	Coronary risk factors. , 2011, , 44-52.		0
1736	Evaluation of paraoxonase 1 arylesterase activity and lipid peroxide levels in patients with type 1 diabetes. Polish Archives of Internal Medicine, 2011, 121, 448-455.	0.3	7
1737	Interpreting Laboratory Tests. , 2012, , 176-204.		3
1742	Are Lipid Panels Altered by a Large Lunch Meal in Type 2 Diabetes?. Open Journal of Endocrine and Metabolic Diseases, 2013, 03, 99-102.	0.2	0
1743	Monogene FettstoffwechselstÃ¶rungen. , 2014, , 387-394.		0
1744	Effect of Short-term Fenofibrate Therapy on Blood Creatinine Levels in Patients with Hypertriglyceridemia. Korean Journal of Medicine, 2014, 86, 702.	0.1	1
1745	Vitamin D Status, C-Reactive Protein and Risk of Coronary Artery Diseaseâ€”A Hospital-Based Study. Pharmacology & Pharmacy, 2014, 05, 1148-1156.	0.2	0
1748	A Closer Look at Cardioprotective Function of HDL: Revise the HDL â€“ Cholesterol Hypothesis?. Indonesian Biomedical Journal, 2014, 6, 17.	0.2	0
1749	Stress, Depression, and Cardiovascular Risk in Children. , 2015, , 1-21.		0
1751	Hypertriglyceridemic-Waist Phenotype is a Useful Global Assessment Tool for Predicting Acute Myocardial Infarction. Journal of Cardiovascular Diseases & Diagnosis, 2015, 03, .	0.0	0
1752	Non-Classical Cardiovascular Disease Risk Factors. , 2015, , 119-122.		0
1754	Insight into the Spectrum of Coronary Atherosclerosis in Asymptomatic Urban Han Chinese Population by Coronary Computed Tomography Angiography. PLoS ONE, 2015, 10, e0132188.	1.1	1

#	Article	IF	Citations
1756	Comorbidities Often Associated with Brain Damage in Hypertension: Salt and Alcohol Intake and Smoking Habits. Updates in Hypertension and Cardiovascular Protection, 2016, , 21-34.	0.1	0
1757	Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. Journal of the Japanese Coronary Association, 2016, 22, 217-227.	0.0	0
1758	15.ÂCardiovascular Disease. , 2016, , .		0
1759	Stress, Depression, and Cardiovascular Risk in Children. , 2016, , 191-211.		1
1760	Newer Lipid Markers: Apolipoprotein B, LDL Particle Concentration, and Triglyceride-Rich Lipoproteins â€“ When Are They Needed?. , 2016, , 145-158.		0
1761	8. Sphingosine-1-phosphate-rich high-density lipoprotein in cardiovascular health and disease. Human Health Handbooks, 2016, , 137-154.	0.1	0
1762	FACEing reality: productive tensions between our epidemiological questions, methods and mission. International Journal of Epidemiology, 2016, 45, dyw330.	0.9	21
1763	INNOVATIONS IN DIAGNOSTICS AND TREATMENT OF PATIENTS WITH HYPERTRIGLYCERIDEMIA. Science and Innovations in Medicine, 2017, 2, 43-51.	0.2	1
1764	25 Dietary Fats and Coronary Heart Disease. , 2017, , 639-666.		1
1766	Rs214101 Variation of NUCB2/Nesfatin-1 Gene: Effects on Metabolic Parameters Independent of Type 2 Diabetes or Obesity in Coronary Artery Disease. Journal of Human Genetics and Genomics, 2017, In Press, .	0.0	0
1768	16. The role of dietary saturated fatty acids in cardiovascular disease. Human Health Handbooks, 2017, , 321-356.	0.1	0
1770	Atherostenosis and Thrombosis of Extracranial Vessels. , 2018, , 109-136.		0
1771	An update on the measurement and management of cholesterol with specific reference to secondary prevention of cardiovascular disease (CVD). South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2018, 60, 15-21.	0.2	1
1772	The High Density Lipoprotein Cholesterol Hypothesis Revisited. Indonesian Biomedical Journal, 2018, 10, 84-103.	0.2	0
1773	Triglyceride and high density lipoprotein metabolism in diabetes. Journal of Diabetes, Metabolic Disorders & Control, 2018, 5, 158-165.	0.2	0
1774	Significance of Non HDL-cholesterol and Triglyceride to HDL-cholesterol Ratio as Predictors for Metabolic Syndrome among Korean Elderly. Korean Journal of Clinical Laboratory Science, 2018, 50, 245-252.	0.1	7
1775	Effect of lipid parameters on carotid artery disease progression in patients undergoing carotid endarterectomy and unoperated patients with non-severe carotid artery stenosis. The European Research Journal, 2019, 5, 159-165.	0.1	0
1777	A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis. Vnitrni Lekarstvi, 2018, 64, 1124-1128.	0.1	1

#	Article	IF	Citations
1783	Time course of changes in lipid profile measures in patients with early psoriatic arthritis during adalimumab therapy. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 511-516.	0.2	0
1785	Effects of aged garlic extract on arterial elasticity in a placeboâ€'controlled clinical trial using EndoPATâ„¢ technology. Experimental and Therapeutic Medicine, 2020, 19, 1490-1499.	0.8	3
1786	Non-HDL cholesterol is better than LDL-c at predicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A report from a Venezuelan population. F1000Research, 0, 7, 504.	0.8	0
1787	Colesterol-no HDL como objetivo terapÃ©utico. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 28-33.	0.4	3
1788	Lipid disorders. , 2020, , 2055-2097.		0
1789	Quality over Quantity: A Case Based Review of HDL Function and Dysfunction. International Journal of Clinical Cardiology, 2020, 7, .	0.1	1
1790	Supplementation with aqueous extract of Talinum triangulare and effect on the hematology and serum biochemistry in growing pullets. Turkish Journal of Veterinary and Animal Sciences, 2020, 44, 487-494.	0.2	0
1791	Valid cardiac biomarkers. Part I. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2573.	0.4	3
1792	LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 3005-3014.	1.1	6
1793	Genetically-engineered hamster models: applications and perspective in dyslipidemia and atherosclerosis-related cardiovascular disease. Medical Review, 2021, 1, 92-110.	0.3	1
1794	Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides. ACS Applied Bio Materials, 2020, 3, 8978-8988.	2.3	8
1796	Fine genetic mapping of the chromosome 11q23.3 region in a Han Chinese population: insights into the apolipoprotein genes underlying the blood lipid-lipoprotein variances. Journal of Genetics and Genomics, 2020, 47, 756-769.	1.7	0
1797	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. Contemporary Cardiology, 2021, , 139-158.	0.0	2
1798	The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. Contemporary Cardiology, 2021, , 121-138.	0.0	0
1799	Ersonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins. Vestnik Medicinskogo Instituta REAVIZ ReabilitaciÃ¢, VraÄ•I ZdorovÊ¹e, 2020, , 88-104.	0.1	0
1800	Cardiovascular Risk Assessment: From Global Risk Scoring to Risk Enhancing Factors. Contemporary Cardiology, 2021, , 35-59.	0.0	1
1801	How ApoB Measurements Could Improve Prevention of Cardiovascular Disease. Contemporary Cardiology, 2021, , 545-563.	0.0	0
1802	Cardiometabolic Parameters Among Transgender Adolescent Males on Testosterone Therapy and Body Mass Index-Matched Cisgender Females. Transgender Health, 2021, 6, 369-373.	1.2	6

#	Article	IF	Citations
1803	Joint effect of multiple air pollutants on lipid profiles in obese and normal-weight young adults: The key role of ozone. Environmental Pollution, 2022, 292, 118247.	3.7	12
1804	HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease â€“ Insights from randomized clinical trials and human genetics. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159063.	1.2	19
1805	SekundÃrprÃvention. , 2020, , 149-181.		0
1806	Peculiarities of Clinical Presentations and Longâ€“Term Complications in Patients with Coronary Artery Disease and Metabolic Syndrome, depending on their Serum Triglyceride Levels. UkraÃ¯nsÊ¹kij Å¾urnal Medicini BÃ¬ologÃ¬Ã¯ Ta Sportu, 2020, 5, 125-134.	0.0	0
1807	Non-HDL cholesterol level and depression among Canadian elderlyâ€”a cross-sectional analysis of the baseline data from the CLSA. Facets, 2020, 5, 1006-1018.	1.1	1
1808	Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib. ACS Symposium Series, 2020, , 339-372.	0.5	1
1809	Coronary heart disease: Epidemiology and prevention. , 2020, , 3603-3616.		0
1810	High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?. Vascular Pharmacology, 2021, 141, 106928.	1.0	7
1812	DYSLIPIDEMIA IN NEWLY DIAGNOSED ELDERLY HYPERTENSIVE PATIENTS (>60 YEARS) IN A RURAL TEACHING INSTITUTE OF SUBHIMALAYAN REGION. , 2020, , 1-2.		0
1814	Investigation of Cardiovascular Health and Risk Factors Among the Diverse and Contemporary Population in London (the TOGETHER Study): Protocol for Linking Longitudinal Medical Records. JMIR Research Protocols, 2020, 9, e17548.	0.5	0
1815	Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Texas Heart Institute Journal, 2011, 38, 160-2.	0.1	49
1816	Lifestyle interventions for hypertension and dyslipidemia among women of reproductive age. Preventing Chronic Disease, 2011, 8, A123.	1.7	21
1818	Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Canadian Family Physician, 2013, 59, 1169-80.	0.1	38
1819	Impact of estimated HDL particle size via the ratio of HDL-C and apoprotein A-I on short-term prognosis of diabetic patients with stable coronary artery disease. Journal of Geriatric Cardiology, 2014, 11, 245-52.	0.2	3
1820	Break the fast? Update on patient preparation for cholesterol testing. Canadian Family Physician, 2014, 60, 895-7, e471-4.	0.1	6
1821	Associations of common SNPs in the SORT1, GCKR, LPL, APOA1, CETP, LDLR, APOE genes with lipid trait levels in an Algerian population sample. International Journal of Clinical and Experimental Pathology, 2015, 8, 7358-63.	0.5	6
1822	Association of variants in CELSR2-PSRC1-SORT1 with risk of serum lipid traits, coronary artery disease and ischemic stroke. International Journal of Clinical and Experimental Pathology, 2015, 8, 9543-51.	0.5	17
1823	Pediatric Metabolic Syndrome: Pathophysiology and Laboratory Assessment. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2017, 28, 25-42.	0.7	22

#	Article	IF	Citations
1824	The Influencing Factors of Serum Lipids among Middle-aged Women in Northeast China. Iranian Journal of Public Health, 2018, 47, 1660-1666.	0.3	0
1825	Lipids in Children and Links to Adult Vascular Disease. Clinical Biochemist Reviews, 2018, 39, 65-76.	3.3	5
1827	The association between the rs10248618 SNP and serum lipid traits, the risk of coronary artery disease, and ischemic stroke. International Journal of Clinical and Experimental Pathology, 2018, 11, 4585-4594.	0.5	1
1828	Difficulty of falling asleep and non-high-density lipoprotein cholesterol level among Canadian older adults: a cross-sectional analysis of the Canadian Longitudinal Study for Aging baseline data. Journal of Geriatric Cardiology, 2021, 18, 597-608.	0.2	0
1829	Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Disease: The Japan Epidemiology Collaboration on Occupational Health Study. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1295-1306.	0.9	5
1830	Comparison of risk factors for ischemic stroke and coronary events in a population-based cohort. BMC Cardiovascular Disorders, 2021, 21, 536.	0.7	14
1831	Association between the Plasma-Glycosylated Hemoglobin A1c/High-Density Lipoprotein Cholesterol Ratio and Carotid Atherosclerosis: A Retrospective Study. Journal of Diabetes Research, 2021, 2021, 1-10.	1.0	6
1832	Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2021, 19, .	0.8	1
1833	Effects of schoolâ€based â€œWe Fitâ€ weight control programme in adolescents. Nursing Open, 2022, 9, 721-732.	1.1	3
1834	Monocyte/High-Density Lipoprotein Ratio Predicts the Prognosis of Large Artery Atherosclerosis Ischemic Stroke. Frontiers in Neurology, 2021, 12, 769217.	1.1	10
1835	Prevalence and clinical risk prediction of hypertriglyceridaemia in a community cohort. Internal Medicine Journal, 2023, 53, 363-372.	0.5	2
1836	Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease. Molecules, 2021, 26, 6862.	1.7	3
1837	Treadmill Exercise Ameliorates Short-term Memory Impairment by Suppressing Hippocampal Neuroinflammation in Poloxamer-407-Induced Hyperlipidemia Rats. International Neurourology Journal, 2021, 25, S81-89.	0.5	7
1838	Lipid Profile of Coronary Heart Disease Patients: A Prospective Observational Study. World Journal of Cardiovascular Surgery, 2021, 11, 114-124.	0.1	0
1839	High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?. Handbook of Experimental Pharmacology, 2021, , 157-200.	0.9	3
1840	Long Term Outcome Prediction in Stemi/Nstemi Patients By Means of the Model Consisting of Simple Clinical Parameters. Emergency Medical Service, 2021, 8, 159-170.	0.1	0
1841	Sex Difference in the Association between Lipid Profile and Incident Cardiovascular Disease among Young Adults. Journal of Atherosclerosis and Thrombosis, 2021, , .	0.9	5
1842	Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly. Minerva Medica, 2022, 112, .	0.3	7

#	Article	IF	Citations
1843	Functional Deletion/Insertion Promoter Variants in SCARB1 Associated With Increased Susceptibility to Lipid Profile Abnormalities and Coronary Heart Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 800873.	1.1	2
1844	Heart Disease and Stroke Statisticsâ€"2022 Update: A Report From the American Heart Association. Circulation, 2022, 145, CIR0000000000001052.	1.6	2,561
1845	Effects of dietary and exercise treatments on HDL subclasses in lactating women with overweight and obesity: a secondary analysis of a randomised controlled trial. British Journal of Nutrition, 2022, 128, 2105-2114.	1.2	2
1846	Addressing dyslipidemic risk beyond LDL-cholesterol. Journal of Clinical Investigation, 2022, 132, .	3.9	51
1847	Sida acuta leaf extract attenuates oxidants-induced animal model of nephrotoxicity and hepatotoxicity. Clinical Phytoscience, 2022, 8, .	0.8	3
1848	Structured transition is associated with improved outcomes in diabetes. Practical Diabetes, 2022, 39, 18.	0.1	1
1849	Hypertriglyceridemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, Publish Ahead of Print, .	1.2	0
1850	Rare coding variants in 35 genes associate with circulating lipid levelsâ€"A multi-ancestry analysis of 170,000 exomes. American Journal of Human Genetics, 2022, 109, 81-96.	2.6	24
1851	U-Shaped Relationship of High-Density Lipoprotein Cholesterol and Incidence of Total, Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study. Stroke, 2022, 53, 1624-1632.	1.0	19
1852	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	6.3	69
1853	Long-term exposure to air pollution and the blood lipid levels of healthy young men. Environment International, 2022, 161, 107119.	4.8	24
1854	LCAT- targeted therapies: Progress, failures and future. Biomedicine and Pharmacotherapy, 2022, 147, 112677.	2.5	18
1855	HDL maturation and remodelling. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159119.	1.2	3
1856	Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults. International Journal of Epidemiology, 2022, 51, 1178-1189.	0.9	5
1857	The Cholesterol Uptake Capacity: The search for scalable HDL function tests continues. Atherosclerosis, 2022, 345, 39-40.	0.4	0
1858	Mendelian randomization. Nature Reviews Methods Primers, 2022, 2, .	11.8	393
1860	Identification of Symptomatic Carotid Artery Plaque: A Three-Item Scale Combined Angiography With Optical Coherence Tomography. Frontiers in Neuroscience, 2021, 15, 792437.	1.4	4
1861	High-density lipoprotein cholesterol and cardiovascular mortality: a prospective cohort study among 15.8 million adults. European Journal of Preventive Cardiology, 2022, 29, 844-854.	0.8	15

#	Article	IF	Citations
1863	Sex Differences in Coronary Atherosclerosis. Current Atherosclerosis Reports, 2022, 24, 23-32.	2.0	14
1864	Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions. Methods in Molecular Biology, 2022, 2419, 3-19.	0.4	9
1865	APOE and KLF14 genetic variants are sex-specific for low high-density lipoprotein cholesterol identified by a genome-wide association study. Genetics and Molecular Biology, 2022, 45, e20210280.	0.6	2
1866	Cardiovascular Risk According to Body Mass Index in Women of Reproductive Age With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 822079.	1.1	6
1867	Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF. Frontiers in Cardiovascular Medicine, 2022, 9, 820178.	1.1	3
1869	Approach to the Patient With Moderate Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1686-1697.	1.8	5
1871	Omega-3 Fatty Acids Improve Functionality of High-Density Lipoprotein in Individuals With High Cardiovascular Risk: A Randomized, Parallel, Controlled and Double-Blind Clinical Trial. Frontiers in Nutrition, 2021, 8, 767535.	1.6	11
1873	Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review. Geriatrics (Switzerland), 2022, 7, 38.	0.6	0
1874	Managing Atherosclerotic Cardiovascular Risk in Young Adults. Journal of the American College of Cardiology, 2022, 79, 819-836.	1.2	72
1876	Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nature Reviews Cardiology, 2022, 19, 577-592.	6.1	59
1877	Inflammatory Links Between Hypertriglyceridemia and Atherogenesis. Current Atherosclerosis Reports, 2022, 24, 297-306.	2.0	15
1878	Differential Roles of Life-Course Cumulative Burden of Cardiovascular Risk Factors in Arterial Stiffness and Thickness. Canadian Journal of Cardiology, 2022, 38, 1253-1262.	0.8	10
1879	Prognostic Role of Hypertriglyceridemia in Patients With Stroke of Atherothrombotic Origin. Neurology, 2022, 98, .	1.5	7
1880	Effects of Anthocyanin-rich Berries on the Risk of Metabolic Syndrome: A Systematic Review and Meta-analysis. Review of Diabetic Studies, 2022, 18, 42-57.	0.5	6
1881	Per- and Polyfluoroalkyl Substances and Risk of Myocardial Infarction and Stroke: A Nested Caseâ€“Control Study in Sweden. Environmental Health Perspectives, 2022, 130, 37007.	2.8	16
1882	The association between the non-HDL-cholesterol to HDL-cholesterol ratio and 28-day mortality in sepsis patients: a cohort study. Scientific Reports, 2022, 12, 3476.	1.6	5
1883	Multiple categories of polycyclic aromatic hydrocarbons in atmospheric PM2.5 associated with changes in lipid profiles: A longitudinal study in Beijing. Atmospheric Environment, 2022, 275, 119005.	1.9	1
1884	Evaluation of the apolipoprotein E (apoE)-HDL-associated risk factors for coronary heart disease using duo-functional electrochemical aptasensor. Analytical and Bioanalytical Chemistry, 2022, , 1.	1.9	1

#	Article	IF	Citations
1885	Sex-Specific U-Shaped Relationships Between High-Density Lipoprotein Cholesterol Levels and 10-year Major Adverse Cardiovascular Events: A Nationwide Cohort Study of 5.7 Million South Koreans. Annals of Laboratory Medicine, 2022, 42, 415-427.	1.2	7
1886	Plant-Based Diet as a Strategy for Weight Control. Foods, 2021, 10, 3052.	1.9	22
1887	Impact of retinal vein occlusion on cardiovascular events in elderly Japanese patients. Medicine (United States), 2021, 100, e28424.	0.4	3
1888	Modification of High-Density Lipoprotein Functions by Diet and Other Lifestyle Changes: A Systematic Review of Randomized Controlled Trials. Journal of Clinical Medicine, 2021, 10, 5897.	1.0	6
1889	Development and Validation of Decision Rules Models to Stratify Coronary Artery Disease, Diabetes, and Hypertension Risk in Preventive Care: Cohort Study of Returning UK Biobank Participants. Journal of Personalized Medicine, 2021, 11, 1322.	1.1	2
1890	Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. European Heart Journal, 2022, 43, 1416-1424.	1.0	27
1891	Non-HDL cholesterol as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years. Translational Research, 2022, 243, 52-59.	2.2	2
1892	The association of apolipoproteins with later-life all-cause and cardiovascular mortality: a population-based study stratified by age. Scientific Reports, 2021, 11, 24440.	1.6	5
1893	Circulating Interleukin-6 Levels and Incident Ischemic Stroke. Neurology, 2022, 98, .	1.5	29
1895	Global prevalence of dyslipidaemia in adult populations: a systematic review protocol. BMJ Open, 2021, 11, e049662.	0.8	5
1896	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. Annals of Medicine, 2022, 54, 1036-1046.	1.5	9
1898	Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. Acta Cardiologica, 2024, 79, 20-29.	0.3	8
1899	GuÃa ESC 2021 sobre la prevenciÃ³n de la enfermedad cardiovascular en la prÃ¡ctica clÃnica. Revista Espanola De Cardiologia, 2022, 75, 429.e1-429.e104.	0.6	27
1904	Consumption of ultra-processed foods and incidence of dyslipidaemias: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). British Journal of Nutrition, 2023, 129, 336-344.	1.2	6
1905	Relation Between New York Heart Association Functional Class and Remnant Cholesterol, and Non-high Density Lipoprotein Cholesterol in Coronary Heart Disease Patients With Type 2 Diabetes Mellitus. Angiology, 2022, , 000331972210913.	0.8	1
1909	Genetic variation of apolipoproteins, diet and other environmental interactions; an updated review. Nutricion Hospitalaria, 2013, 28, 999-1009.	0.2	9
1910	A genetic variant of the CAPN10 gene in Mexican subjects with dyslipidemia is associated with increased HDL-cholesterol concentrations after the consumption of a soy protein and soluble fiber dietary portfolio. Nutricion Hospitalaria, 2014, 30, 671-7.	0.2	5
1911	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3235.	0.4	37

#	Article	IF	Citations
1912	The relationship between socio demographic characteristics, health behaviors, and biochemical parameters and nutritional status in patients with coronary heart disease: A cross-sectional study. , 2016, 50, 7-12.		0
1913	HDL and Diabetes. Advances in Experimental Medicine and Biology, 2022, 1377, 119-127.	0.8	4
1916	Protein-based HDL subspecies: Rationale and association with cardiovascular disease, diabetes, stroke, and dementia. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159182.	1.2	5
1917	Longitudinal effects of lipid indices on incident cardiovascular diseases adjusting for time-varying confounding using marginal structural models: 25 years follow-up of two US cohort studies. Global Epidemiology, 2022, 4, 100075.	0.6	2
1918	Use of Digital Technology Tools to Characterize Adherence to Prescription-Grade Omega-3 Polyunsaturated Fatty Acid Therapy in Postmyocardial or Hypertriglyceridemic Patients in the DIAPAsOn Study: Prospective Observational Study. JMIR Cardio, 2022, 6, e37490.	0.7	1
1919	Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE). Journal of Stroke, 2022, 24, 224-235.	1.4	14
1920	Discordance of Apolipoprotein B, Non-HDL-Cholesterol, and LDL-Cholesterol Predicts Risk of Increased Arterial Stiffness and Elevated Carotid Intima-Media Thickness in Middle-Aged and Elderly Chinese Adults. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	5
1921	Clinical Impact of the Capacity-Motivation-Opportunity Pharmacist-Led Intervention in People Living with HIV in Spain, 2019â€“2020. Journal of Multidisciplinary Healthcare, 0, Volume 15, 1203-1211.	1.1	7
1922	A SNP in the 5â€™ flanking region of the SAA1 gene is associated with serum levels of serum amyloid A and cardiovascular risk factors. Translational Medicine Communications, 2022, 7, .	0.5	0
1923	<scp>ApoB</scp> and <scp>Nonâ€HDL</scp> Cholesterol Versus <scp>LDL</scp> Cholesterol for Ischemic Stroke Risk. Annals of Neurology, 2022, 92, 379-389.	2.8	9
1924	Association between plant and animal proteins intake with lipid profile and anthropometric indices: A cross-sectional study. Nutrition and Health, 0, , 026010602211043.	0.6	9
1925	The LDL Apolipoprotein B-to-LDL Cholesterol Ratio: Association with Cardiovascular Mortality and a Biomarker of Small, Dense LDLs. Biomedicines, 2022, 10, 1302.	1.4	5
1926	Omega-3-fatty acids: Do they prevent cardiovascular disease?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2023, 37, 101681.	2.2	5
1930	Atherogenic index of plasma is associated with epicardial adipose tissue volume assessed on coronary computed tomography angiography. Scientific Reports, 2022, 12, .	1.6	4
1931	Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 638-651.	8.2	69
1932	Association between serum apolipoprotein B and atrial fibrillation: a caseâ€“control study. Scientific Reports, 2022, 12, .	1.6	6
1933	Elevated plasma triglyceride concentration and risk of adverse clinicalÂoutcomes in 1.5 million people: a CALIBER linked electronic health record study. Cardiovascular Diabetology, 2022, 21, .	2.7	6
1934	Impact of different training modalities on highâ€density lipoprotein function in HFpEF patients: a substudy of the OptimEx trial. ESC Heart Failure, 2022, 9, 3019-3030.	1.4	3

#	Article	IF	Citations
1935	Lipoprotein profiles associated with exposure to poly- and perfluoroalkyl substances (PFASs) in the EuroMix human biomonitoring study. Environmental Pollution, 2022, 308, 119664.	3.7	9
1936	Vasculome. , 2022, , 441-451.		0
1937	Childhood beverage intake and risk of hypertension and hyperlipidaemia in young adults. International Journal of Food Sciences and Nutrition, 2022, 73, 954-964.	1.3	5
1938	Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 2022, 146, .	1.6	80
1939	High-Density Lipoprotein and Cardiovascular Diseaseâ€"Where do We Stand?. Endocrinology and Metabolism Clinics of North America, 2022, , .	1.2	2
1940	U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
1941	Circulating metabolites associated with incident myocardial infarction and stroke: A prospective cohort study of 90â€‰438 participants. Journal of Neurochemistry, 2022, 162, 371-384.	2.1	1
1942	Hypertriglyceridaemia: an update. Journal of Clinical Pathology, 2022, 75, 798-806.	1.0	10
1944	Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk. Current Cardiovascular Risk Reports, 0, , .	0.8	0
1945	Fasting triglycerides are positively associated with cardiovascular mortality risk in people with diabetes. Cardiovascular Research, 2023, 119, 826-834.	1.8	10
1946	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. Journal of Clinical Medicine, 2022, 11, 4464.	1.0	13
1947	Effect of CSL112 (apolipoprotein Aâ€‰[human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a crossâ€study comparison. Clinical and Translational Science, 0, , .	1.5	3
1948	Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. International Journal of Molecular Sciences, 2022, 23, 9417.	1.8	17
1949	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€"2022 Update. Endocrine Practice, 2022, 28, 923-1049.	1.1	146
1950	Colesevelam â€“ a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia. Expert Opinion on Pharmacotherapy, 2022, 23, 1363-1370.	0.9	2
1951	Coronary CT angiography and serum biomarkers are potential biomarkers for predicting MACE at three-months and one-year follow-up. International Journal of Cardiovascular Imaging, 2022, 38, 2763-2770.	0.2	3
1952	Remnant Cholesterol and the Risk of Coronary Artery Disease in Patients With Type 2 Diabetes. Angiology, 2023, 74, 745-753.	0.8	2
1953	HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism. Journal of Pharmacological Sciences, 2022, 150, 81-89.	1.1	9

#	Article	IF	Citations
1954	Paradoxical Long-Term Impact Between Serum Apolipoprotein E and High-Density Lipoprotein Cholesterol in Patients Undergoing Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis, 2022, , .	0.9	1
1955	Effects of â€œReed A Dreamâ€•Insecticide on Selected Biomarkers of Kidney, Liver, and Lipid Profile in Wistar Rats. BioScientific Review, 2022, 4, .	0.0	0
1956	Determining independence and associations among various cardiovascular disease risk factors in 9-12 years old school-children: a cross sectional study. BMC Public Health, 2022, 22, .	1.2	3
1957	Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research. Current Opinion in Lipidology, 2022, 33, 264-269.	1.2	1
1958	Non-high-density lipoprotein cholesterol and treatment targets in vascular surgery patients. Vascular, 2024, 32, 210-219.	0.4	0
1959	Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease:Âa cohort study of 911,360 individuals from the United Kingdom. BMC Nephrology, 2022, 23, .	0.8	10
1960	Non-HDL-C/HDL-C ratio is associated with carotid plaque stability in general population: A cross-sectional study. Frontiers in Neurology, 0, 13, .	1.1	6
1961	Thoughts on hypertriglyceridaemia in clinical practice. Journal of Clinical Pathology, 0, , jcp-2022-208513.	1.0	0
1962	Approach to risk stratification of atherosclerotic cardiovascular disease. Canadian Family Physician, 2022, 68, 654-660.	0.1	2
1963	Approche de la stratification du risque de maladies cardiovasculaires athÃ©rosclÃ©reuses. Canadian Family Physician, 2022, 68, e256-e263.	0.1	0
1964	Estimating the changing disease burden attributable to raised low-density lipoprotein cholesterol in South Africa for 2000, 2006 and 2012. South African Medical Journal, 0, , 607-616.	0.2	1
1965	Dietary Risk Factors and Eating Behaviors in Peripheral Arterial Disease (PAD). International Journal of Molecular Sciences, 2022, 23, 10814.	1.8	10
1966	Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segmentâ€“Elevation Myocardial Infarction: Results of REAL-TIMI 63B. Circulation, 2022, 146, 907-916.	1.6	10
1967	Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysis. European Journal of Preventive Cardiology, 2022, 29, 2374-2385.	0.8	13
1968	Biomarkers of Exposure and Potential Harm in Exclusive Users of Nicotine Pouches and Current, Former, and Never Smokers: Protocol for a Cross-sectional Clinical Study. JMIR Research Protocols, 2022, 11, e39785.	0.5	1
1969	Associations Between Life-Course Lipid Trajectories and Subclinical Atherosclerosis in Midlife. JAMA Network Open, 2022, 5, e2234862.	2.8	12
1970	Apolipoprotein B: An essential cholesterol metric for atherosclerotic cardiovascular disease. American Journal of Health-System Pharmacy, 0, , .	0.5	0
1971	Emerging Markers for Cardiovascular Risk Assessment. Advances in Clinical Medicine, 2022, 12, 9155-9161.	0.0	0

#	Article	IF	Citations
1972	Small High-Density Lipoprotein and Omega-3 Fatty Acid Intake Differentiates Japanese and Japanese-Americans: The INTERLIPID Study. Journal of Atherosclerosis and Thrombosis, 2023, 30, 884-906.	0.9	2
1973	Hyperlipidemia and mortality in patients on peritoneal dialysis. BMC Nephrology, 2022, 23, .	0.8	3
1974	C1QL1/CTRP14 Is Largely Dispensable for Atherosclerosis Formation in Apolipoprotein-E-Deficient Mice. Journal of Cardiovascular Development and Disease, 2022, 9, 341.	0.8	2
1975	World Heart Federation Cholesterol Roadmap 2022. Global Heart, 2022, 17, 75.	0.9	34
1976	Atherogenic Indices as a Predictor of Aortic Calcification in Prostate Cancer Patients Assessed Using 18F-Sodium Fluoride PET/CT. International Journal of Molecular Sciences, 2022, 23, 13056.	1.8	3
1977	Current Nanomedicine for Targeted Vascular Disease Treatment: Trends and Perspectives. International Journal of Molecular Sciences, 2022, 23, 12397.	1.8	11
1978	Alterations of HDLâ€™s to piHDLâ€™s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. Pharmaceuticals, 2022, 15, 1278.	1.7	9
1979	Associations of Hypertriglyceridemia Onset Age With Cardiovascular Disease and Allâ€Cause Mortality in Adults: A Cohort Study. Journal of the American Heart Association, 2022, 11, .	1.6	5
1980	Association between hypercholesterolemia and mortality risk among patients referred for cardiac imaging test: Evidence of a â€œcholesterol paradox?â€• Progress in Cardiovascular Diseases, 2022, 74, 60-69.	1.6	4
1981	Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterolâ€“related inflammatory parameters as predictors. Coronary Artery Disease, 2023, 34, 66-77.	0.3	11
1982	Twenty-first century epidemiology of dyslipidemia in Greece: EMENO national epidemiological study. Hellenic Journal of Cardiology, 2023, 69, 1-8.	0.4	6
1983	Dynamic Resistance Exercise Alters Blood ApoA-I Levels, Inflammatory Markers, and Metabolic Syndrome Markers in Elderly Women. Healthcare (Switzerland), 2022, 10, 1982.	1.0	0
1984	Comparison of the Effectiveness of Low Carbohydrate Versus Low Fat Diets, in Type 2 Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2022, 14, 4391.	1.7	8
1985	Exploring the Novelty in Lipid Profiling of Patients: A Non-fasting Approach from Eastern India. Journal of Laboratory Physicians, 0, , .	0.4	0
1986	The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study. Journal of Clinical Lipidology, 2023, 17, 124-130.	0.6	3
1987	Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study. Cardiovascular Diabetology, 2022, 21, .	2.7	28
1988	Prevalence and predictors of dyslipidemia among hypertensive patients attending a secondary healthcare center in southwestern Nigeria. Saudi Journal of Obesity, 2019, 7, 21.	0.3	0
1989	Correlation of Triglyceride-Rich Lipoprotein Cholesterol and Diabetes Mellitus in Stroke Patients. International Journal of Endocrinology, 2022, 2022, 1-8.	0.6	0

#	Article	IF	Citations
1990	Anger and Dementia Caregiving: A Systematic Review of the Effects of Anger and Hostility on Caregiversâ€™ Physical Health. Journal of Alzheimer's Disease Reports, 2022, 6, 685-698.	1.2	3
1991	Association between Dietary Diversity and Sociopsychological Factors and the Onset of Dyslipidemia after the Great East Japan Earthquake: Fukushima Health Management Survey. International Journal of Environmental Research and Public Health, 2022, 19, 14636.	1.2	0
1993	National Institute for Health and Care Excellence guidelines for lipid management. Heart, 2023, 109, 661-667.	1.2	5
1994	Further proof of a paradoxical relationship between high-density lipoprotein levels and adverse cardiovascular outcomes: are there implications for cardiovascular disease prevention?. European Journal of Preventive Cardiology, 2023, 30, 290-292.	0.8	3
1995	The quantifying relationship between the remission duration and the cardiovascular and kidney outcomes in the patients with primary nephrotic syndrome. Renal Failure, 2022, 44, 1925-1933.	0.8	1
1996	Comparison of the effects of triglyceride variability and exposure estimate on clinical prognosis in diabetic patients. Cardiovascular Diabetology, 2022, 21, .	2.7	2
1997	Study protocol of the PROUD48 study comparing the effects of pemafibrate and omega-3 fatty acid ethyl esters on ApoB-48 in statin-treated patients with dyslipidaemia: a prospective, multicentre, open-label, randomised, parallel group trial in Japan. BMJ Open, 2022, 12, e061360.	0.8	2
1998	High-density lipoprotein revisited: biological functions and clinical relevance. European Heart Journal, 2023, 44, 1394-1407.	1.0	51
2000	Beneficial effects of high-density lipoprotein (HDL) on stent biocompatibility and the potential value of HDL infusion therapy following percutaneous coronary intervention. Medicine (United States), 2022, 101, e31724.	0.4	1
2001	Different profiles of lipoprotein particles associate various degrees of cardiac involvement in adolescents with morbid obesity. Frontiers in Pediatrics, 0, 10, .	0.9	3
2002	Revisiting secondary prevention in coronary heart disease. Indian Heart Journal, 2022, 74, 431-440.	0.2	7
2003	Effects of smoking cessation using varenicline on the serum concentrations of oxidized high-density lipoprotein: Comparison with high-density lipoprotein cholesterol. PLoS ONE, 2022, 17, e0277766.	1.1	0
2004	Pleiotropic Effects of APOB Variants on Lipid Profiles, Metabolic Syndrome, and the Risk of Diabetes Mellitus. International Journal of Molecular Sciences, 2022, 23, 14963.	1.8	3
2005	To ApoB or Not to ApoB: New Arguments, but Basis for Widespread Implementation Remains Elusive. Clinical Chemistry, 2023, 69, 3-5.	1.5	2
2006	Relationship between the neutrophil to high-density lipoprotein cholesterol ratio and severity of coronary artery disease in patients with stable coronary artery disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
2007	Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease. Journal of the American College of Cardiology, 2022, 80, 2104-2115.	1.2	15
2008	State-level metabolic comorbidity prevalence and control among adults age 50-plus with diabetes: estimates from electronic health records and survey data in five states. Population Health Metrics, 2022, 20, .	1.3	0
2009	Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology Study. Annals of Laboratory Medicine, 2023, 43, 237-243.	1.2	9

#	Article	IF	Citations
2010	Data mining approaches for type 2 diabetes mellitus prediction using anthropometric measurements. Journal of Clinical Laboratory Analysis, 2023, 37, .	0.9	19
2011	Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment. Annals of Laboratory Medicine, 2023, 43, 221-222.	1.2	3
2012	Hyperuricemia increases the risk of cardiovascular mortality associated with very high HdL-cholesterol level. Nutrition, Metabolism and Cardiovascular Diseases, 2023, 33, 323-330.	1.1	8
2013	The triglyceride glucose index and cardiovascular disease outcomes. The Lancet Healthy Longevity, 2022, , .	2.0	0
2014	Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice. Nature Metabolism, 2022, 4, 1812-1829.	5.1	12
2015	Expression of trefoil factor 2 and 3 and adrenomedullin in chronic periodontitis subjects with coronary heart disease. Journal of Periodontology, 2023, 94, 694-703.	1.7	5
2016	Discovering comorbid diseases using an inter-disease interactivity network based on biobank-scale PheWAS data. Bioinformatics, 2023, 39, .	1.8	5
2017	Longitudinal Association between Physical Activity, Blood Lipids, and Risk of Dyslipidemia among Chinese Adults: Findings from the China Health and Nutrition Surveys in 2009 and 2015. Nutrients, 2023, 15, 341.	1.7	4
2018	Long-term visit-to-visit variability in low-density lipoprotein cholesterol is associated with poor cardiovascular and kidney outcomes in patients with primary nephrotic syndrome. International Urology and Nephrology, 2023, 55, 1565-1574.	0.6	1
2019	Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions. Vascular Health and Risk Management, 0, Volume 19, 31-41.	1.0	0
2020	The Apparent Organ-Specificity of Amyloidogenic ApoA-I Variants Is Linked to Tissue-Specific Extracellular Matrix Components. International Journal of Molecular Sciences, 2023, 24, 318.	1.8	2
2021	Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis. Genome Biology, 2022, 23, .	3.8	17
2022	Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current Atherosclerosis Reports, 2023, 25, 1-17.	2.0	28
2023	Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins on cardiovascular and non-cardiovascular outcomes. Communications Medicine, 2023, 3, .	1.9	4
2024	The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.1	2
2025	Role of Serum Lipids, Blood Glucose and Blood Pressure in Breast Cancer Risk for Women with Type 2 Diabetes Mellitus. Clinical Epidemiology, 0, Volume 15, 109-121.	1.5	1
2026	Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease. Circulation Research, 2023, 132, 452-464.	2.0	12
2027	Comment on: LDL-C â€“ when to calculate and when to measure?. Journal of Clinical Pathology, 2023, 76, 156-157.	1.0	0

#	Article	IF	Citations
2030	Residual risks and evolving atherosclerotic plaques. Molecular and Cellular Biochemistry, 2023, 478, 2629-2643.	1.4	6
2031	Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis. Atherosclerosis, 2023, 371, 21-31.	0.4	12
2032	Dysfunctional antioxidant capacity of highâ€density lipoprotein in rheumatoid arthritis. European Journal of Clinical Investigation, 2023, 53, .	1.7	1
2033	Zebrafish as outgroup model to study evolution of scavenger receptor class B type I functions. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2023, 1868, 159308.	1.2	1
2034	Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease?. Current Opinion in Endocrinology, Diabetes and Obesity, 2023, 30, 128-135.	1.2	6
2035	What is really new in triglyceride guidelines?. Current Opinion in Endocrinology, Diabetes and Obesity, 2023, 30, 73-80.	1.2	0
2036	Dairy foods and cardiometabolic diseases: an update and a reassessment of the impact of SFA. Proceedings of the Nutrition Society, 2023, 82, 329-345.	0.4	5
2037	Association of triglycerides to high-density lipoprotein cholesterol ratio with incident cardiovascular disease but not end-stage kidney disease among patients with biopsy-proven diabetic nephropathy. Hypertension Research, 2023, 46, 1423-1432.	1.5	2
2038	Using Mathematical and Statistical Analysis to Investigate the Correlation between Exacerbation of Chronic Obstructive Pulmonary Disease and Risk of Subclinical Atherosclerosis. Diagnostics, 2023, 13, 623.	1.3	0
2039	The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
2040	Assessment of Cardiovascular Risk in Women: Progress so Far and Progress to Come. International Journal of Women's Health, 0, Volume 15, 191-212.	1.1	2
2041	The association between meat intake and the risk of coronary heart disease in Korean men using the Framingham risk score: A prospective cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 2023, 33, 1158-1166.	1.1	0
2042	Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine, 2023, 112, 154716.	2.3	3
2043	Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345Â000 men and women aged 20â€“79 years. International Journal of Epidemiology, 2023, 52, 1257-1267.	0.9	4
2044	Elevated remnant cholesterol increase 6-year type 2 diabetes mellitus onset risk. Clinica Chimica Acta, 2023, 541, 117253.	0.5	2
2045	Effect of withholding food versus feeding on creatinine, symmetric dimethylarginine, cholesterol, triglycerides, and other biochemical analytes in 100 healthy dogs. Journal of Veterinary Internal Medicine, 2023, 37, 626-634.	0.6	2
2046	A New Antidiabetic Agent Showing Short- and Long-Term Effects Due to Peroxisome Proliferator-Activated Receptor Alpha/Gamma Dual Agonism and Mitochondrial Pyruvate Carrier Inhibition. Journal of Medicinal Chemistry, 2023, 66, 3566-3587.	2.9	0
2047	Development and validation of a nomogram for evaluating the incident risk of carotid atherosclerosis in patients with type 2 diabetes. Frontiers in Endocrinology, 0, 14, .	1.5	0

#	Article	IF	Citations
2048	Intrapartum Factors Affecting Abnormal Lipid Profiles in Early Postpartum Period. Journal of Personalized Medicine, 2023, 13, 444.	1.1	1
2049	Complexity of triglyceride-rich lipoprotein remnant cholesterol with atherosclerotic cardiovascular disease risk. European Journal of Preventive Cardiology, 2023, 30, 1139-1141.	0.8	4
2051	Hyperlipidemia and Cardiovascular Risk in Children and Adolescents. Biomedicines, 2023, 11, 809.	1.4	6
2052	The Effect of Plant-Based and Mycoprotein-Based Meat Substitute Consumption on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis of Controlled Intervention Trials. Dietetics, 2023, 2, 104-122.	0.4	3
2053	Understanding the Impact of Added Sugar Consumption on Risk for Type 2 Diabetes. Journal of the California Dental Association, 2016, 44, 619-626.	0.0	4
2054	HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS. International Journal of Molecular Sciences, 2023, 24, 5391.	1.8	1
2056	Role of Adhesion G Protein-Coupled Receptors in Immune Dysfunction and Disorder. International Journal of Molecular Sciences, 2023, 24, 5499.	1.8	2
2058	Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. Cardiovascular Diabetology, 2023, 22, .	2.7	4
2059	Determination of the quality of lipoproteins by Raman spectroscopy in obese and healthy subjects. Analyst, The, 2023, 148, 2012-2020.	1.7	2
2060	The relationship between triglyceride, cholesterol and lipoprotein levels, and immune responses to hepatitis B vaccine. Frontiers in Medicine, 0, 10, .	1.2	0
2061	CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Postâ€“Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 855-869.	1.1	5
2062	Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics. , 2023, , 97-135.		0
2063	The encounter of elevated high-density lipoprotein cholesterol and high blood pressure lowers life expectancy. European Journal of Preventive Cardiology, 0, , .	0.8	0
2064	Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4+ T cells. Cardiovascular Diabetology, 2023, 22, .	2.7	2
2065	Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nature Reviews Cardiology, 2023, 20, 600-616.	6.1	22
2066	Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1Î± Expression. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 16, 1063-1074.	1.1	1
2067	Towards a consensus definition of allostatic load: a multi-cohort, multi-system, multi-biomarker individual participant data (IPD) meta-analysis. Psychoneuroendocrinology, 2023, 153, 106117.	1.3	7
2069	Triglycerid level as a potential marker of residual cardiovascular risk and its relation to HeartScore. Technology and Health Care, 2023, , 1-9.	0.5	1

#	Article	IF	Citations
2095	Triglyceride- and Cholesterol-Rich Remnant Lipoproteins in Risk of Cardiovascular Disease in Diabetes Mellitus. Contemporary Diabetes, 2023, , 195-222.	0.0	0
2096	Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2. Contemporary Diabetes, 2023, , 637-679.	0.0	0
2108	Special Patient Populations. , 2024, , 287-297.e2.		0
2109	Measurement of Low-Density Lipoprotein Cholesterol, Nonâ€“High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Low-Density Lipoprotein Particle Concentration. , 2024, , 21-31.e1.		0
2144	Cholesterol and lipids. , 2023, , .		0
2162	Leptin and Obesity: Understanding the Impact on Dyslipidemia. , 0, , .		0
2174	Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Current Atherosclerosis Reports, 2024, 26, 35-44.	2.0	2
2176	Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nature Reviews Cardiology, 0, , .	6.1	1
2189	Nutritional Aspects of Fats and Oils. , 2024, , 13-38.		0
2193	Implementation of Machine Learning Algorithms for Cardiovascular Disease Prediction. Lecture Notes in Electrical Engineering, 2024, , 473-486.	0.3	0